Development of Binary Composite Solid Microparticles for Improved Intranasal Absorption of Low Permeation Drug Molecules by Vasa, Dipy Madhukar
Duquesne University
Duquesne Scholarship Collection
Electronic Theses and Dissertations
Spring 1-1-2017
Development of Binary Composite Solid
Microparticles for Improved Intranasal Absorption
of Low Permeation Drug Molecules
Dipy Madhukar Vasa
Follow this and additional works at: https://dsc.duq.edu/etd
This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.
Recommended Citation
Vasa, D. M. (2017). Development of Binary Composite Solid Microparticles for Improved Intranasal Absorption of Low Permeation
Drug Molecules (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/152
  
 
 
DEVELOPMENT OF BINARY COMPOSITE SOLID MICROPARTICLES 
FOR IMPROVED INTRANASAL ABSORPTION OF LOW PERMEATION 
DRUG MOLECULES 
 
 
 
A Dissertation 
Submitted to the Graduate School of Pharmaceutical Sciences 
 
 
 
Duquesne University 
 
In partial fulfillment of the requirements for 
the degree of Doctor of Philosophy 
 
By 
Dipy M. Vasa 
 
May 2017
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Dipy M. Vasa 
 
2017
iii 
 
 
 
 
 
DEVELOPMENT OF BINARY COMPOSITE SOLID MICROPARTICLES  
 
FOR IMPROVED INTRANASAL ABSORPTION OF LOW PERMEATION  
 
DRUG MOLECULES 
 
 
 
 
 
By 
 
Dipy M. Vasa 
 
Approved March 17, 2017 
 
 
 
________________________________ 
Peter L. D. Wildfong, Ph.D. 
Associate Professor of Pharmaceutics 
Graduate School of Pharmaceutical 
Sciences (Committee Chair) 
 
 
 
 
 
 
 
 
 
 
 
________________________________ 
Ira S. Buckner, Ph.D.  
Associate Professor of Pharmaceutics  
Graduate School of Pharmaceutical 
Sciences (Committee Member) 
________________________________ 
Lauren A. O’Donnell, Ph.D. 
Associate Professor of Pharmacology 
Graduate School of Pharmaceutical 
Sciences (Committee Member) 
 
 
 
 
 
 
 
 
 
______________________________ 
Wilson S. Meng, Ph.D. 
Associate Professor of Pharmaceutics 
Graduate School of Pharmaceutical 
Sciences (Committee Member) 
________________________________ 
Maureen D. Donovan, Ph.D.  
Professor of Pharmaceutics and 
Translational Therapeutics, Associate 
Dean for Undergraduate Education, 
University of Iowa (Committee Member)  
________________________________ 
Rehana Leak, Ph.D.  
Associate Professor of Pharmacology 
Graduate School of Pharmaceutical 
Sciences  
 
 
 iv 
ABSTRACT 
 
DEVELOPMENT OF BINARY COMPOSITE SOLID MICROPARTICLES 
FOR IMPROVED INTRANASAL ABSORPTION OF LOW PERMEATION 
DRUG MOLECULES 
 
 
By 
Dipy M. Vasa 
May 2017 
 
Dissertation supervised by: Peter L.D. Wildfong, Ph.D. 
 The objective of this work was to introduce a novel formulation strategy for 
intranasal delivery of two low permeation candidates: levodopa (L-DOPA; 
antiparkinsonism drug) and ribavirin (RBVN; an antiviral drug). The central hypothesis 
states that preparation of binary composite microparticles with Pluronic® triblock 
copolymers (polyethylene glycol-polypropylene glycol-polyethylene glycol) should allow 
increased drug transport across nasal mucosal tissue relative to drug alone. Testing the 
hypothesis necessitated execution of specific aims directed to addressing issues inherent 
to the proposed approach. The work herein is presented with respect to two separate 
subjects: (1) material understanding and (2) formulation development. In the first two 
chapters, the feasibility of direct deposition of dry, solid drug microparticles on intranasal 
 v 
permeation was explored. Further, specific emphasis was placed on selection of the most 
suitable solid form which can sustain the stresses of the chosen manufacturing processes.  
The concluding part of this work is devoted to illustrating the use of binary 
composite polymeric microparticles, ultimately stemming from the materials and 
methodologies developed in the initial stages. The rate and extent of ribavirin transport 
was significantly higher from solid polymeric microparticles compared to standalone 
drug powder and its aqueous solution. Increased drug transport was attributable to 
permeation enhancement afforded by Pluronic® accompanied with a high initial 
concentration gradient established across the model tissue.  
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Chapter 1: Introduction  
 
1.1. Introduction 
The selectively permeable nature of the blood-brain barrier (BBB) presents a 
considerable challenge for effective delivery of drug molecules to the central nervous 
system (CNS). According to one estimate, < 2% of all small molecules and virtually no 
large molecules reach the CNS after systemic administration.1 Several potential neuro-
therapeutic drug candidates that are efficacious in vitro fail during the clinical phase 
owing to the inability to enter the CNS. In general, the BBB limits substrate transport 
based on lipophilicity, molecular size, and specificity for a variety of ATP-dependent 
transport systems. Although there is a positive correlation between lipophilicity and the 
BBB permeability,2 many of these substrates and their metabolites are removed almost 
instantly by the efflux transporters (such as P-glycoprotein; P-gp) expressed in the 
endothelial cells of the BBB. In addition to Pgp, the ATP binding cassette transporters of 
the multidrug resistance protein (MRP) family and the breast cancer resistance protein 
(BCRP) have a role in central drug uptake.3-5  
Early assessment of the ability of a drug candidate to cross the BBB is critical. 
Over the past several years, academia and industry have invested significant effort in the 
development and optimization of screening procedures, including in vitro assays and 
computational models to evaluate CNS penetration. This information can be used to 
discover new chemical entities (NCEs) amenable to BBB transport, however, the 
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financial burden that it puts on a pharmaceutical company often questions the feasibility 
of this seemingly straightforward choice. The decline of “blockbuster” drug development 
over the last decade further echoes the increasing need for exploring alternate routes of 
administration and/or innovative formulations to effectively deliver extant therapeutic 
molecules to the brain.  
A key focus of intranasal (IN) drug delivery research is to afford direct entry of 
drug molecules into the CNS using the unique anatomy and physiology of the nasal 
cavity.6-10 The olfactory bulb is the only region of the CNS in direct contact with the 
nasal cavity, which potentially allows molecules to bypass the BBB. Additionally, IN 
delivery offers avoidance of first-pass hepatic metabolism along with local intestinal 
metabolism/toxicity/efflux/degradation. Recent patents detailing IN delivery for the 
treatment of Parkinson’s disease, multiple sclerosis, Alzheimer’s disease,11-14 dementia15 
and migraine16 support ongoing interest in this route of administration. Large bio-
molecules, including cytokines and growth factors,17 have also shown promise for CNS 
entry through IN administration. From a quantitative standpoint, however, IN 
administration has shown relatively poor accumulation of drug in the CNS.6,18,19 
According to recent reports, the average fraction of nasally administered dose that 
reached the CNS was < 1 %.20,21,22 This is primarily attributed to (1) inadequate drug 
deposition in the desired region of the nasal cavity which facilitates direct CNS access 
i.e., the olfactory region and (2) rapid removal of drug from the site of deposition via 
mucociliary clearance. 
 
 3 
Optimizing drug deposition in the olfactory region for targeted nose-to-CNS 
delivery is rather complicated.  The convoluted geometry and narrow passages of the 
nasal cavity make access to the olfactory region challenging. Nonetheless, there are some 
unique delivery devices, such as OptiNose® and ViaNaseTM that have effectively 
administered drugs deep into the nasal cavity, with considerable exposure in the olfactory 
region.23,24  Impel NeuroPharma® has also designed a novel nasal delivery technology to 
provide targeted olfactory deposition via a pressurized aerosol device.24 These reports 
represent an important step towards the ultimate goal of nose-to-CNS delivery and 
invigorate pharmaceutical investment in this area.  
Conversely, mucociliary clearance, which leads to rapid elimination of IN-
administered products in the gastroinstential tract (GIT), cannot be effectively addressed 
via change of delivery device. Briefly, the nasal mucus layer is renewed every 10-20 
min,25 which reduces total absorption of the deposited drug. To overcome this limitation, 
an increased residence time (tres) of drug preparations in the nasal cavity is desirable. 
This, in turn, is heavily dependent on the selection of formulation design and the 
components. Reports suggest that drug administered as solid powder is likely retained at 
the deposition site longer than corresponding aqueous solution. Prolonged tres increases 
the contact time between the formulation and the nasal mucosa, which can result in 
increased absorption and enhanced bioavailability. Use of mucoadhesive polymers has 
also shown promise in increasing nasal retention time. The cross-linking between 
polymer and components of nasal mucus presumably increases the viscosity of the 
mucus, and eventually decreases the rate of clearance. This, in turn, may enhance nose-
to-CNS drug uptake.26-29  
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Several mucoadhesive polymers are commonly used as permeation enhancers. 
These can act by one or more of the following mechanisms: 
 Alteration of the physical properties of the olfactory membrane 
 Transient opening of tight junctions between epithelial cells 
 Inhibition of P-gp drug efflux transporters 
 Increasing membrane fluidity by extraction by creating disorder in the 
phospholipid domains of the membrane 
For targeted nose-to-CNS delivery, these excipients may be most favorable for the 
molecules that lack adequate permeability (BCS Class III, IV) and are often dismissed as 
viable development candidates.  
Other than increase in the residence time, nasal powders offer the advantages of 
stability (chemical and microbiological) and patient safety (lack of preservatives). There 
is a great deal of interest in the pharmaceutical industry to develop solid dosage forms 
that can be administered nasally with a state-of-the-art delivery device. Currently, we are 
far from having a well-optimized solid drug product with exclusive delivery to the 
olfactory region. But some underlying trends suggest that specific control over particle 
size distribution (PSD) could be significant. Typically, microparticles in the size range of 
10 – 45 m provide nasal deposition profiles favorable for nose-to-CNS delivery.30 
Proper identification of manufacturing processes which can easily and reproducibly 
generate microparticles in the desired size range is crucial to the success of this 
formulation platform.  
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Traditionally, dry powder formulations with nasal or pulmonary therapeutic 
application are prepared by mixing micronized drug particles (1 – 5 m) with larger 
carrier particles.31 The inter-particle force is relatively weak which may promote 
segregation of components upon insufflation. To avoid this, it is imperative to combine 
the ingredients of the formulation as solid composites that can potentially withstand the 
agitation of pressurized delivery. Often, binary solid composites such as eutectics and 
amorphous solid dispersions, are considered as enabling technologies for low solubility 
drug candidates.32 However, with adequate modifications, the application of these solid 
composites can be expanded to low permeation molecules that necessitate specialized 
route of administration.  
 
1.2. Hypothesis and research objectives 
The central hypothesis of this dissertation is that direct deposition of solid 
microparticles containing a low permeation drug alone or as a composite with a 
permeation-enhancing polymer, will enhance mass transport across olfactory 
epithelial tissue relative to aqueous drug solution. 
In order to test this hypothesis, the following research objectives were proposed and 
executed: 
1. An excised epithelial tissue permeation model that is simple yet translatable to 
humans was identified. To test the usability of this model, L-DOPA epithelial 
transport was measured when given as aqueous solution and standalone solid 
microparticles.  
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2. Consistent with regulatory guidance on the use of polymorphic solid materials 
in drug products,33 a thorough characterization of the relevant solid forms of 
ribavirin was undertaken. It was expected that this would enable selection of 
appropriate micronization equipment and procedures to avoid process-induced 
polymorphic conversion during composite microparticle preparation. 
3. Binary composite solid microparticles of ribavirin and a permeation-
enhancing polymer were prepared, characterized and evaluated for toxicity, 
drug release and permeation in vitro. Collectively, these data provided 
sufficient evidence regarding effective IN delivery of ribavirin. 
 
1.3. Nasal cavity 
Drug deposition and clearance are heavily influenced by nasal anatomy and 
physiology. The anatomical features of the olfactory mucosa important for nose-to-CNS 
delivery are detailed throughout the literature.6,9,18 
The mammalian nasal cavity has three distinct functional regions: vestibular, 
respiratory, and olfactory. The vestibular region opens to the outside at the nares and 
provides protection by filtration of airborne particles. The respiratory region constitutes 
the inner part of each nasal cavity, including three lateral turbinates (or conchae) on the 
lateral sides of the cavity and the nasal septum on the medial side of each nostril (Figure 
1.1).  
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Figure 1.1. Schematic representation of the lateral wall of the human nasal cavity. The 
boxed region delineates the olfactory region.30 
 
1.3.1 Respiratory region 
The respiratory epithelium covers approximately 50% of the nasal cavity in rats 
and 80–90% in humans.34 The human respiratory epithelium is comprised of goblet cells, 
ciliated cells, intermediate cells, and basal cells. Primarily, goblet cells secrete mucus, 
which covers the entire respiratory region (~10 µm thick) with a lower sol layer and an 
upper gel layer. The normal pH range of nasal mucus is approximately 5.5-6.5; however, 
the nasal mucosa tolerates solutions having a pH range of 3-10.35 The ciliated cells 
project hair-like protrusions from the surface, which beat very rapidly in synchronized 
fashion. In humans, the ciliary beat frequency is 1000 strokes per minute resulting in an 
average nasal clearance rate of 8 mm/min.36 Consequently, nasal mucus is propelled 
towards the nasopharynx where it is either swallowed or expectorated. The presence of 
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dense microvilli on the epithelial cells, combined with high vascularization of this region, 
makes it suitable for systemic drug absorption.  
1.3.2 Olfactory region 
The olfactory region (also known as the olfactory mucosa) is located within the 
recesses of the skull, just under the cribriform plate of the ethmoid bone, approximately 7 
cm from the nostril, at the roof of the nasal cavity, lying partly on the nasal septum and 
partly on the superior turbinate (delineated in Figure 1.1). The surface area of the 
olfactory mucosa in humans is estimated at 10 cm2.37 Conversely in dogs, this region 
constitutes 150 cm2, indicating the importance of olfaction in the daily functions of dogs, 
unlike humans. 
The olfactory mucosa is comprised of three cell types: olfactory receptor cells 
(also called olfactory receptor neurons, or ORN), supporting epithelial cells, and basal 
cells (Figure 1.2). The ORN are bipolar neurons with a spherical cell body. A single 
dendritic process extends from the cell body to the free apical surface (lumen of the nasal 
cavity) where it terminates as a small knob-like swelling. This, in turn, bifurcates into 
numerous long fibers and modified cilia. On the end of CNS, the ORN taper into an 
unmyelinated axon, which penetrates the basal membrane to join other axons and form 
large bundles in the lamina propria. The axons cross into the cranial cavity through small 
holes in the cribriform plate and synapse in the olfactory bulb, thereby establishing a 
direct anatomical connection between these two regions.  
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Figure 1.2. Anatomical representation of olfactory epithelium. Yellow dashed line (----) 
indicates the paracellular pathway, purple dashed line (---) indicates the transcellular 
pathway and the red dashed line (---) represents the transneuronal pathway.30 
 
The cilia on the ORN are different from those on the respiratory epithelium,36 and 
exist as three distinct, ciliated sub-regions: mobile, non-mobile, and intermingled. The 
combination of ciliated sub-regions disturbs the systematic beating of the cilia, thereby 
reducing the mucus clearance rate to 1-2 mm/h, which is ~240 times slower relative to 
the respiratory region.9,36 This potentially allows for greater retention of IN formulations 
in the olfactory region.  
Previously, it was believed that drug transport from the nasal cavity to the CNS 
was mediated directly by the ORNs (neuronal pathway), through the supporting epithelial 
cells (epithelial pathway), or between the epithelial cells in the olfactory region 
(paracellular pathway) (Figure 1.2). However, CNS entry may also occur through cells 
outside of the olfactory region, such as the trigeminal nerves that innervate different 
 10 
regions of the nasal mucosa. It has also been shown that transporter systems in the 
olfactory region have a role in drug uptake. Co-administration of transporter-efflux 
inhibitors resulted in enhancement of drug absorption in the CNS.38,39 Other plausible 
mechanisms for nose-to-CNS transport are discussed in the comprehensive work by 
Dhuria et.al.9 It is likely that multiple pathways are responsible for drug uptake into the 
CNS, although one pathway may predominate depending on the properties of the 
therapeutic, characteristics of the formulation, and delivery device used. 
1.3.3. Evidence of nose-to-CNS pathway 
It is well known that the euphoria derived from sniffing cocaine occurs rapidly 
(within 3–5 min). It has been suggested that the reason, apart from a rapid nasal 
absorption, is the presence of a direct pathway from the nasal cavity to the CNS and the 
ability of the drug to concentrate selectively in specific regions in the brain. Various 
animal studies have confirmed that, at early time points after nasal administration, the 
concentration of cocaine in the brain was higher with IN administration relative to IV, 
thereby showing the existence of the pathway from nose-to-brain.40,41  
Okuyama42 was the first to attempt a direct assessment of nose-to-brain transport 
of compounds in humans. Using a radiotracer 99m-technetium-labelled 
diethylenetriamine-penta acetic acid (99mTC-DTPA) mixed with hyaluronidase sprayed 
deep into the nasal cavity; gamma-scintigraphy was used to record the amount of activity 
appearing in the intracranial space. A significant rise in cerebral radioactivity was 
observed 5 min after introduction of the nasal spray. In another example, it was shown 
that 27-times higher [3H]-dopamine reached the olfactory lobe after nasal administration 
relative to intravenous injection in rodent model.43 Fehm44 reported a significant 
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accumulation of insulin in the CSF after a single nasal administration of 40 IU insulin, 
whereas no increase was seen in insulin plasma levels.  
Evidence of direct nose-to-brain transport of drugs has also been gathered in 
humans, mostly in terms of pharmacodynamic effects on the CNS, comparing drug 
administration via nasal and intravenous routes of delivery.45 A list of the drugs studied 
in humans is given in Table 1.1.  
Table 1.1. Drugs used in nose-to-CNS drug transport studies in humans.45 
Functional evidence in man of facilitated transport to the brain was provided by changes 
in event related potential during performance of an oddball task 
Arginin-vasopressin (n=15) 
Cholecystokinin-8 (n=20) 
Angiotensin II (n=12) 
Adrenocorticotropin 4-10 (n=54) 
Insulin (n=12) 
 
1.4. Factors influencing nasal absorption 
Whether a drug is nasally administered to induce systemic or CNS effects, 
absorption from the nasal mucosa is a pre-requisite for successful delivery. Several 
physiological and physicochemical factors play a crucial role in determining the rate and 
extent of nasal absorption. 
1.4.1. Physiological considerations 
1.4.1.1. Targeted deposition 
For desirable therapeutic outcomes, it is essential to target an appropriate 
deposition site for inhaled particles. Locally acting drugs are best targeted to the middle 
meatus,46 while the turbinates and septum wall are best for systemic delivery owing to 
efficient drug absorption.6 Deposition on the anterior portion of the nose typically 
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provides a longer nasal residence time; however, this region is not amenable to 
permeation and thereby nasal absorption. In contrast, deposition of formulations in the 
posterior chamber of the nasal cavity enables greater uptake but is subjected to rapid 
mucociliary clearance, which ultimately limits nasal absorption. For direct nose-to-CNS 
transport, the olfactory region is the best target.47  
From a mechanistic standpoint, inertial impaction and gravitational sedimentation 
predominantly govern deposition of pharmaceutical materials.48-52 Briefly, turbulent 
airflow is needed to displace the relatively stagnant air volume in the upper nasal cavity 
in order to allow impaction of mucosa with drug particles.53 Reports suggest that the 
choice of dosage form (drops versus sprays) and the physical properties (particle size and 
size distribution, plume angle, and plume velocity) play a crucial role in determining the 
extent of nasal deposition targeted specifically to the olfactory region. These are 
discussed in later sections. 
1.4.1.2. Mucociliary clearance 
Mucociliary clearance is a natural phenomenon that protects the lungs from 
foreign particles. When allergens, microbes, toxins, etc. adhere to, or dissolve in the 
mucus of the nasal cavity, they are transported towards the nasopharynx for eventual 
discharge into the gastrointestinal tract (GIT). Mucociliary clearance results from the 
coordination between the overlying mucus and the wavelike movement of the cilia, 
therefore, the efficiency depends on the length, density and beat frequency of cilia as well 
as the amount and viscoelastic properties of the mucus. Clearance rates may vary owing 
to any environmental or pathological factor that alters mucus production, mucus viscosity 
or ciliary beat frequency. Increase in body temperature and cigarette smoking has shown 
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decrease in clearance rates possibly from dehydration of mucus layer and/or impaired 
cilia.54 The effects of disease conditions on normal mucociliary clearance rates are 
summarized in Table 1.2.  
Table 1.2. Pathological conditions and their impact in nasal mucociliary 
clearance.54,55 
 
Pathological conditions Effect on mucociliary clearance and reason 
Ciliary dyskinesia Impaired: absence or dyskinetic beating cilia 
Asthma Increased: inflammatory process and irritation  
Decreased: epithelial damage 
Cystic fibrosis  Decreased: dehydration of mucus 
Viral and bacterial 
infections 
Impaired: loss of cilia and change of mucus properties 
Diabetes mellitus Decreased: dehydration and microvascular damage 
 
Theoretically, the mucus layer is transported at 5 mm/s and renewed every 10-20 min,37 
which can reduce total absorption of the intranasally deposited drug. Slow clearance 
allows increased time of contact between drug molecules and the mucosal layer and 
subsequently enhances nasal absorption. 
 Clearance of a drug formulation can be influenced by its deposition site. 
Fortunately, ciliated epithelium is not uniformly located across the nasal cavity. While 
the middle and posterior turbinates are covered with ciliated epithelium, cilia are mostly 
absent from the anterior regions. Differences in ciliation significantly changes the 
clearance kinetics for particles deposited in different regions, and in turn alters tres. This is 
perhaps the reason for the biphasic clearance pattern observed for inhaled particles in 
human studies.49,56,57 Initially, particles deposited in the ciliated regions of the posterior 
nasal cavity were rapidly cleared, followed by a comparatively slower secondary 
clearance attributable to particles deposited on the non-ciliated anterior region of the 
nose. While ciliary movement is the primary mechanism for clearance from the 
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respiratory region, the presence of non-mobile cilia in the olfactory region makes it most 
likely that the upright position of the human head results in the removal of mucus in this 
region due to gravity.26 This may provide an opportunity for decreased mucociliary 
clearance and enhanced direct nose-to-CNS uptake for a drug formulation targeted for 
deposition in the olfactory region.  
1.4.1.3. Enzymatic degradation 
Even though nasally administered drugs are thought to avoid first-pass heaptic 
metabolism, the bioavailability of nasally administered drug molecules and proteins can 
be limited by a spectrum of metabolic enzymes localized in the nasal mucosa.  
Carboxyl esterases, aldehyde dehydrogenases, epoxide hydrolases and glutathione S-
transferases have been found in nasal epithelial cells.58,59 Cytochrome P450 isoenzymes 
expressed in the nasal mucosa are also reported to limit absorption of drugs such as 
cocaine, nicotine, alcohols, progesterone and decongestants.59 Likewise, proteolytic 
enzymes (aminopeptidases and proteases) reported to impede intestinal uptake of 
peptides such as calcitonin, insulin and desmopressin are also expressed in nasal cells.59 
Xenobiotic metabolizing enzymes may affect the pharmacokinetic and 
pharmacodynamic profiles of drugs administered intranasally.  It is important to 
acknowledge that several pathological conditions, including the common cold, nasal 
polyps, and rhinitis may alter the relative expression of xenobiotic enzyme, thereby 
influencing nasal absorption.  
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 1.4.1.4. Nasal permeation 
For successful nose-to-CNS delivery, it is of utmost importance that the drug 
molecule demonstrates a balanace of solubility in the mucus layer and permeation across 
the olfactory epithelium. Lipophilic drugs such as propranolol, progesterone and fentanyl 
are, in general, well absorbed from the nasal cavity, presenting pharmacokinetic profiles 
similar to those obtained after intravenous administration with a nasal-to-systemic uptake 
near to 100%.60 However, it is important to note that this is predominantly true for 
lipophilic compounds presenting a molecular weight <1 kDa. The extent of nasal 
absorption for lipophilic drugs >1 kDa is significantly reduced.61 The nasal membrane is 
predominantly lipophilic, hence, drug absorption is expected to diminish with a decrease 
in lipophilicity. The rate and degree of nasal absorption of polar drugs with molecular 
weight higher than 300 Da is notoriously low.38,61  
For some small polar molecules, a bioavailability of only 10% may result. 
Furthermore, polar drugs are more likely to be affected by mucociliary clearance, owing 
to greater solubility in the nasal fluid. Thus, it is evident that polar drugs are not easily 
transported across nasal mucosa, and necessitate formulation strategies that reduce 
clearance rates. The apparent distribution coefficient (K’) is also an important factor 
influencing the permeability through nasal mucosa. This depends on both the drug pKa 
and the pH at the absorption site (estimated to be 5.0-6.5 in human nasal fluid). 
According to the pH-partition theory, a biological membrane is more permeable to the 
non-ionized fraction of a drug relative to the ionized fraction, therefore, it can be assumed 
that the nasal absorption of weak electrolytes depends on the extent of their ionization, 
with the most rapid absorption occurring for the unionized species. It is notable, however, 
 16 
that drugs such as acetylsalicylic acid and bucolome have been observed to be well 
absorbed across the nasal membrane, even in environments in which they were expected 
to be primarily ionized.62, 63 Further, multidrug resistance transporters have been 
identified in human nasal respiratory and olfactory mucosa, which may be involved in the 
transport of a wide variety of hydrophilic and amphiphilic drugs.60   
1.4.2. Formulation / Dosage form considerations 
1.4.2.1. Nasal drops and sprays 
 
Liquid formulations are commonly used for IN delivery. Common drawbacks 
associated with liquid formulations, such as drug substance aqueous solubility, chemical 
stability in a liquid vehicle, and formulation sterility should, however, be considered. 
Additionally, most liquid formulations require preservatives, which have demonstrated 
ciliotoxic effects in animal models following chronic use.64,65 Nonetheless, controlled 
volumes of formulated solutions can be easily delivered into the nasal cavity as sprays or 
drops, making them attractive as a delivery system. The differences in deposition pattern 
and clearance kinetics for these dosage forms merit particular attention. 
The type of liquid dosage form selected heavily influences deposition and 
clearance. Drops are one of the oldest delivery methods for nasal administration of 
liquids. Despite being relatively inexpensive and easy to manufacture, their main 
disadvantage stems from the complex maneuvers of the delivery device for effective 
administration. Several papers have highlighted the difficulty of identifying a single “best 
technique” for the administration of nasal drops.66-68 There is tremendous variability in 
deposition and clearance owing to varied administration procedures, anatomy, and head 
position. Generally, drops tend to be deposited in the posterior region over a larger area 
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in the respiratory epithelium, with minimal (or no) deposition in the olfactory region.  As 
a result, drops are cleared more rapidly than sprays.56,69-71 Moreover, slight changes in 
dosing volume in nasal drops can lead to erratic pharmacokinetic profiles and strict 
patient compliance becomes necessary.67  
Given the advantages of dosing precision and reproducible droplet size 
characteristics, nasal sprays are most widely used for IN delivery of solutions and 
suspensions. The diversity of pump choices and actuator fittings makes these sprays 
suitable for targeted, region-specific nasal delivery. Mechanistically, metered sprays 
build hydraulic pressure in the metering chamber upon compression of the pump, which 
when it reaches an adequate level, pushes the liquid formulation out of the small orifice at 
the tip of the actuator. Shear forces and surface tension act upon the formulation, 
converting the liquid stream into a plume with unique geometric and droplet properties. 
1.4.2.2. Nasal powders 
Although dry powders benefit from improved chemical and microbiological 
stability relative to solutions, they are less frequently used for IN drug delivery. In 
addition to better stability, nasally administered solid particles may also result in better 
patient compliance, especially for children if the smell and taste of the drug in solution or 
suspension is unacceptable. Most powder formulations do not require preservatives, 
which have demonstrated ciliotoxic effects in animal models following chronic use.64,65 
Furthermore, powders allow delivery of the highest mass of active ingredient without the 
necessity of a liquid vehicle or propellant, making for simpler formulations. Nonetheless, 
nasal powder formulations should allow for reproducible dose delivery, which is 
ultimately governed by several physical attributes such as particle shape, particle size and 
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size distribution, bulk density, hygroscopicity and flow properties. Furthermore, these 
formulations should also be appropriate for aerosolization to allow targeted nasal 
deposition and distribution. 
Through in vitro and in vivo comparisons of IN delivered dry powder and liquid 
formulations, it is generally held that solid particles deposit locally in the nasal cavity, 
providing higher concentrations at the deposition loci, which combined with improved 
residence time, affords higher bioavailability relative to liquids. The reason for this 
advantage may be associated with the un-hydrated state of any solid dosage form.57 At 
the deposition sites, the powder is hydrated owing to the presence of water in the nasal 
mucus, but at the cost of dehydration of the latter. Consequently, sporadic regions having 
increased local viscosity are generated, which may increase resistance to the ciliary beat, 
in comparison to an equivalent solution form. Results of studies comparing drug 
uptake/bioavailabilities from different dosage forms are summarized in Table 1.3. Since 
most of these studies were pursued for systemic delivery, additional research efforts 
focusing on nose-to-CNS transport are warranted to determine full potential of solid nasal 
carriers.
 19 
Table 1.3: Comparison of liquid and powder formulations for nasal deposition and 
clearance. 
 
Drug of interest Model Observation and inference 
Insulin72 Beagle dogs Crystalline insulin provided higher 
hypoglycemic effect relative to insulin 
suspension (pH 5.8) at a similar dose of 5 IU/kg 
 
Insulin + dimethyl-β-
cyclodextrin 
(permeation enhancer – 
1.9 µmol/dose) 73 
Rabbits Use of freeze dried powder formulation resulted 
in higher systemic bioavailability of insulin (~ 
13%) compared to same formulation as solution 
(~ 1%) at a consistent dose of 4 IU/rabbit 
 
Calcitonin and 
Glucagon74 
Human Administration of spray solution and powder did 
not give significantly different (p < 0.001) 
absorption profiles 
 
Dihydroergotamine 
(DHE) combined with 
randomly methylated-
β-cyclodextrin 
(solubilizer – 10 
mg/kg)75 
Rabbit DHE serum bioavailability with nasal powder 
(56%) was not significantly enhanced (p > 0.05) 
relative to liquid spray form (44 - 50%). DHE 
was administered at 0.1 mg/kg for all 
formulations 
 
Ribavirin22 Rat Concentration in the olfactory bulb was > 3-fold 
higher for  dry powder relative to aqueous 
solution 
 
Cromoglycolate loaded 
in polymeric 
microsphere system76 
Human Small volumes of liquid or powder particles 
have almost the same clearance rate in the 
absence of bioadhesive excipients. However, in 
the presence of bioadhesive excipients, solid 
formulations cleared slower. 
 
Chitosan57  Sheep Clearance time of chitosan solution and chitosan 
microspheres was 43 min and 115 min 
respectively. 
 
1.4.2.3. Physical properties 
Although estimates of particle sizes (PS) have shown that droplets or particles 
having aerodynamic diameters of ~5 µm typically deposit in the upper respiratory tract, 
the latest FDA guidance for nasal devices recommends minimizing the fraction of 
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respirable particles below 9 μm in order to avoid lung inhalation.77 With PS increased 
>10 µm, total nasal deposition was shown to effectively increased to ~100%.78 More 
detailed analyses of sub-regional nasal deposition (especially olfactory region) are less 
common, but can be helpful for optimizing drug product characteristics.  
Physical properties of IN liquid formulations, particularly droplet size, have a 
significant influence on the deposition pattern, with droplet diameters >20 µm resulting 
in ~100% nasal deposition.70,79 Analysis of sub-regional deposition suggests that larger 
droplets primarily deposit in the anterior or vestibular regions (Dv50 = 40 µm),
79 leaving a 
significant portion of the nasal cavity unexposed to the drug. Among other relevant 
physical properties, plume angle and spray velocities have shown to heavily influence 
sub-regional nasal deposition.80,81   
For powder formulations, a study was attempted to identify the optimum particle 
size range needed to maximize total and regional deposition in the nasal cavity. Briefly, 
different size ranges of β-cyclodextrin powder were released in the silicone nasal cast and 
evaluated for distribution upon aerosolization.82 In these experiments, particles up to 45 
µm provided a more uniform covering of the nasal surface, whereas larger diameter 
particles (125-250 µm) were found to be sparsely distributed. 
Computational fluid dynamic (CFD) modeling has been used to augment inertial 
impaction and gravitational sedimentation, and help identify factors that potentially affect 
nasal deposition. Garcia and Kimbell83 developed a CFD model of a rat nose for 
quantifying the deposition of inhaled nanoparticles into the rat olfactory region at 
different particle sizes (1-100 nm) and airflow rates. The simulations indicated a strong 
influence on PS with a 6-9% of the inhaled dose as the maximum deposition achieved in 
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the olfactory region for 3-4 nm particles. Although this study focused on 
pharmaceutically impractical PS range, this study suggests that human CFD models could 
be generated for predicting the fraction of olfactory deposition as a factor of physical 
properties. 
1.4.2.4. Mucoadhesives 
As discussed earlier, MCC is one of the most important factors limiting nasal 
absorption owing to reduction in the time allowed for drug uptake. Intuitively, therefore, 
nasal absorption can be improved by prolonging the contact time between drug and 
mucosal membrane. In this regard, mucoadhesive drug delivery systems have been 
developed for IN delivery. Use of polymeric ingredients, among others, in the dosage 
form markedly reduces the rate of MCC. Several theories have been proposed to explain 
the mechanism of polymer–mucus interactions that lead to mucoadhesion.84 The most 
commonly accepted theory includes intimate contact between polymer and the biological 
tissue followed by wetting of the polymer chains. Subsequently, cross-linking between 
polymer and mucus occurs. This increases the viscosity of the mucus, and eventually 
decreases the rate of mucociliary clearance. Therefore, it is logical that changes in 
polymer properties, such as surface roughness, work of adhesion, hydration potential, 
molecular mass, cross-linking density, ionic strength, pH, and surface charge can 
considerably alter the extent of mucoadhesion. 
In an recent example, Charlton et al. compared the abilities of several polymeric 
formulations to reach the olfactory region and increase the residence time on the 
epithelium.26 Different bioadhesive formulations were prepared using polymers such as 
pectin and chitosan, the amount of which was determined based on ease of delivery of the 
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final solution from the nasal delivery devices and adequate gelling characteristics at nasal 
physiological conditions. Distribution and clearance of the formulation from the olfactory 
region was assessed by taking photographs over time using endoscopy. From these 
studies, the authors concluded that all bioadhesive formulations were retained on the 
olfactory epithelium for more than four times longer than relative control solutions (See 
Figure 1.3).  
 
Figure 1.3. Tres for each formulation averaged over the whole test group. Error bars 
represent the S.E.M., n = 12. There was no statistical difference between the average Tres 
values for each polymer formulation. Reprinted from European Journal of 
Pharmaceutical Sciences, 30, S. Charlton, N.S. Jones, S.S. Davis, L. Illum, Distribution 
and clearance of bioadhesive formulations from the olfactory region in man: Effect of 
polymer type and nasal delivery device, pp:295-302, Copyright 2007, with permission 
from Elsevier. 
 
Likewise for polymeric solid microparticles, Tafaghodi et al. compared the 
clearance rates to highlight the importance of selecting the correct polymer for an 
optimum nasal absorption. Briefly, technetium-labeled microspheres of PLGA, alginate, 
Sephadex® and lactose were prepared and administered to healthy human volunteers. The 
clearance rates were compared using two regions of interest; the initial site of deposition 
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and the nasopharynx. Alginate and PLGA microspheres showed the lowest clearance rate 
compared to lactose powder (p < 0.0001 and p < 0.001) respectively.85   
In a recent clinical study, the plasma area under the curve (AUC) of desmopressin 
acetate following administration of a nasal powder formulation was increased 3-fold in 
the presence of sodium starch glycolate (SSG).86 The drug was homogenously distributed 
on SSG microparticles and, owing to complete hydration of this carrier material, 
increased release and absorption of the active drug was expected. In another study, it was 
concluded that a lyophilized insulin powder combined with Carbopol® 934 resulted in the 
highest systemic absorption of insulin relative to other formulations.87 The authors 
explained that the gelling of Carbopol® 934 following hydration may have led to longer 
adhesion with the nasal mucosa, thereby allowing more time for enhanced insulin 
absorption.  
1.4.2.5. Permeation enhancers 
The key to successful nose-to-CNS delivery, however, is not only an increase in 
nasal residence time but also increased CNS uptake of drugs. Hydrophilic drug molecules 
may poorly permeate the nasal epithelium and, thereby, exhibit insufficient 
bioavailability. It is possible to greatly improve their absorption by combination with 
absorption enhancers which induce transient modifications on the structure of epithelial 
barrier. In IN delivery, the most widely used absorption enhancers include surfactants 
(laureth-9), bile salts, fatty acids (taurodihydrofusidate) and polymers (chitosan, 
cyclodextrins, poly-L-arginine, polyethylene glycol and polyoxyethylene).26,88-90 The 
mechanism of action of these permeation enhancers is not well known but they typically 
alter the permeability of epithelial cell layer by modifying the phospholipidic bilayer, 
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increasing membrane fluidity or opening tight junctions between epithelial cells and, 
thus, increasing paracellular transport.91 Although the absorption promoters enhance drug 
bioavailability, chronic use may damage the integrity of the olfactory membrane which 
should not be overlooked. 
Recently, Vaka et al. demonstrated that formulations containing chitosan 
glutamate enhanced the hippocampal bioavailability of IN administered nerve growth 
factor (NGF) solution up to 14-fold.92 This observation was attributable to the permeation 
enhancement of chitosan, which transiently opens tight junctions between the olfactory 
epithelial cells. In another study, an alternative strategy involved conjugation of 
therapeutic agents with receptor-targeting moieties, which showed promising results for 
direct CNS uptake.93  For example, the olfactory bulb concentration of 1.0% horseradish 
peroxidase (HRP) protein was almost 700 times (p < 0.001) higher when conjugated with 
wheat germ agglutinin (WGA) relative to HRP itself.  It was hypothesized that WGA 
conjugation provided accessibility to receptor mediated endocytosis into olfactory 
sensory neurons. Subsequently, a fraction of the internalized protein transcytosed to axon 
terminals in the olfactory bulb. Such strategies can open possibilities of nose-to-CNS 
transport for other therapeutic agents used in neurodegenerative diseases. Use of chitosan 
glutamate (CG) as both a mucoadhesive agent and a permeation enhancer has shown 
exciting results for nose-to-CNS delivery of zolmitriptan, an anti-migraine drug. 
Microparticles (2.7 – 9.4 µm) of 1:1 drug:polymer ratio were prepared through spray 
drying process and assessed for ex vivo permeation enhancement and adhesiveness.94 
Although, the formulation showed comparable mucoashesion relative to drug alone (p < 
0.05), the drug permeation was increased by 28% for the CG containing microparticles as 
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compared to the spray dried drug (p < 0.05). When the authors compared the CSF 
concentrations of zolmitriptan following nasal administration as suspension versus drug-
loaded chitosan-based microparticles, the solid formulation resulted in a modest 1.6-fold 
increase in drug in the CSF, verifying that polymers helped enable CNS targeting of the 
drug. In a similar study, the CSF-to-blood ratio of an anti-ischemic agent was 
respectively 4.3 and 57.5 for mannitol-lecithin and chitosan-loaded microparticles. The 
CSF concentration of the same drug through nasal suspension, however, was 
undetectable at the same dose.95 
1.4.3. Delivery device considerations 
There are a wide variety of delivery devices available for IN delivery of powders. 
Correct choice of delivery device is important because differences in actuation pressure 
and device tip dimensions can affect both the volume of the emitted dose and its nasal 
deposition pattern.96-100 Pringels et al. studied the effect of delivery devices on deposition 
patterns of dry powder formulations.101 In their work, a silicone human nose model was 
insufflated with freeze-dried, radiolabeled lactose powder from three different devices: 
the Monopowder P® system, the Pfeiffer system, and an experimental device developed 
in-house. Of these, the Monopowder P® system showed the greatest deposition near the 
upper turbinate region, whereas the experimental device resulted in highest deposition in 
the anterior regions of the nasal cavity. Administration using the Pfeiffer system resulted 
in homogenous distribution throughout the nose, which led to faster clearance. The 
authors controlled both size fraction and bulk density of the powders; however, device-
specific comparisons of airflow velocity at the time of actuation, administration angle, 
and device insertion depth were less clear. Additionally, an explanation for the 
 26 
differences in deposition behavior between delivery devices was not provided, making it 
difficult to identify the particular device attributes that favor site-specific deposition. 
Such parameters can alter the deposition site, as described in a study investigating overall 
nasal deposition of budesonide powder from a unique breath actuated delivery device 
(Turbuhaler®).102 
In 2006, Djupesland et al.97 developed the OptiMistTM device, a modified version 
of the traditional nasal spray that allowed penetration of the emitted dose beyond the 
anterior region of the nasal cavity, which had previously been a substantial challenge. 
This device utilizes the positive dynamic pressure of exhalation, which expands the 
narrow nasal passages, allowing the inhaled particles to reach the posterior regions of the 
nasal cavity. The results of a study comparing nasal deposition and clearance of drug 
administered from the OptiMistTM device with a traditional nasal spray were highly 
promising. Human volunteers were administered technetium labeled saline using both 
devices on separate days. The devices were characterized for the reproducible dose 
volume and droplet size (48 μm). Both delivery technique and head position of the 
volunteers were kept constant for all administrations. Regional deposition analysis 
indicated that the OptiMistTM device delivered more than 70–80 % of the dose beyond the 
anterior region when compared with the traditional nasal spray device. Additionally, the 
OptiMistTM device provided ∼3× more deposition in the upper posterior region of the 
nasal cavity, which houses the olfactory region (p < 0.004). Although a major fraction 
(about 50%) of the OptiMistTM deposited in this region was cleared within 6 min of 
administration, it can be anticipated that the use of bioadhesive components in the 
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formulation will increase the residence time in the olfactory region to improve CNS 
uptake. 
 Recently, the regional human nasal deposition and clearance patterns of lactose 
powder delivered by the breath actuated bi-directional powder device (OptiNoseTM) were 
compared with those from a traditional liquid nasal spray (droplet size = 48.5 μm).103 
Radiolabeled lactose powder (d10 = 3 μm, d50 = 15 μm, d90 = 38 μm) was delivered 
through the breath-actuated powder device. The method of administration and head 
position of the volunteers were kept consistent between two methods. Upon 
administration, gamma scintigraphy images were collected for studying nasal deposition 
and clearance. Results showed that both powder and spray were distributed to all nasal 
regions. However, in the upper posterior region, which is of concern to nose-to-CNS 
transport, the initial deposition of OptiNoseTM powder was approximately nine times 
higher than the traditional spray (See figure 1.4).  
  
2
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Figure 1.4. Gamma camera image information from the nasal cavity is superimposed on the corresponding sagittal MRI section. The 
images are from the same subject and present deposition 2 min after delivery using (a) a traditional liquid spray, (b) the breath-
powered Opti-Nose™ powder device, and (c) the breath-powered Opti-Mist™ liquid spray device incorporating the same spray pump 
as used in a. The initial deposition following traditional spray was greatest in the lower anterior regions of the nose, whereas 
deposition with the breath-powered delivery devices was greatest in the upper posterior regions of the nose. The less broad distribution 
in b following breath-powered Opti-Nose™ powder device is believed to be due to the slower clearance for powder the first 6–8 min, 
reflecting the dissolution of the powder into the mucosal layer.23 
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Currently, it is difficult to make conclusions regarding the relative performance of 
breath-actuated novel devices, namely, OptiMistTM and OptiNoseTM, despite similar 
underlying mechanisms. Due to the inconsistency of formulation ingredients and 
essential physical properties such as particle size and particle density in the present data, 
supplementary studies to overcome these differences can greatly substantiate it. 
Nevertheless, it is encouraging to observe that the remarkable influence of delivery 
devices on olfactory deposition. Presently, this novel device is being studied for delivery 
of sumatriptan and fluticasone for migraine and chronic rhinosinusitis, respectively.  
In another study, a pressurized olfactory device (POD) consistently delivered a 
majority of its dose to the olfactory region of adult rats.104 Pressurized nitrogen was 
mixed with a dye solution to create an energetic aerosol directed towards the roof of the 
nasal cavity. The insertion depth and dose volumes were well controlled from animal-to-
animal.  Qualitative deposition analysis suggested that the POD results in preferential 
localization in the olfactory region. To monitor nose-to-brain delivery, the dye solution 
was replaced with either radiolabeled mannitol (hydrophilic) or radiolabeled nelfinavir 
(lipophilic) liquid as model solutions. Following nasal administration, the radioactivity of 
samples was determined in excised brain tissues and blood. Using the POD, mannitol 
concentrations increased 25.6-fold (p < 0.05) in the olfactory bulb when compared with 
administration of drops. Similarly, nelfinavir concentrations were increased at the 
olfactory bulb (5.8-fold) and cortex (13.8-fold, p < 0.05). Further, the cortex-to-blood 
ratio for mannitol (3.6-fold, p < 0.05) and nelfinavir (13.6-fold, p < 0.05) increased with 
POD administration.  These results support the possibility of enhanced nose-to-brain 
transport with increased deposition in the olfactory region. 
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1.5. Chemical profile 
1.5.1. Levodopa 
      Levodopa (L-DOPA; L-3,4-dihydroxyphenylalanine) is an amino acid and 
precursor of dopamine, which remains the mainstay of treatment for Parkinson’s disease 
(PD). The molecular formula of L-DOPA is C9H11NO4 and its molecular weight is 197.2 
g/mol. L-dopa exists as zwitterions in solution, owing to the presence of an amine group 
(pKa 8.11) and a carboxylic acid group (pKa 2.30). The cLogP of L-DOPA
105 is -2.19 and 
this molecule demonstrates good aqueous solubility at 1.65 mg/ml (20 °C).106  
       L-DOPA crosses the BBB and is rapidly taken up by dopaminergic neurons and 
converted to dopamine (Figure 1.5) by the enzyme aromatic L-amino acid decarboxylase 
(DOPA decarboxylase). Consequently, moderate increases in the levels of dopamine 
alleviate the complications associated with PD. 
 
 
Figure 1.5. Chemical reaction showing (a) conversion of L-DOPA to dopamine (b) 
oxidation of L-DOPA to L-dopaquinone and (c) zwitterionic nature of L-DOPA between 
pH of 3 to 9.107 
 
  31 
 Traditional peroral L-DOPA therapy is limited by poor relative bioavailability of 
approximately 5-15%, with less than 1% of the administered dose reaching the brain.108 
For this reason, large peroral doses of L-DOPA are required for adequate therapeutic 
effect, which may often be accompanied with painful side effects such as motor 
fluctuations, dyskinesia, nausea and vomiting, some of which are attributable to 
dopamine formed in extracerebral tissues.109,110 Potential reasons for the low 
bioavailability of orally administered L-DOPA therapy include site-specific absorption of 
the drug in the duodenum, carrier-mediated active transport from the gut wall, extensive 
metabolism in the gastrointestinal tract and inter-individual variability in the degree of 
first-pass metabolism.108,111 
Recently, CNS targeting of L-DOPA was investigated in an aqueous solution 
through IN versus IV administration (Figure 1.6).20 The pharmacokinetic analysis 
showed that the amount of L-DOPA that reached the CNS was therapeutically 
ineffective.  
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Figure 1.6. Time courses of plasma and brain l-dopa concentrations following intranasal 
administration of l-dopa (2.5 mg/kg) in the presence and absence of C-dopa (0.63 mg/kg) 
(mean ± SD, n = 6). Reprinted from European Journal of Pharmaceutical Sciences, 38, 
Tae Kyung Kim, Wonku Kang, In Koo Chun, Seaung Youl Oh, Yeon Hong Lee, Hye 
Sun Gwak, Pharmacokinetic evaluation and modeling of formulated levodopa intranasal 
delivery systems, pp:525-523, Copyright 2009, with permission from Elsevier. 
 
 
This was attributable to the low aqueous solubility of L-DOPA, which restricted 
the amount of drug that could be loaded per dose volume. Furthermore, the fluctuations 
in CNS concentration of the drug suggested inconsistent delivery from liquid vehicles 
potentially due to rapid removal of the drug from the absorption site initiated by mucus 
turnover. In another study, water-soluble prodrugs of L-DOPA in liquid vehicles were 
formulated and the issue of solubility was minimized,106  however, IN administration of 
the prodrugs showed nearly complete absorption of the drug in the systemic circulation, 
defeating the purpose of nose-to-brain transport. This study also suggested the potential 
role of mucociliary clearance in limiting the nasal retention of aqueous formulations. 
Additionally, the chemical instability of the prodrugs in aqueous media, similar to the 
drug itself, limited the usefulness of this strategy. Based on these observations, it can be 
speculated that the use of solid platforms for intranasal delivery of this drug may be 
beneficial in addressing the aforementioned issues. 
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1.5.2. Ribavirin 
Ribavirin (1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide), an anti-viral 
drug, is a synthetic nucleoside analog structurally related to guanine. The molecular 
formula of ribavirin is C8H12N4O5 and molecular weight is 244.2 g/mol. The structure of 
ribavirin is shown in figure 1.7. 
 
Figure 1.7. Chemical structure of Ribavirin 
 
Ribavirin is a polar compound with clogP of -3.23 and an experimental logP 
(MlogP) reported as -1.85.112 Ribavirin is an ampholyte having both an acidic and a basic 
group, the pKa values of which are reported as 12.95 and 1.00 respectively for the acid 
and base.112 These values indicate that at most physiologically relevant pH values, the 
compound is unionized. 
Ribavirin is typically administered orally in doses of 400, 500, or 600 mg twice 
daily. It is rapidly absorbed into the systemic circulation, with the uptake mechanism 
being active transport by the human concentrative nucleoside transporter 2 (hCNT2) in 
the proximal small bowel. Saturable uptake of ribavirin in the human intestine is the most 
likely explanation for the observation that, at very high doses (1200-2400 mg), the 
maximal plasma concentration of ribavirin after oral administration of the drug does not 
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increase in proportion with the dose.113,114 The combined use of ribavirin and pegylated 
interferon-α is approved by the US Food and Drugs Administration (FDA) for treatment 
of hepatitis C in normal and HIV-infected individuals.115 According to the Essential 
Medicines List of the World Health Organization, ribavirin can also be used to treat viral 
hemorrhagic infections, such as Lassa fever and Crimean-Congo fever.116 Further, it is 
also used to treat respiratory syncytial virus infections in moderately to severely 
immunocompromised patients.117  
Despite demonstrating high antiviral activity in vitro against CNS-borne 
pathogens,118-120 the in vivo effectiveness of RBVN is restricted by its inability to cross 
the BBB. Studies reveal that intraperitoneal (IP), subcutaneous (SC) and intramuscular 
(IM) injections of RBVN were ineffective against several encephalitis viruses in 
mice.121,122 The drug improved the survival of subacute sclerosing panencephalitis 
(SSPE) in measles virus-infected hamsters only when administered intracranially (IC),122  
which, though effective, is not a route of administration amenable to patient self-
administration. For this reason, alternative means of administering RBVN or innovative 
formulation strategies are sought in order to increase the extent of drug that reaches the 
CNS. 
A recent study investigated distribution of ribavirin in the CNS after IN 
administration in the form of aqueous solution or powder at the same dose. IV solution 
was used as control group.  It was found that 20 min after administration, the 
accumulation of ribavirin in olfactory bulb was comparable between IV and IN solutions, 
whereas the powder led to significantly higher levels (figure 1.8).22 The extent of drug 
accumulation, however, was not enough to be efficacious. This supports the rationale that 
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solid nasal dosage forms have the ability to potentially deliver therapeutic quantities of 
drug to the CNS if formulated appropriately with permeation enhancing excipients. 
 
Figure 1.8. (a) Ribavirin brain concentrations after in vivo nasal administration of an 
aqueous solution (white bars) versus intravenous injection (gray bars). (b) Ribavirin brain 
concentrations after in vivo nasal administration of an aqueous solution (white bars) 
versus ribavirin powder (black bars). The measured values were normalized by the dose 
administered. OB: olfactory bulb; CTX Ant and CTX Post: anterior and posterior 
cerebral cortex; BG: basal ganglia; Hip: hippocampus; CSF: Cerebrospinal fluid. 
Reprinted from Antiviral Research, 92(3), Gaia Colombo,  Luca Lorenzini,  Elisa Zironi,  
Viola Galligioni,  Fabio Sonvico,  Anna Giulia Balducci,  Giampiero Pagliuca,  
Alessandro Giuliani,  Laura Calzà,  Alessandra Scagliarini, Brain distribution of ribavirin 
after intranasal administration, pp: 408–414, Copyright 2011, with permission from 
Elsevier. 
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1.5.3. Poloxamers 
Poloxamers, also known by trade names Pluronics® or Kolliphor®, are tri-block 
copolymers of poly(oxyethylene)–poly(oxypropylene)–poly(oxyethylene). They are 
predominantly used as surfactants, solubilisers, wetting agent for microemulions and as 
drug reservoir post micellization. All Pluronics® have similar chemical structures but 
with different molecular weights and composition of the hydrophilic PEO block (a) and 
hydrophobic PPO block (b) (shown in figure 1.9).  
 
Figure 1.9. General chemical structure of Poloxamers® or Pluronics®. 
 
 
For pharmaceutical applications, two of the most commonly used grades of 
Pluronics® are F-68 (also referred as Poloxamer 188; a=80, b=27) having an average 
molecular weight of 8400 Da, and F-127 (or Poloxamer 407; a=101, b=56) having an 
average molecular weight of 12200 Da. These polymers exhibit inverse 
thermosensitivity; therefore, they are soluble in aqueous solutions at low temperature, but 
gel at higher temperatures. 
Pluronics® are widely used in drug delivery owing to the relatively low toxicity 
and potential for permeation enhancement. For hydrophilic drug molecules, these 
copolymers have been shown to promote permeation via inhibition of the P-gp and MRP 
mediated efflux.123-6 For lipophilic molecules, however, the process of permeation may 
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be facilitated by adsorption of copolymer on the cell membrane, followed by 
translocation of drugs molecules across lipid membranes.127 Pluronics® in this regard, 
offer universal applicability of BCS class II, III and IV molecules. 
According to a recent report,128 CNS delivery of curcumin (a form of turmeric and  
naturally occurring food color) was significantly enhanced in the presence of poloxamers. 
In the rodent model, nasal in-situ hydrogels comprising of Pluronic F-68 and F-127 
exhibited higher nasal retention time resulting from possible gelation at the physiological 
temperature, thereby promoting curcumin uptake into the CNS.  Results from in vivo 
mucoadhesion tests revealed that yellow color in the oropharynx appeared 67 min after 
IN administration of hydrogels. This was almost 10-fold longer than the mucociliary 
transit time recorded for curcumin aqueous solution (see figure 1.10).  
 
Figure 1.10. in vivo mucociliary transit time recorded for curcumin loaded in aqueous 
solution and poloxamer containing hydrogel. Reprinted from Journal of Pharmacy and 
Pharmacology, 65, Xi Chen, Feng Zhi, Xuefeng Jia, Xiang Zhang, Rohan Ambardekar, 
Zhengjie Meng, Anant R. Paradkar, Yiqiao Hu, Yilin Yang, Enhanced brain targeting of 
curcumin by intranasal administration of a thermosensitive poloxamer hydrogel, pp:807-
816, Copyright 2013, with permission from John Wiley and Sons. 
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The superiority of intranasally administered curcumin hydrogels was also reflected 
in the pharmacokinetic evaluations where the drug targeting efficiency (DTE; calculated 
as AUCbrain part/AUCplasma) in the olfactory bulb, cerebellum and hippocampus was 
significantly higher (p < 0.01) than the equivalent dose of i.v. solution. Authors deduced 
that curcumin may be absorbed in the cerebral tissues via olfactory pathway.  
In another study,129 the use of Pluronics® improved the delivery of zidovudine to the 
brain. This is an antiviral drug which chemically resembles the structure of ribavirin. 
Briefly, a 20% w/v solution of F-127 was prepared in phosphate buffer (pH 5.5). The 
solution exhibited desired gelation characteristics between 27–30 °C. In vitro permeation 
experiments performed in rabbit nasal mucosa using side-by-side diffusion cells showed 
a 53% rise through incorporation of copolymers. These results also confirmed that 
entrapment of zidovudine in a hydrogel network does not inhibit the diffusivity of the 
molecule. It was concluded that the absorption of zidovudine may not be limited by the 
rate of drug release from the gel rather governed by the rate of drug diffusion through the 
biological membrane. The pharmacokinetic and brain distribution studies further 
supported the observation in vitro.  Almost 56 times higher amounts of zidovudin 
accumulated in the brain and cerebrospinal fluid (CSF) from nasal application of the in 
situ gelling formulation when compared with i.v. dose. At any rate, this study shows 
promise that IN administration of a polar compound such as zidovudine could also 
preferentially enter into the CNS possibly via the olfactory route. 
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1.6. Summary 
Intranasal drug delivery systems have shown variable and limited success in direct 
CNS uptake. Hence, the clinical usefulness of this pathway is a topic of current 
discussion. Targeted olfactory deposition and adequate residence time of the 
formulation within this region are essential to successful IN delivery. Currently, an 
ideal formulation or delivery device that enables exclusive drug delivery to the 
olfactory region has yet to be identified; however, research continues to maximize the 
fraction of dose delivered to this location. Generally, solid powder dosage forms show 
greater site-specific nasal deposition and reduced clearance relative to liquid dosage 
forms. Combining a well-optimized solid drug product with a state-of-the-art nasal 
delivery device can provide adequate drug targeting to the olfactory epithelium. Even 
though there are a number of challenges in IN delivery, the potential of this route to 
provide direct access to the CNS continues to encourage academic and 
industrial research. Exciting developments in formulation design and delivery device 
can enhance clinical developments and eventually time-to-market of new products. 
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Chapter 2: Improved flux of levodopa via direct 
deposition of solid microparticles on nasal tissue  
 
2.1. Introduction 
          Parkinson’s disease (PD) is a progressive neurodegenerative disorder resulting in 
tremors, physical rigidity, and difficulty with walking, balance and coordination. 
Currently, 1 million Americans are affected with PD, with an estimated 60,000 new 
diagnoses each year.130 As of 2012, the Center for Disease Control (CDC) ranks the 
complications of PD as the 14th leading cause of death in the United States.130 Although 
the average age of onset is 60, the Parkinson’s Disease Foundation estimated that 4% of 
PD patients experienced "early-onset," prior to age 50.131 The US Census Bureau 
indicates that the fastest growing segment of the U.S. population is individuals over the 
age of 65, suggesting the potential for a commensurate increase in the incidence of PD in 
the near future.  
       Descriptions of the origin and progression of PD are reviewed in detail 
elsewhere.132-134 In brief, PD motor symptoms manifest when approximately 60–80% of 
the dopamine-producing cells are damaged in the substantia nigra. If left untreated, PD 
progresses to the point at which the patient becomes totally disabled, leading to a decline 
in all brain functions and an early death. Direct dopamine supplementation as an 
approach for symptomatic relief in PD patients is ineffective owing to the high 
ionizability of the molecule, which limits transport across the blood-brain-barrier (BBB). 
Therefore, oral administration of the metabolic precursor of dopamine i.e., levodopa (L-
DOPA, L-3,4-dihydroxyphenylalanine) has been the mainstay of PD management for 
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decades.133-136 Currently marketed peroral formulations contain carbidopa (SINEMET® 
and STALEVO®), a DOPA decarboxylase enzyme inhibitor which has shown remarkable 
improvement in the oral bioavailability of L-DOPA (> 70%).137 However, the problems 
associated with erratic absorption, pulsatile delivery, and rapid rise and fall in CNS levels 
of the drug still persist.137,138 
        Innovation in L-DOPA formulations and delivery is an active area of research, 
aimed at accumulating consistent drug concentration in the brain. Although continuous 
intravenous infusion of L-DOPA alone or in combination with a decarboxylase inhibitor 
demonstrably reduces the frequency of motor fluctuations,139 and provides significant 
improvement in mobility,140 it is impractical and inconvenient for routine patient self-
administration. Solution-based IN administration of both dopamine141 and many water 
soluble prodrugs, including L-DOPA has been demonstrated.20,106 Unfortunately, low 
brain levels of L-DOPA accompanied with dramatic fluctuations in drug concentration 
suggest inconsistent delivery from liquid vehicles. Further, these formulations were 
confronted with the issue of rapid mucociliary clearance and oxidation of L-DOPA in 
solution limiting the effective dose delivered.   
While liquid formulations offer a potentially easy method of IN delivery (via 
nasal pump or spray), it is well established that liquid vehicles are most likely to have to 
contend with rapid clearance from the nasal cavity, highlighting one of the major factors 
that limits direct nose-to-CNS drug uptake. Normal mucociliary transit time in humans 
has been reported to be between 10–20 min, during which the mucus lining moves 
towards the nasopharynx for eventual drainage to the gastrointestinal tract. As a 
consequence, the majority of the administered dose is cleared from the nasal mucosa, 
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which is exacerbated by the drainage of solution droplets via the same channel owing to 
gravity. In contrast, semisolid platforms (such as gels) and direct deposition of solid 
particles (via insufflation) provide longer retention times in the nasal cavity, making them 
increasingly favorable approaches for IN delivery.  It is anticipated that these dosage 
forms increase the viscosity of nasal mucus, leading to reduced clearance rate. At the 
very least, they are less prone to gravitational drainage than their liquid counterparts.  
To take advantage of IN delivery, while circumventing stability and clearance 
issues, this work evaluates permeation of L-DOPA from solid microparticles placed in 
direct contact with nasal epithelial tissue relative to permeation from solution 
formulation. It is expected that IN delivered solid particles will be retained on olfactory 
epithelial tissue longer relative to solution droplets, resulting in greater cumulative mass 
transport. Further, it is hypothesized that L-DOPA molecules delivered from solid 
particles deposited directly in contact with the mucosal membrane will result in more 
rapid flux relative to L-DOPA in solution, due to an increase in localized concentration in 
nasal fluid, resulting in a higher concentration gradient, which leads to a more rapid 
diffusion rate.  Ultimately, this research finding can provide a foundation for 
development of innovative sustained release solid dosage forms for IN application and 
potentially minimize problems associated with fluctuations in drug levels, in PD patients. 
 
2.2. Experimental Section 
2.2.1. Chemicals and Reagents  
L-DOPA, > 99% pure, was obtained from Acros OrganicsTM, (New Jersey, USA) 
and stored in a low relative humidity desiccator over anhydrous CaSO4 (Drierite
TM) prior 
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to experimentation. Solubility studies were conducted by preparation of simulated nasal 
electrolyte solution (SNES), which combined 8.77 g NaCl, 2.98 g KCl, 0.59 g CaCl2 
anhydrous in 1000 mL of deionized water.142 The pH of the solutions was adjusted 
between 5.5 and 6.0 with 1N HCl to simulate the pH of nasal fluid. Kreb’s Ringer Buffer 
(KRB) was used for permeation studies, and was prepared by adding 0.05 g MgCl2, 0.34 
g KCl, 7.0 g NaCl, 0.18 g Na2HPO4, 0.1 g NaH2PO4, 1.8 g D-Glucose, 0.28 g CaCl2, and 
1.26 g NaHCO3 to 1000 mL deionized water. Both buffer solutions contained 0.021 g/L 
sodium metabisulphite to control oxidation of L-DOPA.143 All reagents were purchased 
from Sigma Aldrich (Saint Louis, MO, USA). 
2.2.2. L-DOPA solid microparticles 
2.2.2.1. Solid-state characterization 
Powder X-ray diffraction (PXRD) patterns were obtained using an X’Pert Pro 
MPD system (PANalytical B.V., Almelo, the Netherlands), equipped with a copper anode 
(Cu Kα, λ = 1.5406 Å), an auxiliary elliptical mirror, and X’CeleratorTM detector. L-
DOPA powder was loaded between two layers of Kapton® film (ChemPlex, Palm City, 
FL) and spun in a vertical sample stage; consistent irradiation times of 135 s per step with 
an angular step size of 0.017 °2 were used for all diffraction experiments. PXRD data 
were collected over the range of 5–50 °2θ, using an operating voltage and amperage set, 
respectively, to 45.0 kV and 40.0 mA. 
Thermogravimetric analysis (TGA) was performed in an open Pt pan using a TA 
instruments TGA (Model Q50, New Castle, DE). Approximately, 10 mg of sample was 
accurately weighed and placed in the pan. The furnace temperature was increased at a 
constant rate of 5 °C/min from 40 °C to 400 °C, as precise sample weights were recorded. 
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Differential scanning calorimetry (DSC) was performed using a TA instruments DSC 
(Model Q100, New Castle, DE). Accurately weighed samples (4.0–5.0 mg) were 
hermetically sealed in Al pans, and the furnace temperature was increased at a constant 
rate of 5 °C/min from 0 °C to 350 °C under constant 50 mL/min dry N2 gas purge. A 
three-point enthalpy-temperature calibration was performed at 10 °C/min using o-
terphenyl, In, and Sn standards. Measurements were performed in triplicate and the mean 
+ standard deviation is reported. 
2.2.2.2. Particle Size analysis 
Sieve fractionation (Performer III Model: SS-3, Gilson Company, Lewis Center, 
OH) was used to separate different size fractions of 5 g L-DOPA powder (Table 3.1). 
Collected fractions were weighed at intervals ranging from 15–30 min until the measured 
weight change was less than 0.1 g. The fine sieve cut representing 20–53 μm of L-DOPA 
was retained and stored for use in subsequent experimentation. Additionally, L-DOPA 
fines were analyzed using an Olympus BX-51 optical microscope equipped with 
polarizing filter, under 10x and 25x magnification. Photomicrographs were obtained to 
evaluate morphology and measure Feret diameter for approximately 300 particles.  
2.2.3. L-DOPA solution 
2.2.3.1. Assessment of chemical stability 
To ensure chemical integrity during the course of tissue experiments, the 
concentration of L-DOPA in aqueous solution was determined using HPLC. Briefly, 
solid L-DOPA was dissolved in water and vortexed until no undissolved particles were 
observed. The solutions were analyzed for decreased potency under the conditions 
summarized in Section 2.3.2. Triplicate samples of each test combination were removed 
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from stock solutions following storage for 0, 1, 2, 3 and 7 days, and L-DOPA 
concentration was assayed in every sample. Previous reports indicate that aqueous 
stability of L-DOPA is unaffected by light,144 however, care was taken to avoid over-
exposure, and all samples were stored in the dark. 
L-DOPA concentration in all samples was determined using a Waters Alliance 
2690 HPLC system (Millford, MA) equipped with photo diode array (PDA) detector 
using a Lichrospher 100 RP-18 column (25 cm x 4 mm with 5 µm particle size). 
Previously filtered and degassed mobile phase comprising of 97:3 mixture of monobasic 
potassium phosphate (0.01 M, pH = 2 adjusted with phosphoric acid) and acetonitrile was 
used. It has been previously demonstrated that L-DOPA remains chemically stable in the 
presence of strong acids.145 The mobile phase was pumped continuously at a flow rate of 
1.0 mL/min with an injection volume of 20 µL. Standard solutions and test samples were 
analyzed at the detector wavelength of 280 nm. All solutions were diluted in mobile 
phase. Data were analyzed using one way analysis of variance (ANOVA) model. Post-
hoc comparisons of individual time points were conducted using paired t-test statistics 
with a Bonferroni corrected significance level of 0.05 (two-tailed).    
2.2.3.2. Measurement of L-DOPA saturation solubility 
Equilibrium solubility of L-DOPA was determined by placing excess solid in 
SNES containing antioxidant in glass vial enclosures. Vials were stirred mechanically 
(200 rpm) in an orbital water bath shaker (Lab-Line instruments Inc., Melrose Park, IL, 
Model No. 3540) maintained at a constant temperature (25 °C or 37 °C). At pre-
determined time intervals, aliquots of 10 mL were withdrawn, filtered using 0.45 µm 
nylon filter (Millipore), and measured spectrophotometrically (UV Spectrophotometer 
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8453, Hewlett Packard, Germany) at λ = 280 nm. Experiments were carried out in 
triplicate; therefore, only mean values with S.D. error bars are reported.  
2.2.4. L-DOPA Transport in Nasal Mucosa 
Bovine olfactory mucosa was used as a model tissue for permeation studies, 
where L-DOPA permeability was measured by adapting the methods published by 
Chemuturi et al.143 Briefly, cow heads were obtained from Bud’s Custom Meats 
(Riverside, IA). The olfactory turbinates, which were covered by a pale yellow olfactory 
mucosa, were removed within 15 min of decapitation. The excised tissues were 
thoroughly rinsed with KRB and transported in fresh KRB maintained on ice; all studies 
were conducted within 4 h of procurement to ensure tissue viability.   
The permeability of L-DOPA molecules through the bovine olfactory mucosa was 
measured during experiments that used NaviCyte vertical chambers (Harvard Apparatus, 
South Natick, MA). Tissue was carefully removed from the underlying cartilage and 
affixed with the mucosal side facing the donor compartment, between the opposing faces 
of the two half-chambers (donor and receiver), using a series of pins that surrounded the 
opening. L-DOPA was loaded into the donor compartment either as a solution in KRB (1 
mL of 0.75 mg/mL) or as solid microparticles (1.5 mg L-DOPA powder), which were 
evenly sprinkled directly on the mucosal side of the tissue during apparatus assembly. It 
should be noted that the mass of L-DOPA microparticles deposited on tissues was 2-fold 
greater than that in solution samples to enable accurate weighing of the solid and 
reproducible transfer, while minimizing powder loss. The temperature of the diffusion 
cells was maintained using a heating block (Brinkmann Instruments Co., New York, 
NY). Tissue samples were equilibrated for 30 min in KRB at 37°C, followed by 
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replacement of donor and receiver with L-DOPA solution and fresh KRB, respectively. 
Alternatively, the equilibration step was performed prior to assembly of the chambers 
that were loaded with L-DOPA microparticles. The cells were aerated by constant 
carbogen flow (95% O2 + 5% CO2) at a rate of 3–4 bubbles/s. The pH of the donor and 
receiver solutions was adjusted to 5.7 + 0.2 with 1 N HCl. Every 15 min, 200 µL samples 
were withdrawn from the receiver compartment and replaced with fresh, pre-warmed 
KRB. L-DOPA permeation was measured from the receiver compartment aliquots using 
the previously described HPLC method. Tests were performed in triplicate; results are 
expressed as mean + SEM. At the end of each transport study, tissue viability was 
confirmed by measurement of the electrical resistance across the mucosal membrane, 
where non-viable tissue samples were considered those having measured control trans-
epithelial resistance values (approximately 180 ohm/cm2) that dropped by more than 
20%.  Based on the TEER measurements, the viability of all tissue explants was 
maintained during the course of all transport studies. It is noted, however, that a 
paracellular transport marker (Lucifer yellow, LY) or histopathology tests could be used 
as an additional tool to verify tissue integrity. 
Calculations of steady-state and apparent permeability coefficients were based on 
Fick’s First Law of diffusion. Steady-state flux (Jss) was calculated according to 
Equation 2.1:  
𝐉𝐒𝐒 =  
𝐝𝐌
𝐝𝐭
 
𝟏
𝐀
                                                                                                                  (2.1) 
where M is the cumulative amount of drug in the receiver cell at time t, dM/dt is the mass 
transport rate obtained from linear regression of the initial steady-state portion (µg/min) 
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and A is the area of the exposed membrane, i.e., diffusion area (0.64 cm2). The apparent 
permeability coefficients (Papp) were calculated using Equation 2.2: 
𝐏𝐚𝐩𝐩 =  
𝐉𝐬𝐬
𝐂𝟎
 𝐱 𝟔𝟎                                                                                                      (2.2) 
where Co is the initial donor concentration (µg/mL), resulting in units for Papp of cm/s. 
The underlying assumption of these equations is that the donor concentration of analyte 
remains constant for the period of steady state. 
2.3. Results and Discussion 
2.3.1. L-DOPA Solid 
As with many other dosage forms involving crystalline particles, solid state 
characterization of the drug substance is necessary for development of dry powder 
inhalation products. In that regard, it is important to identify the presence of 
ordered/disordered phases that may significantly impact the reproducibility of 
manufacturing and therapeutic performance. L-DOPA powder was characterized using 
PXRD, DSC and TGA. The PXRD pattern of the vendor-supplied L-DOPA is shown in 
Figure 2.1, and corresponds well with the respective calculated reference pattern 
(Cambridge Structural Database refcode: LDOPAS03) indicating the presence of a single 
solid phase.146  
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Figure 2.1. Experimental PXRD pattern for vendor-supplied L-DOPA powder (black 
solid line) is compared with simulated diffraction pattern (ICDD reference code: 
LDOPAS03 grey solid line).146 The data indicate that the powder sample is comprised of 
a single phase solid form. 
 
In Figure 2.2, the DSC data show a single endotherm attributable to melting with 
an onset temperature (Tm) of 276.6 (1.3) 
oC, n = 3, which agrees closely with reported 
values (30, 31). Melting was followed immediately by rapid thermal degradation of L-
DOPA at approximately 298.3 (3.8) oC (Td), n = 3, which was consistent with the rapid 
12.90% weight-loss observed in the TGA data. This suggested that proper care should be 
taken in all preparation and experimental procedures to avoid temperatures exceeding Td. 
Neither TGA nor DSC data showed signal consistent with desorption of water, 
suggesting that the applied storage conditions were appropriate for solid L-DOPA.   
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Figure 2.2. Experimental DSC thermogram of L-DOPA (solid line) showing Tm = 276.6 
oC. Post-melting baseline is indicative of rapid thermal degradation. Superimposed TGA 
thermogram (dashed line) represents 12.90% weight loss beginning immediately at Td, 
confirming degradation at T>Tm. 
 
 
Particle size (PS) is an important parameter that is known to influence nasal 
delivery, therefore, sieve fractionation of L-DOPA powder was performed and the 
particle size distribution (PSD) was represented as cumulative percent undersize (Table 
2.1).  
Table 2.1. Particle size distribution of L-DOPA determined by sieve analysis. 
Particle size distribution for levodopa by sieve analysis 
 
L-DOPA 
Cumulative Percentage Undersize 
< 20 µm < 53 µm < 75 µm < 125 µm < 180 µm < 250 µm < 500 µm 
4.2 47.0 54.8 79.3 97.2 99.8 100.0 
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Recognizing that optimum in vivo olfactory deposition requires particles sized 
approximately 10–45 µm, the fraction of L-DOPA fines collected on the 20 µm sieve 
were retained for mass transport studies involving solid microparticles. It is 
acknowledged that, although sieve fractionation yielded a sufficient quantity of L-DOPA 
fines for the present studies, larger scales, and undoubtedly, manufacturing, would likely 
require comminution to homogenize L-DOPA particle size to this specification.  In those 
cases, solid state characterization would be essential to ensure that the much harsher 
processing did not deleteriously change the L-DOPA solid. In the present study, the 
selected sieve fraction was characterized for surface and bulk morphology, with 
photomicrographs showing that the majority of L-DOPA crystallites exhibited a plate-
like morphology (Figure 2.3a – 2.3c). The median primary particle size (d50) was 20.93 
µm, with d10 and d90 respectively measuring 9.5 µm and 43.7 µm (See Fig. 2.3d).  
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Figure 2.3. (a) Micrograph depicting morphology of L-DOPA primary particles 
immersed in oil, observed through a 25× objective; (b,c) typical micrographs used to 
measure Feret diameter (n = 300), 4x objective; (d) particle size distribution of primary 
particles observed in (b and c). 
 
Although the morphology of particles obtained from analytical samples may not 
be particularly favorable for reproducibly emitted doses from nasal devices, it is expected 
that the size reduction step necessary at larger scales will likely make the particle 
morphology more regular; making it suitable for insufflation and nasal deposition. 
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2.3.2. L-DOPA Solution 
The potency of L-DOPA solutions was evaluated when stored in combination 
with an antioxidant (0.021 g/L sodium metabisulphite). To simulate both storage and 
physiological conditions, 0.4 mg/mL L-DOPA solutions were held at 25 oC and 37 oC, 
respectively. The % recovery vs. time profiles of L-DOPA, subjected to experimental 
conditions are shown in Figure 2.4.  
 
Figure 2.4. Effect of temperature and presence of antioxidant on the concentration of L-
DOPA in aqueous solution. Data are shown as mean + SD. Bonferroni multiple 
comparison (α = 0.05) between groups is shown to denote the extent of loss in L-DOPA 
concentration on day 7. The rate constants for degradation are summarized in Table 2.2. 
 
Generally, it was noted that the extent of L-DOPA degradation increased with 
experimental temperature, as expected. In the solutions containing antioxidant, however, 
the L-DOPA content was less significantly reduced at both temperatures, suggesting that 
the sodium metabisulfite inhibited oxidative degradation in solution. After 7 days, a 
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maximum of 3.8% and 7.7% decrease in the amount of L-DOPA was recorded 
respectively for solutions maintained at 25 oC at 37 oC. In contrast, solutions without 
antioxidant resulted in greater L-DOPA degradations of 18.3 % (at 25 oC) and 31.4 % (at 
37 oC).  A moderate green discoloration in these samples was observed, suggesting 
solution-mediated oxidation of L-DOPA to L-dopaquinone as a primary degradation 
pathway.147 The data are in agreement with earlier reports and show goodness of fit to 
pseudo first-order kinetics.144,147,148 
The degradation rate constants were determined using Equation 2.3: 
−
𝒅𝑪
𝒅𝒕
= 𝒌(𝑪)  ↔ 𝒍𝒏
𝑪𝟎
𝑪
= 𝒌𝒕                                                                                   (2.3) 
where k is the pseudo first-order rate constant and C0 and C represent L-DOPA 
concentrations at time zero and t, respectively. If the results of Figure 2.4 are plotted in 
the form of Equation 2.3, k values can be computed from the slopes of the straight lines, 
which is summarized in Table 2.2.  
 
Table 2.2. Pseudo 1st order rate constants for degradation of L-DOPA in solution. 
L-DOPA aqueous solution (0.4 mg/mL) 
Conditions Rate constant (k) min-1 R2 
25 °C with antioxidant 0.7 x 10-2 0.99 
25 °C without antioxidant 3.4 x 10-2 0.99 
37 °C with antioxidant 1.5 x 10-2 0.99 
37 °C without antioxidant 9.7 x 10-2 0.99 
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These results were important in deciding a rigorous timeline for the permeation 
studies and subsequent quantitative analyses. Accordingly, L-DOPA solutions containing 
antioxidant were prepared on the day of permeation tests, thereby minimizing 
degradation to < 1%. Although it is recognized that chronic use of metabisulphites can 
result in cellular injury,149 the time of antioxidant exposure in these permeation tests is 
not expected to be particularly damaging to the nasal olfactory tissue. 
The saturation solubility of L-DOPA microparticles isolated through sieve 
fractionation (see Section 2.3.1) was evaluated prior to tissue permeation experiments. 
Figure 2.5 plots the concentrations obtained in the dissolution medium for crystalline L-
DOPA microparticles as a function of time, in the presence of excess solid phase.  
 
Figure 2.5. Saturation solubility of L-DOPA microparticles. Closed grey squares (■) and 
closed black circles (●) represent solubility profile at 25° and 37°C, respectively. In 12 h, 
the measured saturation concentration (Cs) of L-DOPA was almost 1.6 times higher at 
37°C (p <0.001, Student’s t-test). 
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At equilibrium, the measured saturation concentration (Cs) of L-DOPA was, 
respectively, 1.73 + 0.15 mg/mL and 2.77 + 0.16 mg/mL at 25 oC and 37 oC. The data 
corroborated earlier reports indicating slight solubility of L-DOPA in aqueous 
medium.150,151  These measurements were not atypical, owing to the zwitterionic nature of 
the L-DOPA molecule at pH values between 3–9, having an amine group (pKa 8.11) and 
a carboxylic acid (pKa 2.30). Consequently, increased solution potencies are possible only 
when the pH of the solution is altered dramatically. For example, the solubility of L-
DOPA is reported to be 10 mg/mL in 0.01 M maleic acid (pH = 2).20 Considering that 
such extreme conditions do not accurately simulate the physiological environment of the 
nasal cavity, and could potentially affect the integrity of nasal tissue, using dissolution 
media having such a low pH is not recommended. In the present experiments, PXRD data 
obtained for solid residue in contact with KRB at either 25 oC or 37 oC was consistent 
with the L-DOPA Cambridge Structural Database powder pattern, suggesting that that the 
solid phase remained unchanged during the experiments (data not shown).  
2.3.3. L-DOPA transport studies 
Permeation of L-DOPA through bovine olfactory tissue was evaluated in vitro. 
Since liquid formulations are the most commonly developed dosage forms for IN 
delivery, 1 mL of a 0.75 mg/mL L-DOPA solution in KRB was chosen as a comparator 
for mass transport resulting from the 1.5 mg of L-DOPA solid microparticles directly 
deposited on the epithelial tissue surface. The amount of L-DOPA measured in the 
receiver compartment over time was used to calculate Jss and Papp as described above 
(Equations 2.1 and 2.2). Figure 2.6(a) demonstrates the permeation profiles across nasal 
mucosa, when L-DOPA was loaded as either solution or solid microparticles. After 120 
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min of contact with nasal mucosa, the cumulative amount of L-DOPA that permeated 
from solution, per unit area tissue, was 225.13 ± 38.31 µg cm-2 (n = 3). In contrast, a 
maximum of 501.07 ± 105.63 µg cm-2 mass transport was measured when the donor side 
was loaded with L-DOPA solid microparticles (n = 2).  
This was also reflected in the average Jss values, where approximately 3-fold 
higher flux was measured in the diffusion cells loaded with L-DOPA solid when 
compared with those containing L-DOPA solution (See Table 2.3). The linear region in 
all permeation profiles, chosen based on goodness-of-fit (R2 >0.97), was used to estimate 
mass transport under steady-state conditions (shown in dashed line).   
Table 2.3. Comparison of average in vitro nasal epithelial flux of L-DOPA from aqueous 
solution and solid microparticles. 
Average steady state flux (Jss)         µg.cm-2.min-1 (correlation) + SD 
L-DOPA aqueous solution a solid microparticles b 
2.13 (0.95) 0.97 6.08 (0.97) 0.69 
a number of replicates = 3 
b number of replicates = 2 
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Figure 2.6. in vitro permeation profiles of L-DOPA across bovine olfactory mucosa from an aqueous solution (empty circles, n = 3) 
and solid particles (filled circles, n = 2). (a) Data are expressed as cumulative L-DOPA permeated with time (mean ± SD). The solid 
connecting line represents the initial steady-state portion that was chosen to calculate Jss according to Eq. 1; (b) data normalized with 
respect to initially loaded mass of L-DOPA i.e., 0.75 mg in 1 mL donor solution and 1.5 mg as solid microparticles. 
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It should be noted that no additional dissolution medium was added to the donor 
compartments containing the solid microparticles, which were directly deposited on 
tissue surfaces. It was expected that dissolution of the L-DOPA in the naturally moist 
surface of olfactory mucosal membrane in these experiments would occur similarly in 
vivo following insufflation.  
Despite a low hydration volume, the relatively rapid dissolution of L-DOPA from 
microparticles in the nasal mucus is proposed to occur by two mechanisms. Given that 
the average size of the primary L-DOPA microparticles was approximately 20 µm, a 
fraction of the solid was expected to rapidly dissolve in the small volume of nasal fluid, 
owing to an increase in the surface energy and thereby improved wettability.152  The 
other contribution to rapid dissolution includes favorable interactions forming between 
the overall negative charge, typical of nasal cell surfaces (resulting from the presence of 
sialic acid in nasal mucin), and the positively charged L-DOPA molecules expected at 
experimental pH.153 As a consequence, the L-DOPA microparticles were expected to 
saturate the mucus layer, the concentration of which was expected to be close to Cs (2.77 
+ 0.16 mg/mL at 37oC). Such a strong driving-force can potentially justify the rapid mass 
transport observed within the first 60–75 min of contact with nasal mucosa. The 
subsequent reduction in L-DOPA flux may be attributed to removal of fine solid particles 
away from the diffusion area under gravity. 
The average apparent permeability coefficient (Papp) of L-DOPA was calculated 
to be 4.73 x 10-5 cm/s from solution samples.  As the chemical structure of the molecule 
was not altered in this study, it was assumed that Papp should remain consistent for L-
DOPA solid samples, even when the measured membrane flux (Jss) was considerably 
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different. Using Equation 2.2, the apparent initial concentration (Co) for solid samples 
was calculated to be 2.14 + 0.24 mg/mL. The closeness of this value to the 
experimentally measured Cs (2.77 mg/mL) supports that the claim the L-DOPA solid 
particles saturated the nasal mucus (refer to Figure 2.7). 
To caluclate Papp, it was taken the donor concentration remains constant for the 
steady state region (dashed line). In order to test the validity of this assumption for the 
solid microparticle group, the cumulative L-DOPA transport at 60 min is used as an 
example. The mean cumulative L-DOPA permeated at 60 min is 220.31 + 50.98 μg. If L-
DOPA trapped within the olfactory tissue is insignificant, the amount of drug remaining 
on the donor side is about 1280 μg which is still expected to saturate the nasal mucus. 
Therefore, it supports the assumption of steady donor concentration. Beyond this time 
point, it can be seen that the permeation profile levels off which may be attributable to 
slow drifting away of particles from the diffusion area under gravity. 
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Figure 2.7. Schematic representation of the L-DOPA permeation of nasal epithelial cells. Green closed circles represent directly 
deposited L-DOPA microparticles on the donor side of tissue, which saturate the mucus layer (Cs = 2.77 mg/mL). This contrasts the 
dark blue shaded region denoting L-DOPA solution contact with the mucus layer at a constant concentration throughout the entire 
donor chamber (0.75 mg/mL). As depicted, saturation of the mucus layer by L-DOPA dissolved from solid microparticles results in a 
much higher steady-state concentration gradient that explains the 3-fold increase in flux relative to L-DOPA solution experiments. 
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It is acknowledged that the starting mass of L-DOPA solid was almost double the 
quantity loaded in solution, which was necessitated in order to minimize weighing errors. 
Therefore, the comparison between the mass transport from either physical form is 
incomplete if the cumulative L-DOPA transport values are not normalized with respect to 
initial concentration. The adjusted data showed that approximately 11.79% of the initial 
amount was permeated from L-DOPA microparticles within 30 min. In contrast, only 
about 7.84% of the initial concentration of L-DOPA was permeated from molecules in 
solution, as shown in figure 2.6(b).  It is clear that, despite normalization of mass 
transport values, the solid microparticles demonstrated greater L-DOPA permeation (up 
to 75 min), which can be related to the higher concentration gradient across the epithelial 
tissue. Notably, the maximum % of L-DOPA transported after 120 min was comparable, 
with 30.1% and 33.4% respectively for the solution and powder samples, however, the 
present data still represent a significant finding in that the delivery of L-DOPA from solid 
microparticles will not be restricted by low dissolution volume in the nasal cavity. 
Moreover, the residence time for solid microparticles is expected to be much greater 
relative to solution, which is rapidly drained away from the delivery site by normal 
mucocilliary clearance and flow due to gravity. As such, the more extensive initial 
permeation from the microparticles suggests that delivery in this physical form may 
provide the opportunity for greater drug absorption. 
 
2.4 Conclusions 
Deposition of solid microparticles on nasal mucosa via insufflation is a potentially 
viable, yet relatively unexplored means of IN drug delivery.  These data showed that total 
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in vitro nasal permeation of L-DOPA dissolved from solid miroparticles was comparable 
with aqueous solution. Almost three-fold greater nasal epithelial steady-state flux was 
observed for L-DOPA absorbed from powder experiments, indicating rapid mass 
transport. Furthermore, well known issues related to chemical stability of aqueous 
solution of L-DOPA as well as potential tissue injury owing to the use of sodium 
metabisulfite in solution formulations were successfully avoided by deposition of solid 
microparticles, which required neither an aqueous vehicle nor antioxidant. Collectively, 
the data demonstrated that dry, solid powder dosage forms could be developed for IN 
delivery of L-DOPA. In the pharmaceutical field, such evidence could be particularly 
important  in treatment of other neurological disorders where no straightforward, non-
invasive therapies exist in current clinical practice.  
 
2.5 Acknowledgments 
The authors thank the generous funding provided by Duquesne University, Hunkele 
Dreaded Disease Award. The authors also acknowledge Dr. Maureen Donovan and Ms. 
Ana Ferreira (Iowa University) for their assistance with L-DOPA transport studies. This 
chapter is the copyright of AAPS PharmSciTech, Improved flux of levodopa via direct 
deposition of solid microparticles on nasal tissue, vol 18, 2017, pp 904–912, 
Dipy M. Vasa, Ira S. Buckner, Jane E. Cavanaugh, Peter L. D. Wildfong. The final 
publication is available at Springer via http://dx.doi.org/10.1208/s12249-016-0581-4. 
 
 
  64 
Chapter 3: Solid-state transformations of ribavirin 
as a result of high shear mechanical processing 
 
3.1. Introduction 
Ribavirin is predominantly administered via solid oral dosage forms. Some 
marketed products include Copegus® (200 mg film coated tablets; Hoffman La-Roche), 
Rebetol® (200 mg hard capsules and 40 mg/mL oral solution; Merck), Ribasphere® (200, 
400 and 600 mg hard capsules; Three Rivers Pharmaceuticals), and ModeribaTM (200, 
400, 600 mg film coated tablets, AbbVie).154 Additionally, it is also given as a powder for 
inhalation solution (Virazole® 6 g vials; Valeant Pharmaceuticals).  Regardless of the 
delivery system, it is likely that solid ribavirin will be subject to some degree of high-
shear mechanical processing, including milling, granulation and compaction, making 
unanticipated solid-state transformations, including crystal-to-crystal and crystal-to-
glassy solids, a possibility during manufacturing.  
Over the last few decades, numerous examples of process-induced phase changes 
of pharmaceutically relevant materials have been reported.154-160 Some estimates suggest 
that approximately 30% of active pharmaceutical ingredients (API) are susceptible to 
solid form changes during mechanical processing.159 The impetus to identify potential 
process-induced transformations during processing, followed by thorough 
characterization and elucidation of the underlying mechanisms is important for product 
development, and consistent with the materials understanding at the heart of worldwide 
regulatory guidances. 
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Ribavirin was previously reported as solidifying as one of two unique crystalline 
polymorphs,161,162 conventionally named R-I and R-II, which respectively represent the 
high-melting and low-melting temperature enantiotropes.163 Careful selection of a 
consistent solid form during pre-formulation, which persists in the final drug product, is, 
therefore, warranted. In addition, the impalpable nature of ribavirin powder, accompanied 
with low and variable tapped densities (reported range 0.32-0.45 g/mL)164 pose 
considerable challenges to material handling. While flow properties and processability of 
ribavirin can be improved through secondary manufacturing procedures, such as 
pelletization,165 roller compaction164 and wet granulation;166 the potential for concurrent 
solid-state transformations during manufacturing has not been investigated. It seems 
likely that, consistent with other small molecule crystalline materials, unanticipated 
partial or complete phase conversions can alter the mechanical properties, processability, 
and performance attributes of the drug substance in the final drug product.  
Polymorphic transformations of pharmaceutically relevant solid materials are a 
known potential consequence of milling, which can affect the quality and performance of 
the final drug product.157,167-169 When a crystalline API is milled, the excessive shear 
stress accompanied by other manifestations of very high mechanical energy (such as 
heat), elicit structural changes to the crystal, while introducing substantial lattice defects 
that alter the physical and chemical properties of the solid. While empirical models of 
mechanical activation potential exist,170,171 their utility is restricted to specific 
experimental conditions such as temperature, equipment dimensions, and sample size, 
making universal predictions elusive. Experimental observation of mechanically induced 
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transformations, therefore, remains important, especially if a range of temperatures, 
processing stresses and other conditions are expected. 
In the present work, the influence of thermal and mechanical stresses on ribavirin 
was investigated as they pertained to the potential to induce solid-state phase 
transformations as a consequence of processing. Following the observation that the 
kinetics of a temperature-mediated enantiotropic conversion was prohibitive for 
unprocessed ribavirin, it was hypothesized that transitions between polymorphs could be 
observed in shorter timeframes when defects resulting from pulverization enabled more 
rapid transformations at elevated temperatures. To test the hypothesis, phase pure 
samples of each ribavirin enantiotrope were generated, and the enantiotropic transition 
temperature (Ttr) was determined. Samples were milled, with and without temperature 
control, and the outcomes of mechanical and/or thermal stimuli were recorded. Particle 
size reduction, commensurate with increased specific surface area, and the extent of 
crystal damage were measured to identify which of these factors predominate in the 
observed phase transformations. This additional effort was expected to provide a better 
understanding of the likelihood of phase conversion during other manufacturing steps 
(such as compaction, which also involves particle fracture and crystal damage). 
Reversibility of the polymorphic transition (R-I  R-II) was also investigated by 
isothermal exposure of the phase-pure metastable polymorphic form to varied conditions 
of relative humidity. Ultimately, these observations serve as a reference for materials that 
may be similarly susceptible to mechanically induced phase changes. 
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3.2. Materials and Methods 
Ribavirin was purchased from Jinan Jiaquan Chemicals Co. Ltd. (Jinan, China, 
Lot number 02110330). Samples were stored in a desiccator containing phosphorous 
pentoxide (P2O5) at ambient temperature prior to use.   
3.2.1. Recrystallization of Ribavirin Polymorphs 
Phase-pure samples of ribavirin polymorphs were prepared by recrystallization 
from solvents, using previously reported methods with slight modification.161,162 To 
obtain pure R-II, a slight excess of vendor supplied ribavirin (R-RW) was dissolved in 
water at 80 °C to form a supersaturated solution. The suspension was filtered and left to 
cool slowly to room temperature. The resulting crystals were vacuum dried at 25 °C 
overnight and stored for further characterization.  
Pure R-I was prepared by fractional recrystallization, where a supersaturated 
solution of R-RW was formed in methanol (> 99% HPLC grade, Fisher Scientific) at 60 
°C and filtered. The filtrate was dried under a current of air, which facilitated rapid 
crystallization, owing to rapid evaporation of organic solvent, accompanied by a 
temperature drop. Upon appearance of the first few crystals, the mother liquor was re-
filtered to harvest pure R-I; phase purity was confirmed by rapid differential scanning 
calorimetry (DSC) and peak-by-peak comparison of powder X-ray diffraction (PXRD) 
patterns with the known crystal structure (CSD refcode: VIRAZL). Experimentation 
demonstrated that the re-filtration to harvest R-I crystals was required to prevent 
recrystallization of a mixture of phases. Isolated R-I crystals were dried in a vacuum 
oven, and used as seeds for producing subsequent batches (0.5-1.0 g) of pure R-I.  
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3.2.2. Generation of Amorphous Ribavirin 
Amorphous ribavirin was prepared in situ during DSC experiments. An accurately 
weighed sample of R-II was heated to Tm + 10 °C at a rate of 5 °C/min, and held 
isothermally for 10 min. The molten sample was rapidly cooled at 40 °C/min, with no 
observation of recrystallization, and the Tg was determined during the subsequent DSC 
heating cycle. 
3.2.3. Isothermal heating experiments 
Conversion to the high-temperature stable enantiotrope, R-I, was attempted using 
a method similar to that reported for chlorpropamide enantiotropes.172 Approximately 
500 mg of R-II powder was placed in glass petri dishes, which were held isothermally at 
150°C (T < Tm for either polymorph) in an Isotemp 13-246-506GA gravity convection 
oven (Fisher Scientific, Dubuque, IA). Thermal exposure was maintained as long as the 
sample did not exhibit signs of thermal degradation. Samples were periodically 
characterized to identify the emergence of the R-I phase, by comparison of experimental 
diffraction patterns with the calculated PXRD patterns of each enantiotrope.   
3.2.4. Milling experiments 
R-II was milled at frequency of 30 Hz in a vibratory impact ball mill (Mixer Mill 
MM200, Retsch GmbH & Co., Germany) for milling durations of 60, 180 and 270 min. 
A 0.5 g powder sample was placed in a 25 mL volume stainless steel jar containing one 
12 mm diameter stainless steel ball. Milled samples were immediately characterized 
using PXRD and DSC. Although care was taken to avoid excess heat accumulation, by 
intermittently opening the milling jar for short time intervals, it is acknowledged that the 
procedure does not allow rigorous temperature control. 
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In contrast, cryogenic grinding of R-II was accomplished using a SPEX Certiprep 
6750 Freezer Mill (SPEX Certiprep, Metuchen, NJ) in which powder samples weighing 
approximately 1.0 g were placed in a polycarbonate milling vessel. A stainless steel 
cylindrical milling rod was placed in the vessel, and samples were allowed to equilibrate 
for 3 min following immersion in a liquid nitrogen bath prior to milling.  Temperature 
control during processing was enabled by consistently maintaining the liquid nitrogen 
bath during the experiments, allowing continuous immersion of the samples and milling 
medium throughout comminution. Similar to a previously published method,167 materials 
were ground for 2 min intervals at a frequency of 10 Hz, separated by 2 min cool-down 
periods, allowing minimization of local sample temperature increases during 
experimentation. Upon completion of milling, triplicate samples were analyzed using 
PXRD and DSC. 
The particle size and size distributions of unmilled R-II and all milled samples 
were determined using an Olympus BX-51 optical microscope equipped with polarizing 
filter, at 10x magnification. Primary particles were separated by preparing a dilute 
suspension in immersion oil, which was placed between microscope slides and a 
coverslip. Photomicrographs for each sample were collected to measure the Feret 
diameter for approximately 300 particles.  
3.2.5. Influence of storage conditions 
Recrystallized R-I was observed for re-conversion to the stable polymorph under 
varied conditions of relative humidity at ambient room temperature (22 + 2°C). Each 300 
mg sample was equilibrated at 0% RH by storage in a desiccator with P2O5, or at % RH 
of 33%, 60%, and 75% by equilibration over saturated solutions, respectively containing 
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MgCl2, NaBr, or NaCl. Repeated hygrometer measurements ensured that each humidity 
condition was maintained at + 3% of the desired values. Samples were evaluated for 
phase changes using PXRD at regular intervals for up to 60 days. 
3.2.6. Characterization 
3.2.6.1. Thermogravimetric Analysis (TGA) 
Samples were evaluated for the possibility of solvate formation using a 
thermogravimetric analyzer (Model Q500, TA Instruments, New Castle, DE). Samples 
weighing  approximately 10 mg were placed on an open platinum pan and heated at 
2°C/min under constant nitrogen purge at 60 mL/min. Subsequent thermograms were 
examined for stepwise weight loss commensurate with desolvation. 
3.2.6.2. Differential Scanning Calorimetry (DSC) 
Conventional and modulated temperature DSC analyses were performed using a 
TA Instruments Q100 differential scanning calorimeter (TA Instruments, New Castle, 
DE) with an attached refrigerated cooling accessory. Dry nitrogen gas (50 mL/min) was 
allowed to constantly purge the DSC cell during all experiments, while a three-point 
temperature and enthalpy calibration was accomplished using Sn (Tm 231.9 
oC), In (Tm 
156.6 oC), and o-terphenyl (Tm 55-56 
oC) standards. Conventional DSC measurements 
were made to determine the melting temperatures (Tm) of ribavirin polymorphs. 
Accurately weighed samples (5.0 + 0.5 mg) were hermetically sealed in an Al sample pan 
and heated at constant rates of 0.5, 2, 5, 10, 20, or 40°C/min to a temperature beyond the 
reported Tm.
162,163 All measurements were performed in triplicate and reported as mean 
values + standard deviation.  
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The heat capacities of R-I, R-II and amorphous ribavirin were determined in the 
MDSC (modulated temperature) mode, using experimental parameters carefully selected 
to produce accurate and artifact-free data.173 A modulation amplitude of + 0.256 °C, 
period of 100 s, and an underlying heating rate of 1 °C/min were used to allow 4-5 
modulation cycles over the critical temperature range of transition (55-65 °C) while 
minimizing the thermal gradient across the sample. Samples weighing approximately 10 
mg were loaded and tightly packed in standard Al pans, which were subsequently 
crimped to ensure good sample-to-pan contact. Background noise was minimized by 
ensuring that sample and reference pan weights matched within + 0.02 mg. Sample heat 
capacities were then obtained by deconvoluting the non-reversing and reversing signals 
from the total heat flow, using instrument software (Universal Analysis 2.0, TA 
Instruments). The heat capacities of both the crystalline and amorphous forms of ribavirin 
were measured over temperatures ranging from Tg – 50 °C to Tg + 50 °C. The heat 
capacity constant (KCp) was previously calibrated using a sapphire disc weighing 
approximately 25 mg. Additionally, vacuum dried samples of crystalline sucrose were 
used as external standard to verify the precision of the instrument, and measured heat 
capacities were compared with the literature reported values.174  
3.2.6.3. X-ray powder diffraction (PXRD) 
Powder X-ray diffraction (PXRD) patterns were obtained using an X’Pert Pro 
MPD diffractometer (PANalytical B.V., Almelo, the Netherlands), equipped with an 
auxiliary elliptical mirror and X’CeleratorTM detector. Powder samples were placed 
between two layers of Kapton® film (ChemPlex, Palm City, FL) and spun in a vertical 
sample transmission stage.  Irradiation with X-rays from a copper source (Cu Kα, λ = 
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1.5406 Å) for a duration of 135 s per step, and incremental angular steps of 0.017 °2 
were used for all diffraction experiments. PXRD data were collected over the range of 5–
50 °2θ, using an operating voltage and amperage set, respectively, to 45.0 kV and 40.0 
mA. 
3.2.6.4. Solution Calorimetry 
The heats of solution (ΔHsol) at 25 °C were determined for ribavirin polymorphs 
using an isothermal heat-conduction microcalorimeter (Model 7211, Calorimetry 
Sciences Corp., Lindon, UT). Solid samples of phase pure polymorphs were accurately 
weighed (25+1 mg), and the integral heat of solution was measured as each was dissolved 
into 25.0 mL of distilled water. The dissolution medium was stirred at 50 rpm by a 
paddle. Triplicate measurements were made and reported as an average + standard 
deviation. 
3.2.6.5. Measurement of aqueous solubility 
The aqueous solubility of ribavirin polymorphs was determined by placing excess 
solid in screw-capped glass vials containing distilled water. Vials were stirred 
mechanically in an orbital water bath shaker (Model 3540, Lab-Line Instruments Inc., 
Melrose Park, IL) maintained at a constant temperature of 25°C and 200 rpm speed. At 
appropriate time intervals, 10 mL aliquots were withdrawn, filtered using 0.45 µm nylon 
filter and measured spectrophotometrically (UV Spectrophotometer 8453, Hewlett 
Packard, Germany) at λ = 207 nm. Experiments were carried out in triplicate; therefore 
only mean values with S.D. error bars are reported. 
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3.2.6.6. Surface area determination (BET) 
Brunauer, Emmett and Teller (BET) surface area quantification was performed 
using a Flow Sorb II 2300 (Micromeritics Corp., Norcross, GA) instrument and a five-
point BET N2 adsorption protocol. Samples weighing approximately 200 mg were 
degassed under dry nitrogen for 12 h prior to analysis. Room temperature was used to try 
and avoid any possible phase transformation. Replicate measurements were performed to 
verify the precision of each measurement. 
3.2.6.7. High performance liquid chromatography (HPLC) 
 Ribavirin was assayed using a published stability-indicating HPLC method with 
slight modifications.175 The analysis employed a Hypersil C18 reverse phase column 
(5 μm, 250 mm × 4.6 mm i.d., Waters, MA, USA) and a Waters 2690 LC system 
equipped with a Waters 996 photodiode array detector and an autosampler (Waters Corp., 
MA, USA). The mobile phase, comprised of 0.01 M potassium dihydrogen phosphate 
solution and pure methanol (95:5, v/v), was eluted isocratically at a flow rate of 
1 mL/min, while the detector response was set at  = 207 nm. Ribavirin was eluted as a 
single peak in the chromatogram at approximately 4.55–4.65 min.  
R-RW, R-II and R-I samples were separately dissolved in distilled water to a final 
concentration of 50 µg/ml, of which 20 L was injected into the column. A calibration 
curve constructed using standard ribavirin solutions within the appropriate concentration 
range (10 – 90 µg/ml) displayed excellent linearity with an R2 larger than 0.99. All 
measurements were performed in triplicate. 
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3.3. Results and Discussion 
3.3.1. Physical characterization of ribavirin polymorphs 
The PXRD pattern for ribavirin obtained from the vendor (R-RW) was compared 
with simulated reference patterns obtained from the Cambridge Crystallographic Data 
Centre (Figure 3.1). All peaks for R-RW corresponded with the reference pattern for R-II 
(CSD refcode: VIRAZL01) with no discernable peaks attributable to R-I (CSD refcode: 
VIRAZL).176  
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Figure 3.1. The experimental PXRD pattern for vendor-supplied ribavirin powder R-RW (red) is compared with recrystallized 
ribavirin R-I (green) and recrystallized ribavirin R-II (blue). Simulated diffraction patterns for R-I (CSD reference code: VIRAZL, in 
grey) and R-II (CSD reference code: VIRAZL01, in black) are also provided. The data indicate that R-RW corresponded entirely with 
the R-II pattern, and did not contain discernable quantities of R-I. 
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DSC thermograms for R-RW collected at 2 °C/min exhibited a melting endotherm 
at 166.05 °C for R-II; followed by partial recrystallization and subsequent melting at 
174.9 °C for R-I (Figure 3.2).  This thermal behavior was in close agreement with that 
reported in the literature,162,163 and not unexpected for enantiotropes characterized by 
DSC. To ensure phase purity of the starting materials used for subsequent 
experimentation, ribavirin polymorphs were recrystallizaed from solvent, as described in 
Section 3.2.1.  As shown in Figure 3.2b, the DSC thermograms of the isolated samples 
of R-I and R-II exhibited no thermal features identifiable with the other solid form, 
suggesting that recrystallization had resulted in pure phases. Additionally, PXRD patterns 
for samples of R-I and R-II recrystallized from solvent (Figure 3.1), were consistent with 
the respective calculated reference patterns obtained from the CCDC. TGA data for each 
recrystallized sample did not show weight loss prior to melting, suggesting that residual 
solvent from recrystallization was removed during vacuum drying, and confirmed that 
neither crystalline form was solvated.  
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Figure 3.2. Comparison of DSC thermograms of R-RW (red) with recrystallized phase pure samples of R-I (green) and R-II (blue). R-
RW melted at 166 °C consistent with R-II (Tm = 168.1 + 0.7 °C) followed by recrystallization and subsequent melting at 174 °C, 
consistent with R-I (Tm = 177.4 + 0.2 °C). The superimposed TGA thermogram (dashed line) shows no weight loss until 
approximately Tm R-I + 30 °C, confirming that both solid forms of ribavirin were thermally stable, and essentially devoid of residual 
solvent. 
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Comparison of relevant crystallographic and thermal properties of ribavirin 
polymorphs, as listed in Table 3.1, revealed that the higher Tm form had a lower 
enthalpy, indicating enantiotropic polymorphism, per the heat of fusion rule.177 The 
reported crystallographic densities of R-I and R-II (at ambient temperature) appear to 
violate the density rule;176 however, these observations are consistent with other small 
molecule solids at room temperature, including hydroquinone178 and resorcinol.179  
 
Table 3.1. Summary of crystallographic and thermal properties of ribavirin solid forms177 
  
Properties R-II R-I 
Crystallographic 
properties 
Unit cell dimensions (Å) 
a = 25.034 
b = 7.719 
c = 5.289 
Density (g/cm3) = 1.587 
Space group = P212121 
Z = 4, Z’ = 1 
Unit cell dimensions (Å) 
a = 14.863 
b = 7.512 
c = 8.788 
Density (g/cm3) = 1.653 
Space group = P212121 
Z = 4, Z’ = 1 
Thermal properties Melting temperature - Tm 
168.1 + 0.7 °C 
 
Enthalpy of melting – ΔHm 
44.1 + 0.8 kJ/mol 
Melting temperature- Tm 
177.4 + 0.2 °C 
 
Enthalpy of melting – ΔHm 
41.3 + 0.1 kJ/mol 
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3.3.2. Estimation of transition temperature (Ttr) and enthalpy (Htr) 
The determination of Ttr for ribavirin was important in order to identify the 
circumstances under which its enantiotropes were subject to conversion. For 
enantiotropically related systems, such as carbamazepine180,181 or sulfamerazine182, 
identification of Ttr allowed assessment of the risks associated with conversions to 
different forms by temperature excursions during processing.183  In the present work, two 
independent methods were used to determine this value: 1) interpolation of a Gc phase 
diagram and 2) solubility extrapolation. 
1) Gc phase diagram method: Configurational thermodynamic quantities have 
traditionally been used to estimate the molecular mobility and physical stability of 
amorphous solid forms.184,185 More recently, however, this has been applied to estimate 
Ttr.
186,187 Calculations of thermodynamic parameters, such as configurational enthalpy 
(Hc) and configurational entropy (Sc) were used to plot Gc versus T using the following 
equations: 
𝑯𝒄(𝑻) =  𝑯𝒂𝒎(𝑻) − 𝑯𝒙𝒕𝒂𝒍(𝑻) = ∆𝑯𝒎 +  ∫ 𝑪𝒑𝒄𝒐𝒏𝒇𝒅𝑻
𝑻𝒎
𝑻
                                                  (3.1) 
𝑺𝒄(𝑻) =  𝑺𝒂𝒎(𝑻) −  𝑺𝒙𝒕𝒂𝒍(𝑻) =  
∆𝑯𝒎
𝑻
+  ∫
𝑪𝒑𝒄𝒐𝒏𝒇
𝑻
𝒅𝑻
𝑻𝒎
𝑻
                                                (3.2) 
𝑮𝑪 (𝑻) =  𝑯𝑪 (𝑻) −  𝑺𝑪 (𝑻) ∙ 𝑻                                                                                     (3.3) 
where 𝐶𝑝𝑐𝑜𝑛𝑓 is the reversing heat capacity (Rev Cp) difference between the amorphous 
and crystalline forms (Refer Figure 3.3). 
𝑪𝒑𝒄𝒐𝒏𝒇(𝑹−𝑰) =  𝑪𝒑
𝒂𝒎 − 𝑪𝒑
𝑹−𝑰                                                                                     (3.4) 
𝑪𝒑𝒄𝒐𝒏𝒇(𝑹−𝑰𝑰) =  𝑪𝒑
𝒂𝒎 −  𝑪𝒑
𝑹−𝑰𝑰 (3.5)
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Figure 3.3. (a) Reversible heat capacity as a function of temperature for crystalline forms of ribavirin; R-II in blue and R-I in green, 
respectively. Amorphous ribavirin is shown in black. (b) Configurational heat capacity for R-I and R-II shown in green and blue 
respectively. 
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The point of intersection of the Gc curves for the two ribavirin solid forms was 
taken as the thermodynamic transition temperature (Ttr), which is shown in Figure 3.4 
(Ttr = 68.4 °C).  
 
Figure 3.4. Configurational free energy (Gc) phase diagram for ribavirin polymorphs. Gc 
of R-I is denoted by green dashed line and of R-II is denoted by blue solid line. 
Intersection (T = 341.6 K) represents Ttr = 68.4 
oC. 
 
Although this technique only provides an estimate of Ttr, the enthalpy associated 
with the polymorphic transition (ΔHtr) was calculated from the difference between the 
experimentally obtained heats of fusion,188 and determined to be 2.8 kJ/mol. While the 
parameters of melting temperatures and heats of fusions derived from thermoanalytical 
techniques are routinely used for estimation of Ttr, if concurrent thermal events occur 
(e.g., commensurate melting and recrystallization or melting with decomposition), then 
the reliability of the data may be questionable. 
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2) Solubility extrapolation: Determination of solution enthalpies (Hsol) is also a 
widely accepted technique used to differentiate between polymorphs.181,182,187  In order to 
confirm the values obtained by interpolation of the Gc data, a complementary method that 
used the heat of solution and solubility data was performed for estimation of Ttr 
(Equation 3.6): 
𝑻𝒕𝒓 =  (
𝟐.𝟑𝟎𝟑 .𝑹 .  (𝒍𝒐𝒈𝑺𝑰𝑰,𝑻−𝒍𝒐𝒈𝑺𝑰,𝑻)
∆𝑯𝒕𝒓,𝑻 
+ 
𝟏
𝑻
)
−𝟏
                                                           (3.6) 
Above, the logarithmic solubility of R-I and R-II were represented as 𝑙𝑜𝑔𝑆𝐼 and 𝑙𝑜𝑔𝑆𝐼𝐼, 
respectively, at temperature T = 25 °C. ∆𝐻𝑡𝑟,𝑇 is the heat of transition corresponding to 
the difference in the heat of solution at temperature, T = 25 °C. Although the heat of 
solution varies with the choice of solvent, the heat of transition corresponding to the 
difference in the heat of solution is theoretically equal. In distilled water, the heat of 
solution for R-I and R-II was measured to be -29.4 + 0.8 kJ/mol and -31.2 + 0.1 kJ/mol, 
respectively, while ∆𝐻𝑡,25 °𝐶 was estimated to be 1.8 + 0.35 kJ/mol.  
Figure 3.5 plots the concentrations of each form of ribavirin in distilled water as a 
function of time, in the presence of excess solid phase. As shown, both solid forms 
reached a plateau of maximum solubility within 30 min, at which the measured saturation 
concentrations at 25 oC of R-I and R-II were, respectively, 162.5 + 3.6 mg/mL and 149.0 
+ 1.7 mg/mL.   
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Figure 3.5. Aqueous saturation solubility of ribavirin polymorphs. Closed green circles 
(●) and open blue circles (○) represent solubility profile of R-I and R-II, respectively. 
Data are represented as mean + standard deviation, n = 3. 
 
In all cases, it was confirmed by DSC and PXRD that the residue did not convert 
to another solid form during the course of the experiment (data not shown), confirming 
that these values are specific to R-I and R-II.  When these measured values were 
substituted into Equation 3.6, the Ttr for R-I and R-II polymorphs was determined to be 
71.3 °C, which agrees well with the value obtained by interpolation of the Gc diagram 
(68.4 °C). The slight difference in values is likely attributable to the underlying 
assumptions of each technique,182 but suggests a good approximation of the actual Ttr. 
Both methods employed here assume that the heat capacity difference between the two 
polymorphs is independent of temperature. Further, the melting method assumes that 
enthalpy of fusion is independent of temperature. Likewise, the solubility – heat of 
solution method assumes the difference between the activity coefficients of two 
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polymorphs is negligible. Ultimately, since this polymorphic pair has a Ttr that is both 
realistic (less than either of the melting points of the polymorphs), and mutually 
supported by independent techniques, their enantiotropism was confirmed.  
3.3.3. Exposure of R-II to T > Ttr 
Following determination of R-I and R-II enantiotropism, and the Ttr, it was 
reasonable to expect that temperature-mediated conversion directly from R-II to R-I 
should be observed upon heating of R-II to T > Ttr without exceeding the Tm for either 
form. R-II was heated in situ in DSC pans at different rates ranging from 2-40 °C/min; 
ultimately the slowest DSC data were selected for their resolution, and the potentially 
reduced likelihood of instrumental artifacts.189 Additionally, it was expected that the 
slower heating rate would enable conversion of R-II to R-I without melting during the 
experiments. However, all DSC thermograms for R-II showed only a single endothermic 
event with an onset temperature of 169.29 + 2.72 °C and an enthalpy of 44.32 + 1.56 
kJ/mol.  The absence of any notable endothermic transition prior to melting, even at the 
slowest heating rates, suggested that the kinetics of the R-II to R-I solid state conversion 
were much slower than those afforded by even the slowest DSC experiment.  
To address the need for longer exposure time at T > Ttr, R-II samples were held 
isothermally at 150 °C, with care taken not to expose samples to temperatures that might 
melt either polymorph. Against expectations, samples of R-II held at 150 °C for 7 days 
persisted without conversion to R-I, as evidenced by characterization of these samples 
using PXRD and DSC. It was also noted that isothermal storage at this temperature 
beyond 7 days resulted in brown discoloration of portions of the samples, suggesting 
thermal instability.  This was confirmed via HPLC by a decrease in ribavirin potency to 
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less than 70 % when compared with the USP standard, for samples held at 150 oC for 
longer than 7 days. Unlike other examples of temperature induced solid-state 
changes,180,190,191 the present work demonstrated that, although enantiotropically related 
transitions are thermodynamically reversible with temperature and pressure, the kinetics 
may prohibit interconversion within reasonable (or applicable timeframes). It is important 
that new chemical entities (NCEs) demonstrating enantiotropism are also tested for 
kinetics of thermally mediated transitions, as shown here.  
3.3.4. Exposure of R-II to high-shear mechanical energy 
Although the R-II to R-I conversion kinetics upon exposure to T > Ttr appear to be 
much slower than the kinetics of chemical degradation at the same temperature, it is 
anticipated that during typical manufacturing operations, ribavirin will be exposed to 
mechanical stress conditions potentially capable of accelerating the kinetics of solid state 
transformations.  Milling of R-II in a vibratory impact mill prior to isothermal 
temperature experiments was expected to damage crystallite surfaces to the extent that a 
commensurate increase in molecular mobility around damage sites would enable either a 
sufficiently rapid polymorphic transformation that observation is possible prior to 
extensive chemical degradation, or, potentially facilitating a direct conversion during 
prolonged mechanical treatment. 
Vibratory impact ball milling: Samples of R-II were extensively milled in a 
vibratory impact mill without temperature control. In a previously published paper,163 
bulk ribavirin that was ball milled for 50 min resulted in only 0.642 % w/w conversion to 
R-I, as estimated using only DSC. Therefore, in the present work, R-II was milled for 60 
min, with the intent of creating surface defects on ribavirin crystallites without causing 
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detectable phase change. This was confirmed using PXRD patterns of milled R-II 
samples, which showed that, even after 60 min milling, the crystallites still diffracted at 
2 angles entirely consistent with the R-II reference pattern (Figure 3.6). 
 
 
Figure 3.6. PXRD patterns of R-II milled for various time intervals in a vibratory impact 
ball mill. Note: Eventual conversion from R-II to R-I at 270 min of milling. 
 
 The diffraction peaks were observed to broaden, relative to the starting material, 
as evidenced in the full width at half maximum (FWHM) of characteristic peaks, 
suggesting a potential reduction in R-II crystallinity as a consequence of impact milling 
(See Table 3.2).  
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Table 3.2. Comparison of full width half maximum (FWHM) between diffraction 
patterns of R-II as a function of milling time in vibratory impact ball mill. 
 
Miller 
indices (hkl) 
Position (°2) Full width at Half Maximum – FWHM (°2) 
R-II 
(before milling) 
R-II 
(milled 60 min) 
R-II 
(milled 180 min) 
(110) 11.92 0.0836 0.1840 0.2676 
(210) 13.43 0.0836 0.2007 0.2676 
(310) 15.59 0.0836 0.1673 0.2676 
(201) 18.15 0.1171 0.1840 0.2676 
(420) 27.12 0.1506 0.4015 0.2342 
- 30.56 
30.82 
0.1171 
0.1171 
0.4015* 0.3346* 
- 32.04 
32.35 
0.1506 
0.1004 
0.2007* 0.5353* 
*double peaks merge into a single peak 
 
Although particle size (PS) reduction can lead to similar PXRD pattern 
broadening,192  optical microscopy of the R-II samples taken before milling (d10 = 8.1 µm; 
d50 = 14.8 µm; d90 = 30.4 µm) and after milling (d10 = 5.4 µm; d50 = 11.2 µm; d90 = 32. 9 
µm) did not show significant reduction in the PS of R-II primary particles.  These data 
suggest that much of the mechanical energy was used to induce defects, resulting in 
dislocated molecules that are lost as contributors to diffracting planes, thereby broadening 
the diffraction pattern.193  Similarly, the BET results for R-II exhibited a comparable 
trend with PS data, in which the specific surface area (SSA) did not change significantly 
for samples measured following milling (1.4 m2/g) relative to those measured prior to 
milling (1.1 m2/g). These results are similar to those from a published study194  in which 
it was reported that cryogenic grinding of ketoconazole particles caused nominal fracture, 
which ceased after 5 min of milling time. In this same study, milling for 10 and 30 min 
did not result in continuous particle size reduction, possibly due to sintering or fusion of 
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fines onto larger particles, which was reflected in BET measurements for milled 
ketoconazole in which the increase in SSA (relative to unmilled samples) after 30 min of 
milling was < 1.0 m2/g. It is important to consider that a tiny fraction of amorphous 
ribavirin (if formed) could remain undetected; hidden under the strong Bragg peaks of the 
milled crystalline ribavirin. To eliminate this ambiguity, DSC analysis of ground R-II 
was performed at multiple heating rates. Slow heating rates of up to 5 °C/min resulted in 
thermograms having a single melting endotherm, attributable to R-I (Tm = 176.09 °C; 
ΔHm = 38.4 KJ/mol) without a recrystallization exotherm or glass transition prior to this 
event.  At first, these data seemed to contradict the PXRD observations, which showed no 
detectable R-I in the milled samples. Close inspection of the thermograms, however, 
showed a small endotherm between 144–146 °C, having an enthalpy of 1.9 kJ/mol, 
suggesting that the milled R-II converted to R-I in situ during DSC experiments, owing to 
the imposition of a temperature ramp on the samples during the experiment (Figure 
3.7a). In contrast, DSC measurements conducted at more rapid ramp rates (10, 20 and 40 
°C/min), showed two endothermic events, corresponding to both R-II and R-I, where the 
area of the peak attributable to R-II progressively increased with increasing experimental 
heating rate, while the onset and peak temperatures for R-II showed a 15-20% decrease 
with milling time (Figure 3.7b). These data suggested that the milled R-II samples 
underwent partial in situ conversion to R-I during the DSC temperature ramp, to an 
extent commensurate with longer times spent at higher temperatures.  As before, the 
PXRD data for milled R-II showed no R-I formation, while the DSC data for unmilled R-
II, showed no in situ conversion to R-I. The data collectively suggest that milling of R-II 
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resulted in the induction of crystal defects, which facilitated rapid conversion to R-I when 
those samples were exposed to T > Ttr.  
 
Figure 3.7. (a) DSC thermogram of R-II milled for 60 min a vibratory impact ball mill is 
compared with the untreated polymorph samples. The dotted circle highlights the 
endotherm associated with R-II to R-I transition in situ (See inset). (b) DSC thermograms 
of 60 min milled R-II, recorded at various heating rates. 
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Solid-state transformations caused in situ during DSC experiments have been 
reported for several pharmaceutically relevant materials.180,195,196 In the example of 
carbamezapine enantiotropes, DSC measurements at 2 °C/min resulted in an endothermic 
event attributable to form III  I transition, followed by melting of form I. It was only at 
higher heating rates (10, 20, 30 and 40 °C/min) that the melting of form III prior to 
melting of form I was observable. Furthermore, the melting of form III in every 
experiment was immediately followed by a distinct exothermic event attributed to 
formation of form I via sublimation. In the present case, the higher relative stability of R-
I near the melting temperature of R-II, and the apparent ease of nucleation and 
crystallization of R-I make direct assessment of the extent of polymorphic conversion 
impossible from a single DSC experiment, conducted at a single heating rate. 
Use of PXRD to characterize processed ribavirin was particularly beneficial in the 
present work. Had the conclusions been based only on DSC measurements, the data 
recorded at slow heating rates might have suggested complete transition to R-I as a 
consequence of milling, while those recorded at higher heating rates would have 
suggested a partial enantiotropic conversion, despite a consistent milling duration. As it 
turned out, neither interpretation would have been accurate, as demonstrated by the 
PXRD data which showed no conversion to R-I during milling. To further examine the 
effects of milling on the facilitation of R-II to R-I solid state conversion, milled R-II was 
held isothermally at 150 °C in a convection oven. In contrast to the unmilled R-II, which 
remained physically stable for 7 days before eventually chemically degrading, the milled 
R-II samples completely converted to R-I within 15 min isothermal storage.  
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Additionally, when the milled R-II samples were annealed at T < Ttr (50 °C), no 
conversion to R-I was observed. These data collectively suggest that the induction of 
defects in R-II crystallites during milling is needed in order to accelerate the conversion 
kinetics sufficiently that complete conversion to R-I at T > Ttr can be observed.  
It seems likely that the commercially available ribavirin products (all of which 
contain R-II), or any innovative new formulations will utilize pulverization during 
primary and/or secondary manufacturing. If the milled R-II particles later experience 
temperature excursions that exceed Ttr, during storage or transport, a relatively rapid 
conversion to R-I becomes much more likely. Should such an unanticipated change result 
in significant alterations in either dosage form performance or downstream material 
handling, a company that is unaware of this possibility may run into major regulatory 
challenges.197  
Additional impact milling experiments were conducted, which involved durations 
beyond 60 min.  As shown in Figure 3.6, when R-II was comminuted for 270 min in the 
uncontrolled temperature impact mill, complete conversion to R-I occurred in the milling 
vessel, as evidenced by the PXRD data.  The DSC data for the same samples, showed 
only a single melting endotherm, observed at all experimental heating rates (Figure 3.8), 
which was unambiguously attributable to R-I. Although there was no evidence in these 
samples of persistent amorphous ribavirin, it is likely that regional disordering during 
pulverization, by the accumulation of defects, provided sites of increased mobility that 
allowed rapid recrystallization to R-I, driven by localized heating inside the milling jar to 
temperatures potentially exceeding both Tg (~ 61 °C) and Ttr.  
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Figure 3.8. DSC thermograms of 270 min milled R-II measured at different heating rates. 
Complete R-II R-I conversion can be seen based on the single melting endotherm 
attributable to high Tm enantiotrope (R-I). DSC data recorded at 2 and 20 °C/min are not 
shown. 
 
In order to evaluate whether extensive comminution caused any chemical 
degradation, all milled ribavirin samples were analyzed using HPLC. Despite 
simultaneous exposure to high-shear mechanical energy and likely increased localized 
temperatures, the concentration of ribavirin recovered in all samples was >99%.  These 
data suggested that, although extensive processing under these conditions elicited a 
physical change in the ribavirin solid, the molecules remained chemically unaltered. 
Cryogenic impact milling: The observations described above starkly contrast the 
results of temperature controlled, cryogenic milling, which maintained samples, medium, 
and milling environment in a constant liquid nitrogen bath throughout processing. In 
order to isolate, as best as possible, the role of mechanical energy in defect formation, 
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from localized temperature build-up, the relative fraction of sample volume in the milling 
jar was kept consistent relative to the vibratory ball milling experiments.  
Characterization of cryomilled samples using PXRD and DSC showed 
progressive reduction of long-range lattice periodicity, resulting in the formation of 
completely disordered ribavirin after 120 min.  As shown in Figure 3.9, diffraction 
patterns for these milled samples have a prominent X-ray amorphous halo, while DSC 
data showed an observable Tg (61-65 °C), consistent with the measured value for 
ribavirin.  These results suggest that the limited molecular mobility attributable to the 
very low milling temperature (T << Tg) likely inhibited recrystallization of the ribavirin to 
either crystalline solid form. Additionally, the difference in particle size and morphology 
as a result of cryogenic grinding was negligible with all milled samples. Instead, 
micrographs revealed considerable de-agglomeration, irregular morphology, and surface 
crack formation, but little change in primary particle size.  This suggests that the 
incoherent scattering of X-rays from the 120 min cryomilled samples was due to 
complete loss of lattice periodicity, as opposed to a PS effect, confirming that the 
mechanical energy was used to disorder the crystalline solid particles rather than 
consumed by sequential fracture events.  
 
  94 
 
Figure 3.9. (a) PXRD patterns of R-II milled for various time intervals in a cryogenic 
impact mill. Note the halo pattern following 120 min cryomilling, suggestive of complete 
loss of lattice periodicity (b) DSC thermogram of R-II milled for 60 and 120 min a 
cryogenic impact mill is compared with the unprocessed starting material (i.e. R-II). The 
inset shows observed glass transition of ribavirin after 120 min of cryomilling, 
confirming transformation to persistent amorphous ribavirin. Data was recorded at 20 
°C/min. 
 
The results of cryomilling ribavirin indicated that the solid form of the “end 
product” was directly influenced by the temperature experienced during milling. These 
data follow nicely with the published observations for fananserine,198 where the milling 
temperature relative to the Tg of the material being milled determined the solid form of 
the end product. Fananserine milled above Tg (19 °C) resulted in transformation to its 
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metastable polymorph, while milling under liquid nitrogen temperatures resulted in 
complete conversion to the amorphous phase. This is because the milling temperature 
was well below Tg – 50 oC, a temperature at which mobility is expected to be too low to 
support recrystallization.  Even if localized temperatures exceeded cryogenic conditions, 
continuous maintenance of the liquid nitrogen bath, accompanied by regular cool down 
cycles during the milling protocol, are expected to keep the powder bed well below Tg for 
the material.167  Based on the observations for fananserine and the Tg for ribavirin (61-65 
°C), milling of R-II might have been expected to convert to the amorphous state as a 
result of either technique used in the present work, given that both the milling 
temperatures were < Tg. The characterization data, however, show that continuous 
impaction without temperature control resulted in conversion to R-I, rather than 
formation of a persistent amorphous solid. This seems likely to have been the result of 
localized temperature excursions in the vibratory impact mill, which exceeded Tg and, 
possibly even Ttr for ribavirin. This appears to be consistent with the results of Chieng et. 
al.199 who, using a similar impact mill, observed that the average temperature of a powder 
bed was increased by 30-35 °C within 60 min of milling and remained constant when 
milling was continued for 180 min. Such a prolonged elevation of the bed temperature for 
ribavirin would approach Tg, allowing for local heating at surfaces to exceed it. Although 
persistent amorphous ribavirin was not observed in samples milled without temperature 
control, it is plausible that R-II  R-I may have been the result of the formation of a 
transient amorphous intermediate, which rapidly recrystallizes to R-I at T > Tg.  
In the present work, the observed transformation of ribavirin is thought to be 
initiated when the long range order of R-II crystals was disrupted via application of high-
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shear stress, without substantial particle size reduction. The resulting defect accumulation 
facilitated sufficient molecular mobility that, when exacerbated by temperatures 
exceeding Tg, allowed collective reorganization of ribavirin molecules and direct crystal-
to-crystal transformation without the formation of a persistent amorphous intermediate. 
This type of mechanism has been observed in cold worked metals200,201 and potentially 
supports the observation of a solid-state change in R-II tablets when compressed at high 
loads.164  
There are several theories in support of formation of amorphous solids as a result 
of milling.  One hypothesis suggests that temperature elevation owing to continuous 
impact and attrition may sufficiently induce local hot points that exceed the Tm of the 
API, whereupon subsequent returns to ambient temperature would quench the material 
allowing for formation of amorphous solid by a series of melt/quench events. In the 
present work, however, the cryogenic environment rigorously maintains the experimental 
temperature ~360 oC below the Tm of ribavirin, making this mechanism unlikely.  
Alternatively, the model adapted by Wildfong et. al.,202 seems more potentially 
relevant.  In that work, the free energy required for incorporation of a critical dislocation 
density was related to the free energy change needed to convert the crystalline material 
into an amorphous solid.  At this critical density, the accumulated dislocations were 
thought to cause overall lattice perturbations such that the collective molecular bonds 
required to maintain periodicity of the lattice were lost. As with the present work, 
experiments conducted in the dislocation-based model, also rigorously controlled the 
milling temperature to inhibit recrystallization of any amorphous solid formed during 
milling, thereby facilitating persistence of the “end product” solid form. 
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Additional support for a dislocation-mediated transformation of R-II to 
amorphous ribavirin during cryogenic milling comes from considering the extension of 
Wildfong’s work by Lin et al.,171 who showed that the potential to become completely 
disordered as a result of continuous cryogenic milling was highly correlated to the 
combination of the Tg of the material being milled and the molar volume (Mv) of the 
molecules comprising the solid. According to their work, values of Tg and Mv that exceed 
the bivariate decision boundary g(Tg,Mv) correspond to materials that are predicted to 
form a persistent amorphous solid via continuous cryogenic milling. Calculation of the 
Mv of R-II (147.64 cm
3/mol), in combination with its Tg, and application to the decision 
boundary function described in Lin et al.,171 results in a value that corresponds with a 
material predicted to become completely amorphous during extensive cryomilling, which 
was confirmed by characterization of the milled samples.  
3.3.5. Recrystallization and kinetic irreversibility 
The reversibility of enantiotropic polymorphism can be identified using DSC.189,203 
Usually, the presence of an exothermic peak in a DSC thermogram occurring during the 
cooling cycle at a temperature close to that at which an endothermic transition occurs 
during heating, suggests that a reversible transition is observable. Accordingly, samples 
of phase pure R-I were allowed to melt in situ in DSC pans, followed by subsequent 
cooling at different rates (2 and 20 oC/min) in order to identify whether a distinct 
exothermic transition associated with re-conversion to R-II could be observed. Neither 
cooling rate, however, resulted in any observable thermal event surrounding the apparent 
transition temperature, suggesting that the high-melting enantiotrope of ribavirin, R-I, is 
kinetically irreversible, even if the temperature is decreased below the estimated Ttr. To 
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verify this observation, R-I samples were stored under various conditions of relative 
humidity (0%, 33%, 60% and 75%) at room temperature (T << Ttr), for 60 days. Despite 
much longer storage at conditions that should be favorable to the conversion from R-I to 
R-II, the high temperature enantiotrope remained unchanged under all humidity 
conditions, as evidenced by PXRD devoid of peaks attributable to R-II, and DSC 
thermograms showing only melting associated with R-I. This is relevant to the scenario 
described above, in which unanticipated conversion of R-II to R-I occur as a result of 
applied high-shear stress and elevated temperatures during processing. The DSC data 
suggest that R-I would be kinetically trapped, potentially resulting in batches that contain 
a mixture of solid forms having variable performance characteristics. Although the high 
aqueous solubility of either form of ribavirin would likely offset any potential differences 
in bioavailability stemming from phase impurity induced during manufacturing, 
differences in material handling and mechanical properties are more likely to be 
impacted, potentially manifesting as product uniformity and other regulatory issues.  
Given the results detailed herein, further investigation of this material seems warranted. 
 
3.4. Conclusion 
Process-induced transformations of solid materials have received a great deal of 
attention in the pharmaceutical industry, where understanding the relationships and 
pathways between different solid forms plays a role in determining the most suitable 
solid phase for a formulation and manufacturing scheme. The enantiotropic relationship 
between ribavirin polymorphs R-II and R-I was previously reported, however, 
determination of the solid state transition temperature of ~70 oC, and characterization of 
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the very slow kinetics of R-I  R-II reconversion are expected to provide more 
information regarding how these polymorphs may interconvert. Additionally, solid-state 
transformations of ribavirin were examined under different thermal and mechanical stress 
conditions. Unprocessed R-II did not transform into R-I, at T > Ttr, even after 7 days, 
however, following grinding, the same isothermal storage conditions resulted in rapid R-
II  R-I conversion.  This suggested that the energy barrier required to produce the high 
Tm enantiotrope was reduced by generating high mobility defects during milling. 
Extensive milling also led to complete R-II  R-I conversion, when the milling 
temperature was not controlled, likely proceeding via formation of a transient disordered 
phase, which rapidly recrystallized at T > Tg (See figure 3.10). In contrast, high shear 
cryogenic milling of R-II, conducted at T << Tg resulted in complete transformation to 
persistent amorphous ribavirin.  
These data suggest that the solid form that results from milling was determined by 
the interplay of two processes: (1) regional disordering of the sample due to continuous 
impact and attrition, and (2) thermally mediated recrystallization. Recrystallization to R-I 
takes advantage of the higher molecular mobility afforded by amorphous regions, which 
at T > Tg favors conversion to a crystalline phase. At T << Tg, however, continuous 
regional disordering eventually spreads throughout the sample as milling continues, and a 
completely disordered state can be achieved. 
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Figure 3.10. Schematic representation of solid state transformation in R-II. 
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Chapter 4: Preparation, characterization and 
evaluation of ribavirin loaded polymer microparticles 
for intranasal uptake  
 
4.1. Introduction 
Ribavirin [RBVN, 1-(-d-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide] is a 
water-soluble synthetic nucleoside (BCS class III drug) having broad spectrum antiviral 
properties.204 Although the activity of RBVN in vitro is promising,118-120 its in vivo 
effectiveness in the treatment of viruses affecting the central nervous system is reduced 
by its inability to cross the blood-brain-barrier (BBB). Previous studies reveal 
administration of RBVN via intraperitoneal, subcutaneous, and intramuscular 
injections121,122 proved ineffective against several encephalitis viruses in mice, and 
showed improved survival against subacute sclerosing panencephalitis (SSPE) in virus-
infected hamsters only when administered intracranially.122 Pursuit of alternative routes 
of administration for RBVN that increases CNS bioavailability, with the potential for 
patient self-care, requires further research. 
Intranasal (IN) drug delivery holds promise for CNS targeting, given its potential 
to bypass the BBB.7-10,17-19 Direct nose-to-CNS delivery occurs through the olfactory 
region of the nasal cavity, offering several advantages, including avoidance of hepatic 
first pass metabolism, rapid onset of action, and the potential for patient self-
administration. Nonetheless, targeted deposition and adequate residence time in the nasal 
cavity remain as challenges. Currently, an ideal formulation or device enabling drug 
deposition exclusively to the olfactory region is not known; however, ongoing research 
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continues to improve the fraction of dose that is delivered to this location.24,30  The 
deposition pattern for liquid IN formulations is influenced, in particular, by droplet size, 
with diameters >20 m resulting in almost 100% nasal deposition.70,75,79 Additionally, 
breath-actuated insufflation of solid particles (D90 <40 m) has indicated that preferential 
deposition of drug occurs on the olfactory tissue, while promoting longer retention of 
particles relative to liquid vehicle dosage forms such as metered sprays.98,103 This is 
suggested to be the result of slow hydration of powder particles in contact with the nasal 
mucus, which increases viscosity and provides greater resistance to mucociliary 
clearance.  
The key to successful nose-to-CNS delivery, is not only increased nasal residence 
time, but also increased CNS uptake of the targeted drug. Certain polymers have 
demonstrated utility in this regard,76,84 including poloxamers, which are tri-block-
copolymers consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO) 
monomer units. Owing to the thermoreversible sol-gel transition at physiological 
temperatures, poloxamers are suited for mucosal adhesion following i.n delivery. 
Additionally, poloxamers have also been shown to enhance permeation across the nasal 
mucosa, possibly owing to a combination of the inhibition of efflux transporters,123 
acceleration of solute diffusion within the lipid bilayer,127 and transient opening of the 
cellular tight junctions.205 One recent study showed that IN administration of the anti-
retroviral drug zidovudine in adult rabbits resulted in nearly 4-fold greater CNS 
concentrations from formulations containing poloxamer, presumably due to longer 
retention in the nasal cavity and/or permeation enhancement of the drug.129  
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Intranasal insufflation is less studied than instillation of droplets or inhalation of 
atomized liquid sprays. As a result, optimization of solid particle formulations intended 
for IN insufflation has received less attention in the literature. Formulation of very fine 
drug particles adsorbed onto the surfaces of larger inert carriers, analogous to dry powder 
inhalers, is unlikely to be successful for IN insufflation as the larger carrier particles 
would be more likely to settle under gravity and provide little or no deposition in the 
olfactory region. Physical mixtures of drug and polymer having comparable particle size 
ranges may be possible in some cases, however, segregation of components upon 
insufflation is undesirable. Consequently, in this study, formulation involved suspension 
of ultrafine drug particles in molten carrier polymer, followed by co-solidification upon 
cooling. Subsequent micronization allowed sizing of compositionally uniform particles 
according to IN delivery-specific recommendations. 
In the present work, preparation and characterization of binary composite solid 
microparticles of RBVN in poloxamer allowed evaluation of their potential use in direct 
CNS targeting using intranasal drug delivery.  It was hypothesized that deposition of 
these solid microparticles on the nasal mucosa would result in higher pemeation of 
RBVN across epithelial cells relative to a RBVN solution.  Solid drug-in-polymer 
microparticles were prepared, optimized, and characterized. Permeation of RBVN across 
olfactory mucosal tissue was studied in vitro and compared with permeation from liquid 
vehicle solutions of the drug. 
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4.2. Experimental Section 
 
Ribavirin was purchased from Jinan Jiaquan Chemicals Co. Ltd. (Jinan, China, 
Lot number 02110330). Poloxamer 188 NF (POX188, also referred to as Pluronic F68) 
was purchased from Spectrum Chemicals, New Brunswick, NJ (CAS Number 9003-11-
6). All powders were stored in a desiccator over P2O5 (~0% RH) for at least one week 
prior to experimentation, to remove environmental water. 
4.2.1. Determination of RBVN solubility in POX188  
Mixtures of RBVN and POX188 were manually prepared by geometric dilution at 
10, 20, 30, 40, 50, 60, 70, 80 and 85 % w/w with respect to polymer. Each physical 
mixture was analyzed using a differential scanning calorimeter (DSC), equipped with a 
refrigerated cooling accessory (Model Q100, TA Instruments, New Castle, DE, USA). 
Three replicate DSC samples (5.0 + 0.5 mg) were prepared at each composition placed in 
an Al sample pan that was hermetically sealed. Samples were heated from ambient 
temperature to 200 C at a constant heating rate of 2 °C/min. Dry N2 gas (50 mL/min) 
was allowed to constantly purge the DSC cell during all experiments, and measurements 
were subject to a three-point temperature and enthalpy calibration  accomplished using 
Sn (Tm 231.9 
oC), In (Tm 156.6 
oC), and o-terphenyl (Tm 55-56 
oC) standards. The 
endotherm attributable to melting of RBVN in the presence of varying amounts of 
POX188 was carefully recorded, and the depression of its extrapolated onset of melting 
(To), peak maximum (Tp) and enthalpy of melting (ΔHm) of RBVN were used to indicate 
solubility in molten POX188 which in turn would influence maximum drug loading. 
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4.2.2. Preparation of binary composite microparticles 
 
Physical blends of RBVN and POX188 were prepared in 1:1 w/w ratio using a 
laboratory scale blender, followed by equilibration at ~0% RH for 24 h.  These blends 
were assessed for content uniformity with a low variation (RSD <5%) chosen as the 
criteria for subsequent use. Physical mixtures were transferred to a crucible, which was 
immersed in a silicon oil bath maintained at 100 ºC which was higher than the melting 
temperature of POX188 (Tm = 55–60 °C), but well below the melting temperature of 
RBVN (Tm  = 168–170 °C). Crystalline RBVN was suspended in molten POX188 and the 
set temperature was maintained isothermally to allow homogeneous mixing.  To 
minimize water vapor sorption, dry N2 gas was continuously streamed over the crucibles 
during preparation. Following mixing, the 1:1 RBVN : POX188 suspensions were 
quenched by immersion of the crucible in liquid nitrogen, resulting in formation of a co-
solidified disc that was removed for further processing. 
To ensure no thermal degradation of the RBVN during suspension preparation, 
blends were held isothermally for 20-30 min in a thermogravimetric analyzer (TGA) at 
100 ºC, and <1% weight loss was recorded. Additionally, physical blends were heated in 
a DSC to 100 ºC and held isothermally for 30 min to assess time-dependent drug 
solubility in polymer.  Following these extended hold times samples were quenched in 
situ in DSC, before reheating. Recorded values for the melting parameters (To, Tp and 
ΔHm) between heating cycles remained consistent with pure component values, indicating 
that the RBVN remained undissolved in POX188 during suspension preparation.   
To make the co-solidified discs suitable for simulation of IN delivery, mechanical 
sizing was accomplished using a cryogenic impact mill (SPEX Certiprep 6750 Freezer 
  106 
Mill, Metuchen, NJ). Approximately 1.0 g of RBVN : POX188 (1:1) solid suspension 
was manually broken down into coarse particles (~3-4 mm), which were placed in a 
cylindrical polycarbonate milling vessel. A stainless steel cylindrical milling rod was 
placed in the vessel, and the sample temperature was allowed to equilibrate for 3 min 
prior to milling, following immersion in the mill liquid nitrogen bath.  The processing 
temperature was continuously maintained during comminution by regular replenishment 
of the liquid nitrogen bath. Similar to Crowley and Zografi,167 materials were ground for 
2 min intervals at a frequency of 10 Hz, separated by 2 min cool-down periods, allowing 
minimization of local sample temperature increases. Upon completion of 20 min total 
milling, the ground sample was sieve fractionated (Performer III Model: SS-3, Gilson 
Company, Lewis Center, OH) and the fines that passed through the 53 µm sieve (US 
standard number 270) were collected and stored over P2O5. Subsequent characterization 
of milled particles was performed to verify maintenance of RBVN phase purity during 
manufacturing, sample potency, chemical stability, particle size, and morphology. All 
characterization experiments were repeated in triplicate. 
4.2.3. Characterization 
 
4.2.3.1. Ribavirin solid phase purity 
Binary microparticles obtained through cryogenic grinding were characterized to 
ensure that processed RBVN maintained a single solid form, using powder X-ray 
diffraction (PXRD) and differential scanning calorimetry (DSC). PXRD patterns were 
obtained using an X’Pert Pro MPD system (PANalytical B.V., Almelo, the Netherlands), 
equipped with a Cu anode (λ = 1.5406 Å), an auxiliary elliptical mirror, and an 
X’CeleratorTM detector. Powder samples were loaded between two layers of Kapton® 
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film (ChemPlex, Palm City, FL) and spun in a vertical sample stage. Consistent 
irradiation times of 135 s per step with an angular step size of 0.017 °2 were used for all 
diffraction experiments. PXRD data were collected over 5–50 °2θ, using a respective 
voltage and amperage of 45.0 kV and 40.0 mA. 
Conventional DSC measurements were made to determine the melting 
temperatures (Tm) of ribavirin polymorphs. Accurately weighed samples of 5.0 + 0.5 mg 
were hermetically sealed in Al sample pans and heated at either 2°C/min or 40°C/min to 
200 ºC.163 All measurements were performed in triplicate and reported as mean values + 
standard deviation. 
4.2.3.2. Assessment of Particle properties 
The particle size and size distribution of sieve cuts containing 20–53 μm 
microparticles were analyzed at 10x magnification using an Olympus BX-51 optical 
microscope equipped with a polarizing filter. Photomicrographs were obtained to 
evaluate size and measure the Feret diameter for approximately 300 particles and 
crystallinity was confirmed through notable birefringence. Additionally, scanning 
electron microscopy (Hitachi S-3400N scanning electron microscope equipped with a 
Bruker Quantax model 400 energy dispersive spectrometer using an XFlash® 5010 EDS 
detector) was used to image particles and assess morphology. Samples were mounted on 
double-sided carbon tape affixed to an aluminum specimen holder. Images were collected 
using a working distance of 15 mm and an accelerating voltage of 2 kV. 
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4.2.3.3. Microparticle drug content and Content uniformity 
Drug content was measured by dissolving a mass of RBVN : POX188 (1:1) 
composite microparticles equivalent to a dose of 20 mg RBVN in distilled water.  The 
resulting solutions were filtered through 0.45 m filter and diluted for HPLC analysis. 
Particle content uniformity was determined by randomly choosing 12 samples from the 
milled and sized powder. A low variation (RSD <5%) was chosen as the acceptance 
criteria for drug uniformity.  
Finally, to ensure RBVN chemical stability during temperature-intense 
suspension preparation, and shear stress-intense particle sizing, the potency of RBVN 
extracted from microparticles was compared with untreated raw material. All 
measurements were reported as mean + SD. Precise RBVN concentration measurements 
for all samples were made with a Waters Alliance 2690 HPLC system (Milliford, MA) 
equipped with photo diode array (PDA) detector using a Hypersil C18 reverse phase 
column (5 m, 250 mm x 4.6 mm i.d., Waters, MA, USA). Previously filtered and 
degassed mobile phase comprising of 95:5 v/v mixture of 0.01 M potassium dihydrogen 
phosphate solution and pure methanol (pH adjusted to 5) was used. The mobile phase 
was pumped continuously at a flow rate of 1.0 mL/min with an injection volume of 20 
L. Standard solutions and test samples were analyzed at the detector wavelength of 207 
nm. All sample solutions were diluted in mobile phase. 
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4.2.4. Evaluation of Microparticle Performance 
 
4.2.4.1. in vitro Drug Release 
The in vitro RBVN release studies were performed using Franz diffusion cells 
(PermeGear, Hellertown, PA). Regenerated cellulose dialysis membrane (Spectrum 
Laboratories Inc., Houston, TX) was mounted between the donor and receiver 
compartments of the diffusion cell. The receiver compartment was filled with 5 mL of 
simulated nasal electrolyte solution (SNES), thermostated at 37+1 ºC and gently agitated 
(200 rpm) by means of a magnetic stirrer. SNES was prepared with 8.77 g NaCl, 2.98 g 
KCl, 0.59 g CaCl2 anhydrous in 1000 mL distilled water with the final pH adjusted 
between 6.0 and 6.5. Microparticles characterized in Section 4.2.3 containing no more 
than 5.0 mg of free drug (dose adjusted accordingly) were evenly sprinkled on the pre-
hydrated dialysis membrane. Only 20 µL SNES containing 2% w/v mucin was added to 
the donor side in order to maintain a hydration environment similar to that in the nasal 
cavity.142  
At predetermined time intervals, 200 µL samples were withdrawn from the 
sidearm of the receiver compartment and replaced with fresh, pre-warmed dissolution 
medium. The amount of drug released was assessed spectrophotometrically (UV 
Spectrophotometer 8453, Hewlett Packard, Germany) at λmax of 207 nm (Linearity range 
= 5 μg/mL to 17.5 μg/mL, R2 = 0.9998). To ensure mass balance, the residual powder in 
the donor compartment was dissolved in 200 µL of fresh, pre-warmed SNES and 
assayed. Each release experiment was performed in triplicate.  
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 4.2.4.2. in vitro Nasal Cell Toxicity 
RPMI 2650 human nasal septal carcinoma cells (ATCC cat. no. CCL 30) cells, 
between passages 27 – 32, were grown in Eagle’s minimal essential medium (MEM) 
supplemented with 10% fetal bovine serum (FBS) 2 mM L-glutamine, 100 units/mL 
penicillin and 100 mg/mL streptomycin, in collagen coated T-75 flasks (Novagen Inc. 
Germany) humidified at 37 °C incubator with 5% CO2. The medium was changed every 
48–36 hours. Cells were trypsinized with a 0.1% trypsin-EDTA solution upon reaching 
80-90% confluency. Cytotoxicity assays were conducted using cells that were passaged at 
a density of 3 x 104 cells per well in 200 µL culture medium to collagen-coated 96-well 
plates (Novagen Inc. Germany), and incubated overnight for cell attachment. 
Subsequently, 100 µL of culture medium was removed from all wells and changed with 
appropriately diluted solutions of only RBVN, only POX188 or RBVN and POX188 
mixture (1:1) in MEM to achieve final concentration spectrum of 0, 7.8, 15.6, 31.25, 
62.5, 125, 250, 500, 1000 µg/mL of each ingredient and incubated for 24 h.  
Cell viability was determined by adding the CellTiter-Glo reagent (Promega). 
For this, 50 µL media containing treated cells was transferred to an opaque-walled 
multiwell plate. About 25 µL of CellTiter-Glo® reagent was added to every well. The 
contents were mixed for 15 minutes on an orbital shaker to induce cell lysis. The plate to 
incubated at room temperature for 10 minutes to stabilize luminescent signal 
andluminescence was measured using a microplate reader (Model 1420-051, Victor3, 
Perkin Elmer, Shelton, CT).  Control wells were prepared by mixing 50 µL of media 
without cells and  25 µL of CellTiter-Glo® reagent to obtain a value for background 
luminescence. 
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4.2.4.3. in vitro Permeation Measurements 
Bovine olfactory mucosa was used as a model tissue for permeation studies, 
where L-DOPA permeability was measured by adapting the methods published by 
Chemuturi et al.143 Briefly, cow heads were obtained from Bud’s Custom Meats 
(Riverside, IA). The olfactory turbinates, which were covered by a pale yellow olfactory 
mucosa, were removed within 15 min of decapitation. The excised tissues were 
thoroughly rinsed with KRB and transported in fresh KRB maintained on ice; all studies 
were conducted within 4 h of procurement to ensure tissue viability.   
The permeability of RBVN molecules through the bovine olfactory mucosa was 
measured during experiments that used Franz diffusion cells displaying a permeation area 
of 0.64 cm2. Tissue was carefully removed from the underlying cartilage and affixed with 
the mucosal side facing the donor compartment, between the opposing faces of the two 
half-chambers (donor and receiver), using a series of pins that surrounded the opening.  
Five mL of Krebs ringer buffer (KRB, pH 6.8), pre-warmed to 37 °C, was added to the 
acceptor chamber. To ensure oxygenation and agitation, a mixture of 95% O2 and 5% 
CO2 was bubbled through the system. The temperature within the chambers was 
maintained at 37 °C. After 30 min equilibration, RBVN was loaded either as a 5 mg/mL 
aqueous solution, 5 mg of solid particles, or 10 mg of 1:1 RBVN : POX188 
microparticles. For the solid sample test groups, an additional 50 L of KRB was added 
to the donor compartment to mimic the low hydration volume of a typical nasal cavity. At 
predetermined time points over a 2 h interval, 250 L samples were withdrawn from the 
acceptor compartment, and replaced with an equal volume of fresh, pre-warmed KRB. 
The samples were appropriately diluted, filtered and used for quantification. The amount 
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of permeated drug was determined using UV-visible spectrophotometry at λ = 207 nm 
(Linearity range = 5 μg/mL to 17.5 μg/mL, R2 = 0.9998). The apparent permeability 
coefficient (Papp) (cm/s) was calculated according to the following equation. 
 𝐏𝐚𝐩𝐩 =  
(
𝐝𝐌
𝐝𝐭
.
𝟏
𝐀
).
𝐂𝐨
𝐱 𝟔𝟎                                                                                                 (4.1.) 
where M is the cumulative amount of drug in the receiver cell at time t, dM/dt is the mass 
transport rate obtained from linear regression of the initial steady-state portion (µg/min), 
A is the diffusion area (0.64 cm2) and Co is the initial donor concentration (µg/mL). 
 
4.3. Results and Discussion 
4.3.1. Preparation of Binary composite microparticles 
Composite microparticles were designed to contain phase-pure inclusions of 
crystalline RBVN suspended by a POX188 matrix to enable intimate mixing between the 
two components and alleviate segregation issue likely with a simple physical mixture of 
RBVN and POX188. This was intended to be achieved by heating 1:1 RBVN : POX188 
mixtures to 100 °C (Tm, polymer < 100 °C < Tm, API), allowing melting of the polymer and 
distributive mixing of the fine solid drug particles.  Rapid solidification of the polymer 
would result in suspension of phase-pure API cyrstallites surrounded by a re-solidified 
polymer matrix, as demonstrated previously.206 Prior to this, the decision of drug loading 
was based on the DSC data taken for physical mixtures of RBVN and POX188 at various 
compositions (Figure 4.1). Each DSC thermogram was observed to have two distinct 
melting endotherms consistent with the values for POX188 (57.07 + 1.31 °C) and the low 
Tm enantiotrope of RBVN, R-II (166.87 ± 2.03 °C) .163 Of note, neither the onset of 
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melting (To) nor the peak maximum temperature (Tmax) deviated significantly relative to 
either pure component, indicating that little to no drug dissolved in the molten polymer 
during preparation, confirming preparation of the desired suspension. Avoiding partial or 
complete dissolution of RBVN in molten polymer was deemed important to prevent 
heterogeneous formation of molecularly dispersed drug-polymer solid solution 
surrounded by variable degrees of suspended crystalline RBVN. It was thought that such 
systems would likely have highly varied delivery rates, the potential for non-uniform 
moisture uptake, and potentially issues with respect to insufflation, nasal deposition, 
dissolution and permeation profiles.  
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Figure 4.1. (a) DSC thermograms of physical mixtures of RBVN and POX188 in varying 
proportions of polymer measured at the heating rate of 2 °C/min. (b) Extrapolated onset 
of melting plotted as a function of polymer composition.  
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These data also suggested that a relatively high fraction of RBVN could be suspended in 
POX188, allowing the formulation to balance the need for reasonable dosing with the 
presence of sufficient polymer to promote permeation enhancement. As such, 
formulations containing 25% or 50% w/w RBVN were selected for subsequent 
experimentation. 
Figure 4.2 shows a schematic representation of the process by which 1:1 RBVN : 
POX188 binary composite microparticles were prepared.  Solidified drug-polymer 
mixtures had to be milled in order to achieve nasally administrable particle sizes. A 
SPEX Certiprep freezer mill was chosen to micronize the samples, owing to cryogenic 
temperature control throughout the comminution process. In Chapter 3, it was noted that 
when RBVN was cryogenically milled for longer than 60 min, changes in solid form 
were observed.  In the present work, therefore, total milling exposure was limited to 
shorter times (i.e. 10 or 20 min). 
 
Figure 4.2. Schematic representation of RBVN : POX188 (1:1) binary composite 
preparation. 
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In this manner, a 2x2 full factorial design of experiments was created with drug 
loading (as factor 1) and milling time (as factor 2). The effect of these factors on physical 
transformation, particle size and size distribution and content uniformity was studied. The 
results are summarized in Table 4.1 and detailed discussion on the chosen formulation is 
provided in the later sections. 
 
Table 4.1. Properties of BCM prepared using 2x2 full factorial design of experiments 
(DoE) with % w/w drug loading (as factor 1) and milling time (as factor 2). 
 
Formulation Drug 
loading 
(% w/w) 
Milling 
time 
(min) 
% Yield 
(20 μm 
sieve cut) 
Evidence of 
physical 
transformation 
Drug 
content 
F1 50 20 48 % No RSD 9.8 
F2 50 10 42 % No RSD 3.0 
F3 25 20 42 % No RSD 4.6 
F4 25 10 30 % No RSD 2.6 
RSD – Relative standard deviation 
 
As the data indicate, none of the four formulations showed evidence that milling 
caused a physical transformation of the RBVN; however the yield from milling varied, 
represented by the sieve fraction of interest, and the drug content. Based on these results, 
F2 (50% w/w drug loaded product milled for 10 min), which demonstrated moderate 
yield with very tight drug content and content uniformity, was used for subsequent 
experiments. 
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4.3.2. Characterization of Microparticles 
4.3.2.1. Solid state properties 
PXRD and DSC were used to characterize the microparticles following 
preparation and processing. The PXRD patterns of pure component RBVN powder, 
POX188 powder, and processed microparticles were compared as shown in Figure 4.3. 
As shown, the reference diffractograms for the RBVN and POX188 show characteristic 
Bragg peaks, respectively at 11.94, 18.15, 20.3, 20.6, 24.44, 27.1 °2θ  and 19.1, 22.0, 
23.2 °2θ, all of which were conserved in both physical mixtures as well as processed 
microparticles. These data indicate that the crystal form of both components was 
preserved throughout preparation. 
 
Figure 4.3. PXRD patterns of 1 : 1 RBVN and POX188 product as it progresses through 
the different stages of manufacturing scheme, PM – physical mixture, SS – solid 
suspension post cooling in ice water, BCM – Binary composite microparticles after sieve 
fractionation. PXRD patterns of pure components are provided for comparison. 
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Figure 4.4 shows a comparison of DSC thermograms for pure components with 
those of a 1:1 physical mixture and 1:1 RBVN : POX188 microparticles. The DSC 
thermogram for pure RBVN showed only a single single sharp endothermic peak at 
168.64 ± 0.21 °C, consistent with melting of the room-temperature stable polymorph, 
Form R-II.163 POX188 thermograms had an endothermic peak at 54.32 ± 1.39 °C, 
consistent with literature values for its melting.206 DSC data for the 1:1 composite 
microparticles showed two distinct endothermic peaks, one at 55.9 ± 1.59 °C and 
168.2 ± 0.48 °C, which were attributable to POX188 and RBVN, respectively, while the 
thermograms for the microspheres, slow heating DSC curve (2 oC/min) was similar to 
that for physical mixture with no reduction in the melting of POX188 and a 3 °C 
depression in the onset of melting of RBVN. These differences could be the effect of 
particle size reduction that the microparticles were subjected to during milling. None of 
the microparticles showed any evidence of a solid form change, confirming that RBVN 
and POX188 remained phase pure. It is noted that high heating rate (40 oC/min) was 
applied for improving detectability of small quantities of amorphous RBVN/R-I, but no 
discernable changes were observed.  
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Figure 4.4. DSC thermograms of pure RBVN, pure POX188 and the milled + sieve 
fractionated composite microparticle drug product at 2 °C/min heating rate. 
 
4.3.2.2. Particle properties 
In the present study, the selected sieve fraction of composite microparticles was 
characterized for particle size distribution and bulk morphology (Figure 4.5a – 4.5b). 
The median primary particle size (d50) was 20.6 µm, with d10 and d90 respectively 
measuring 6.03 µm and 48.1 µm (See Fig. 4.5c). When observed under polarized light, 
particles prominently exhibited birefringence suggesting that RBVN remains in 
crystalline state (data not shown).  
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Figure 4.5. (a and b) Micrograph depicting particle size distribution of 1:1 RBVN : 
POX188 binary composite microparticles. The particles were not immersed in oil, 
observed through a 10× objective. These micrographs were used to measure Feret 
diameter (n = 300) particles; (c) particle size distribution of primary particles observed in 
(a and b). 
 
Scanning electron microscopy (SEM) technique was used to assess the bulk 
morphology of final microparticles. Relative to the agglomerated needle-like morphology 
of standalone RBVN and spherical shape of POX 188, the binary composite 
microparticles demonstrated irregular surface morphology (figure 4.6). Although the 
morphology of particles obtained from analytical samples may not be particularly 
favorable for reproducibly emitted doses from nasal devices, it is expected that the size 
reduction step necessary at larger scales will likely make the particle morphology more 
regular; making it suitable for insufflation and nasal deposition. 
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Figure 4.6. Scanning electron micrographs: (A) unprocessed ribavirin, (B) poloxamer 
188 and (C) 1:1 (w/w) milled + sieved fractionated composite microparticles. 
 
4.3.2.3. Drug content and uniformity 
Samples were randomly withdrawn from the microparticles collected on the 20 
μm sieve and assessed for drug content. Based on spectrophotometric analysis, the mean 
RBVN content was measured to be 50.1 %w/w with a relative standard deviation RSD of 
3.0. This suggests that the two components of the microparticle system were adhered 
strong enough to overcome the mechanical stresses of milling and sieve fractionation. For 
comparison, a control group comprised of a 1:1 physical mixture of RBVN and POX188 
(both components individually milled to 20 – 53 μm particle sizes) was prepared in lab 
scale V-blender. This mixture was exposed to mechanical sieve shaking similar to 
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composite microparticles. Interestingly, segregation into individual components was 
observed within 10 min of mechanical shaking, resulting in a mean RBVN content of 
52.1 %w/w with poor RSD of 8.3, which worsened as shaking continued. Similar to this 
observation, segregation of RBVN and POX188 is likely to occur during transport and/or 
insufflation of a dry, solid, nasal drug product, potentially manifesting as inconsistent 
performance. As a result, physical mixtures of RBVN and POX188 were felt unlikely to 
be viable formulations; therefore only the binary composite microparticles were 
evaluated for in vitro performance. 
 4.3.3. Evaluation of formulation 
4.3.3.1. in vitro Drug Release 
Drug release from microparticles was evaluated in vitro using a semi-permeable 
regenerated cellulose membrane to separate donor and receiver compartments in a Franz 
diffusion cell. A 3000-3500 Da MWCO (molecular weight cut off) was used to facilitate 
selective permeation of dissolved RBVN molecules (molecular weight = 244.21 Da), 
while retaining the POX188 molecules (average molecular weight = 8400 Da) on the 
membrane surface. In contrast to typical diffusion experiments, the dissolution volume on 
donor side of the Franz cell was purposely maintained at 20 µL to mimic the hydration 
volume in a typical adult human nasal cavity. Consequently, in vitro release experiments 
were considered to consist of three-steps: (1) drug dissolution within the hydrated 
polymer matrix (2) drug diffusion through the polymer matrix into the donor fluid, and 
(3) accumulation of drug in the receiver side of the diffusion cell, after passing through 
the membrane.  
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It is acknowledged that the chosen release model only allows for multiple 
sampling from the receiver side which, in turn, provides information about the rate of 
drug accumulation in the receiver side. It does not, however, directly assess the first two 
processes i.e., drug dissolution and diffusion rates. Owing to the complexity associated 
with this setup, a control group of pure component RBVN microparticles was added to 
the experimental design to eliminate one of three abovementioned processes i.e., drug 
diffusion from the polymer matrix.  Furthermore, it is conservatively assumed that RBVN 
permeation through the cellulose membrane is less likely to be rate-limiting as the pore 
size of the membrane (~1-10 nm reported by manufacturers) is considerably larger than 
the size of single drug molecule dissolved in water. By this argument, the observed 
“apparent release” profile from standalone RBVN microparticles (see figure 4.7) is an 
indirect estimation of drug dissolution in the donor side.   It can be seen that dissolution 
of RBVN in the donor side is not instantaneous but proceeds gradually over the course of 
the experiment. Approximately 70% of the drug was released (or dissolved in this case) 
in 45 min, which reaches completion (~97%) within 180 min. 
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Figure 4.7. The apparent cumulative RBVN release from standalone solid drug particles 
(black circles) and binary composite microparticles (grey circles).   
 
When these data are compared with the RBVN release rate from binary composite 
microparticles, the influence/effect of POX188 on drug release became clear. Although 
the extent of cumulative RBVN release from polymer microparticles remained 
comparable at 180 min, it is noteworthy that the initial release rate was slower relative to 
the pure component drug particles. This result was not unexpected because the RBVN 
particles have to not only undergo dissolution in the donor side but the dissolved RBVN 
molecules have to diffuse through the polymer matrix prior to permeation, collectively 
decreasing the rate at which drug molecules appear in the receiver compartment.  
Poloxamers® are known to exhibit reversible thermal gelation and their effect on 
drug release is extensively studied.207-210 Evidence suggests that in an aqueous solution, 
the copolymer molecules aggregate as micelles when the temperature is increased. The 
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micellization is likely due to the dehydration of the hydrophobic PPO blocks with 
temperature. At sufficiently high concentrations and temperature, these micellar 
structures entangle to form rigid gels, which in turn produces a decrease in the number 
and size of water channels, leading to an increased path length for diffusion. A decrease 
in RBVN release rate from binary composite microparticles is attributed to poloxamer 
gelation in the donor compartment. As the release experiments progressed, rapid 
conversion of  solid RBVN : POX188 composite microparticles into a thin film was 
observed; which supports this claim. According to the data, it took approximately 75 
mins for 70% drug to release, which was 1.7 times longer than the control group. While it 
can be argued that such a release rate is not reflective of the human nasal clearance time 
(estimated at 10-20 min, and most drug may remain unabsorbed and lost, there is some 
literature data to suggest that poloxamer containing gel formulations can be retained in 
the nasal cavity for up to 100-110 min.128,129 This suggests that >90% drug release can be 
assumed in the nasal cavity from the microparticles formulated in this study.  
4.3.3.2. in vitro Cytotoxicity 
 During the development of drug-loaded formulations for IN administration, 
preclinical studies assessing transmucosal drug transport or toxic effects of excipients can 
be performed using excised tissue, primary cell cultures, or immortalized cell lines.211 
Excised human tissue is not only difficult to obtain, but also presents inter- and intra-
individual differences. As a consequence, drug permeation studies are usually performed 
in nasal mucosa excised from experimental or slaughtered animals, which introduce other 
drawbacks, such as species differences in tissue composition, transporter expression and 
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ethical concerns. Alternatively, in vitro human cell lines (primary and immortalized) can 
be used to evaluate drug formulations.  
Immortalized cell lines from human origin are of great interest owing to good 
genetic homogeneity, data reproducibility and ease of culture maintenance.212 In 
particular, RPMI 2650, an immortalized cell line derived from an anaplastic squamous 
cell carcinoma of the human nasal septum, is the only commercially available cell line 
having morphological and biochemical resemblance with normal human nasal 
epithelium.211-214 These RPMI 2650 cells were investigated as a permeation model to 
evaluate RBVN : POX188 (1:1) solid microparticle formulations prepared and 
characterized in Section 4.3.1 and 4.3.2, respectively. Prior to the permeation 
experiments, it was imperative to assess the safety of nasal epithelium in the presence of 
the components of microparticles. For this reason, RPMI 2650 cell viability was studied 
after 24 h of incubation with pure RBVN, pure POX188 and 1:1 mixture of RBVN and 
POX188 over a spectrum of concentration and the results are captured in Figure 4.8. 
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Figure 4.8. Cytotoxicity assay using CellTiter Glo® reagent (reported as mean ± SD, 
n ≥ 3): RPMI 2650 cells were incubated with varying concentrations of POX188 only, 
RBVN only and RBVN: POX188 (1:1) mixture for 24 h at 37 °C and 5% CO2 humidified 
atmosphere. 2 mg/mL stock solutions prepared in high-grade sterile water was sterile 
filtered and serially diluted with media to generate the spectrum of concentrations used 
here. For 1:1 physical mixtures, appropriate dose adjustment was done (i.e. 4 mg/mL 
stock) was prepared to obtain concentrations upon dilution that are comparable to the 
other test groups. Statistical differences within the same group are denoted as; **P < 
0.01; ***P < 0.001 and between groups are denoted as #P < 0.05. 
 
 
The effect of increasing ribavirin concentration on the viability of RPMI 2650 
cells is shown here. As expected, higher concentrations of RBVN resulted in a greater 
reduction in cell viability.  In the test group containing only RBVN, the measured cell 
viability was reduced by 25.7 %, 30.1 % and 36.8 % respectively, at concentrations 250, 
500 and 1000 μg/mL. RBVN is known to inhibit the synthesis of DNA within cells, 
resulting in cell death and prevention of cell division.215, 216  
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In contrast to the results above, pure component POX188 showed no significant 
cytotoxic effect  over the entire concentration range studied, which was in close 
agreement with observations in other cell lines.217, 218 Poloxamers® have been shown to 
have cytoprotective effect in vitro and in vivo.219,220 The most well-documented 
characteristic of POX188 is its ability to repair damaged cell membranes by mechanisms 
that, while not entirely clear, may be attributable to helping increase the lipid packing 
density by direct incorporation of POX188 into the phospholipid bilayer.221 In the present 
study, when the cells were exposed to RBVN in the presence of POX188, the viability 
was improved considerably, which was more prominent at higher concentration. At 1000 
μg/ml, cells incubated with RBVN exhibited 63.2% viability, which was improved to 
89.5% in the presence of POX188. It is plausible that poloxamer may have sequestered 
RBVN from entering into the cells through the ability to incorporate in lipid bilayer.  
It is acknowledged that the time of incubation used in these experiments is not 
reflective of human nasal residence time; however, the extension of exposure time 
guaranteed an observable and quantifiable change in viability that enabled a comparison 
of the cytotoxicity between test groups. Based on these results, 1000 μg/mL initial RBVN 
concentration was used for in vitro permeation experiments using a nasal cell line, with 
an exposure period of only 4 h where no cytotoxicity was observed (data not shown). 
Using the method laid out by Bai et. al.213 and Goncalves et. al.222 attempted growth of 
RPMI 2650 monolayers (See figure 4.9a) at air-liquid interface was performed. The 
RPMI 2650 cells were seeded (at a density of 4 × 105 /cm2) onto collagen-coated 
permeable polytetrafluoroethylene inserts and grown at an air–liquid interface for 8-10 
days. Unlike Bai et. al., however, our repeated trials failed to produce polarized 
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monolayers with cells interconnected through tight junction proteins. Instead, clusters of 
cells and distinct open regions resulting in a ‘leaky’ permeation membrane were 
observed, as represented in figure 4.9b. Therefore, it was decided to incorporate freshly 
excised olfactory tissue from bovine source as the model for permeation.  
  
Figure 4.9. (a) A representation of permeation barrier produced with RPMI 2650 nasal 
cell line uniformily grown at an air-liquid interface within the cell inserts. Reprinted from 
International Journal of Pharmaceutics, 515, Vanessa S.S. Gonçalves, Ana A. Matias, 
Joana Poejo, Ana T. Serra, Catarina M.M. Duarte, Application of RPMI 2650 as a cell 
model to evaluate solid formulations for intranasal delivery of drugs, pp:1-10, Copyright 
2016, with permission from Elsevier. (b) A microscopic image of RPMI 2650 cells 
growing as clusters on the inserts, as observed on day 10 from the day of seeding. Media 
was changed on the basolateral side every 48 hours. Reprinted from Journal of 
Pharmaceutical Sciences, 97, Shuhua Bai, Tianzhi Yang, Thomas J. Abbruscato, Fakhrul 
Ahsan, Evaluation of human nasal RPMI 2650 cells grown at an air–liquid interface as a 
model for nasal drug transport studies, pp:1165-1178, Copyright 2008, with permission 
from Elsevier. 
4.3.3.3. in vitro Permeation 
The present work was designed to evaluate RBVN permeation when deposited as 
solid microparticles directly on nasal mucosal tissues. As such, a control group involving 
loading of RBVN in aqueous solution was introduced to compare how the permeation of 
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drug might be affected. It should be noted that the configuration of permeation cells used 
here was different from Chapter 2. In using the vertical tissue diffusion cells for the L-
DOPA work, it was realized that solid microparticles may have drifted away from the 
diffusion area during the course of the experiment, which would manifest itself as a 
premature plateau in the drug transport profile. To avoid this potentially confounding 
variable and ensure that the solid RBVN microparticles remained deposited on the tissue 
throughout experiments, diffusion chambers allowing horizontal tissue mounting were 
used.   
 
 
 
 
Figure 4.10. in vitro permeation profile of RBVN across bovine olfactory tissue, when 
loaded as aqueous solution. Data are expressed as mean + SD, n=3. The dashed line 
denoted steady state region.  
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A 0.2 mL aliquot of a 5 mg/mL aqueous solution of RBVN was added to the 
donor compartment to expose (theoretically) 1 mg of RBVN to the mounted tissue. After 
120 min of contact with the nasal mucosa, the cumulative amount of RBVN that 
permeated from solution, per unit tissue area, was 742.20 ± 16.92 µg cm-2 (n = 3, see 
figure 4.10.). The linearity of the profile (r2 > 0.99), without significant lag-time, 
suggested that drug permeation occurred at a constant rate. The average flux in the 
steady-state region (Jss), calculated based on Equation 4.1, was 4.02 + 0.51 µg/cm
2∙min, 
while the apparent permeability coefficient (Papp) was estimated to be (1.34 + 0.17) x 10
-5 
cm/s based on Equation 4.1. This agreed closely with a previously reported value of Papp 
of RBVN across rabbit nasal mucosa (1.92 + 0.18) x 10-5 cm/s).22 These preliminary 
experiments confirmed high permeability of RBVN across bovine olfactory tissue in 
vitro; however, considering the rapid mucociliary clearance of the nasal cavity, it is likely 
that aqueous solutions containing RBVN would not remain in residence for more than 
10-20 min.  
For a direct comparison with aqueous RBVN solution, direct deposition of 1.0-1.5 
mg RBVN solid microparticles on the excised tissue was planned. Owing to the 
impalpable nature of the solid RBVN microparticles, it was difficult to manually load 
such small quantities of powder and maintain a dose precisely consistent with the 
solution group. Therefore, 5 mg of RBVN solid microparticles was directly deposited on 
the donor side of the tissue, while the dose of RBVN : POX188 (1:1) microparticles was 
adjusted to provide comparable drug exposure (i.e., 10 mg of 1:1 binary microparticles). 
The permeation profile for the two test groups of solid particles is shown in figure 4.11. 
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Figure 4.11. in vitro permeation profiles of RBVN across bovine olfactory tissue when 
loaded as pure component drug particles (open diamonds) and 1:1 RBVN : POX188 
composite microparticles (closed diamonds). Data are expressed as mean + SD, n = 3.  
 
As shown, the cumulative amount of RBVN permeated from polymer 
microparticles (4332.95 + 460.11 µg/cm2) was about 3.3 fold greater than that which 
permeated from pure component RBVN microparticles (1330.79 + 182.83 µg/cm2). This 
was also reflected in the flux values, which were 18.72 + 3.4 µg/cm2∙min (r2 >0.92) and 
47.81 + 22.42 µg/cm2∙min (r2 >0.99) respectively for RBVN particles and RBVN : 
POX188 (1:1) composite microparticles.  
A comparison of the permeation profiles exhibited by each test group notes 
striking differences. The mass transport profile for RBVN loaded as standalone drug 
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microparticles reaches a plateau after approximately 45 min, unlike the 1:1 RBVN : 
POX188 composite microparticles. Given the horizontal setup, loss of microparticles 
from the site of diffusion due to gravity was not expected. Additionally, under the 
parameters maintained during these experiments, the receiver volume was >10 times the 
saturation volume for RBVN (Cs = 149 mg/mL at 25 ºC) (Chapter 3, Section 3.3.2), 
suggesting that it was reasonable to expect that sink conditions were maintained 
throughout permeation measurements.  
Careful examination of the literature offered some logical explanation of these 
data in relation to the mucosal uptake mechanism of ribavirin molecules. Briefly, it is 
known that ribavirin is absorbed into biological compartments (including intestinal cells, 
erythrocytes, striated muscles and neurons) by transporter-mediated uptake, particularly 
nucleoside transporters, CNT 2/3 and ENT 1/2.113,114,223 Owing to the high expression and 
localization of these transporters in the olfactory epithelium, as reported by Al-
Ghabeish,224 it is safe assume that RBVN molecules predominantly underwent active 
uptake in these permeation measurements. Furthermore, the hydrophilic nature of 
ribavirin makes molecular RBVN unlikely to undergo significant passive transport.  
It is well-known that transporter-mediated uptake mechanisms can be saturated if 
the substrate (drug) levels are sufficiently high. Once specific transporters are saturated, 
no additional drug can be absorbed, irrespective of the concentration available in the 
donor side. Reports indicate that ribavirin transport by human ENT1 in the erythrocytes is 
saturable at 420 µM (~100 μg/mL),225 and in intestinal lumen at 44.5 µM (~11 μg/mL).114 
In the absence of direct measurements on olfactory epithelium, it can only be 
hypothesized that at 45 min almost all RBVN powder dissolved in the small volume of 
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donor fluid and saturated the transporters, which in turn would be consistent with the 
observed plateau beyond 45 min in the permeation profile of RBVN solid microparticles.  
Alternatively, it can be speculated that the influx of RBVN molecules in the 
olfactory tissue was counteracted by efflux transporters, resulting in reduced overall mass 
transport. Evidence suggests that P-gp and BCRP efflux transporters are highly expressed 
in the olfactory tissues, which show affinity towards nucleoside analogs structurally 
related to RBVN.226  In contrast to the pure RBVN data, formulation of RBVN : POX188 
(1:1) binary microparticles enabled unrestricted unidirectional transport of RBVN, as 
shown in figure 4.11. Poloxamers® have been widely studied for efflux pump 
inhibition123,124 in the areas of drug delivery beyond the blood brain barrier (BBB) and 
cancer therapy. Additionally, these polymers are known to have an effect on membrane 
fluidization and transient opening of tight junctions. It is speculated that a combination of 
these physiological changes enabled higher flux and greater RBVN mass transport in the 
presence of POX188. A schematic representation of the proposed mechanism is shown in 
figure 4.12.  
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Figure 4.12. Schematic representation of RBVN (blue closed circles) transport across the 
olfactory epithelium. 
 As depicted in the figure, the presence of POX188 enables greater RBVN 
permeation presumably via a combination of opening of tight junctions and inhibition of 
efflux transporters. This is supported by our experimental observations. These data 
confirm the superiority of the 1:1 binary composite microparticles in that it does not 
compromise the cumulative extent of RBVN release, potentially reduces the cytotoxic 
effect of RBVN and improves epithelial flux and overall mass transport. In contrast, the 
usability of aqueous RBVN solutions is likely restricted by long term chemical ingetrity 
of RBVN in dissolved state and rapid clearance from the site of deposition. Standalone 
RBVN microparticles surely circumvent the issue of chemical instability but their full 
potential may not be utilized due to saturable RBVN mucosal uptake.  
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4.4. Conclusion 
In this work, solid microparticles comprised of a 1:1 suspension of fine crystalline 
RBVN in POX188 matrix were developed.  Particles were milled to an average size of 20 
μm to make them suitable for intranasal delivery. The final microparticles were 
physically and chemically stable, with a narrow particle size distribution and precise 
content uniformity. The extent of RBVN release from microparticles was comparable to 
standalone drug particles. Preliminary cytotoxicity tests indicated the effects of RBVN 
and POX188 on the viability of nasal cell lines when exposed individually and as a 1:1 
combination. This helped establish dosing for tissue experiments.  Permeation of excised 
bovine nasal tissue was evaluated in vitro, showing that 1:1 RBVN : POX188 composite 
microparticles allowed the highest mass transport of ribavirin relative to RBVN solid 
particles or RBVN solution.  This was expected to be the result of transient opening of 
tight junction proteins along with inhibition of efflux transporters. These data suggest that 
formulation of a poorly permeating drug, such as RBVN with a permeation enhancer, 
such as POX188, can be advantageous to ultimate mass transport of drug. The effect of 
chronic dosing of permeation enhancer on the integrity of nasal epithelium, however, 
remains to be tested.  
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Chapter 5: Summary 
 
 
Intranasal drug delivery has shown tremendous potential for direct entry of 
permeation rate limited molecules into the CNS, by allowing drugs to bypass the BBB. 
Research on nose-to-CNS uptake has revealed that deposition of formulation in the 
olfactory region of the nasal cavity, allows opportunity for drug to be directly absorbed to 
the CNS, providing the opportunity for treatment of various neurological conditions.   
Research has suggested that deposition of solid particles resists mucocilliary 
clearance, and can allow for greater retention time in the nasal cavity.  Additional time at 
the deposition site results in increased absorption from the nasal cavity when compared 
with drug solutions or other liquid vehicle dosage forms. This was tested in the present 
work, first by measuring epithelial flux and permeability across bovine olfactory tissue 
for L-DOPA when loaded as either an aqueous solution or as dry, crystalline particles. As 
hypothesized, the average steady-state flux (Jss) of L-DOPA from the solid microparticles 
directly deposited on nasal epithelial tissue was 3 times greater than the Jss measured for 
L-DOPA from solution. This was attributed to rapid dissolution of L-DOPA from the 
microparticles that ultimately saturated the mucus layer. Consequently, a high driving 
force was established across the nasal membrane, which enabled improved mass 
transport. These findings suggested that intranasal delivery of small molecule organic 
substances (SMOs) by the administration of solid microparticles might not only benefit 
from improved chemical and microbiological stability but do so without compromising 
the cumulative mass transport of drug across the olfactory membrane. 
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The antiviral compound RBVN has been investigated in the treatment of several 
diseases affecting the CNS, however, bioavailability to this compartment is extremely 
limited, owing to the poor lipid permeation of this molecule. To improve the cumulative 
extent of tissue transport in cases such as these, literature reports suggest the use of 
permeation-enhacing polymers. The present work explored the IN delivery of solid 
binary composite microparticles consisting of ultrafine crystalline RBVN suspended in a 
surrounding solid matrix of Poloxamer F-188 (POX188). Prior to the preparation of 
composite microparticles, it was crucial to investigate the effect of standard micronizing 
techniques on the physical and chemical stability of RBVN. Little has been done 
concerning susceptibility of this material to solid form changes during processing.  In the 
present work, solid-state transformations of RBVN were examined under different 
thermal and mechanical stress conditions. Although the Ttr for RBVN enantiotropes 
wasmeasured at ~70 °C, unprocessed R-II did not transform into high melting 
enantiotrope R-I, at T > Ttr, even after 7 days. However, following grinding, the same 
isothermal storage conditions resulted in rapid R-II  R-I conversion.  This suggested 
decrease in the energy barrier required to produce the high Tm enantiotrope during 
pulverization; potentially by creating crystal defects during milling. Further, a 
comparison of two milling equipments revealed that extensive grinding led to complete 
R-II  R-I  when the mill temperature was not controlled. In contrast, high shear 
cryogenic grinding of R-II, conducted at T << Tg resulted in complete transformation to 
persistent amorphous ribavirin. Ultimately, the findings in this work facilitated intelligent 
selection of manufacturing equipment and process conditions for reproducibly generating 
composite microparticles of RBVN and POX188. 
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Co-solidified mixtures of 1:1 drug and polymer were micronized to dimensions 
between 10-45 µm to promote maximum nasal deposition. Consistent with the RBVN 
characterization work, it was confirmed that the final drug product demonstrated a 
consistent solid form, acceptable chemical stability, and drug content uniformity, even 
following comminution. Additionally, in vitro drug release studies revealed that the 
cumulative RBVN release from the polymeric microparticles was comparable with 
standalone drug microparticles. Although the initial release rate was slower in the 
presence of polymer, it was argued that the mucoadhesive property of POX188 will retain 
the drug product at the deposition site longer and not compromise the extent of RBVN 
release. Further, the presence of POX188 appeared to counteract the observed cytotoxic 
effect of RBVN in vitro by sequestering the latter. Lastly, a 3.3 fold higher amount of 
RBVN cumulatively permeated through excised olfactory tissue when deposited as 1:1 
RBVN : POX188 solid microparticles relative to standalone RBVN solid particles. This 
was attributed to a combination of effects (1) transient opening of tight junctions between 
olfactory epithelial cells and (2) bloackage of efflux transporters. 
Ultimately, these data suggested a potential avenue for pharmaceutical 
formulation research and development that could be particularly important in the 
treatment of other neurological disorders. Indeed, drug molecules having limited CNS 
bioavailability may be subject to greater nasal retention and permeation when introduced 
as solid microparticles, providing the possibility of straightforward, non-invasive therapy 
for current clinical practice. Nonetheless, it will be crucial to investigate the effect of 
multiple dosing of microparticles on the integrity of nasal tissue – a compromised state of 
which may inadvertently provide CNS entry to toxins and allergens. 
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Appendix A: Physical characterization of drug and 
polymer dispersion behavior in PEG 4000 solid 
dispersions using a suite of complementary analytical 
techniques 
 
A.1. Introduction 
As poorly soluble new chemical entities enter drug development pipelines, 
different approaches for solubility enhancement may be attempted as they are considered 
for adoption as candidate molecules.  Among these, preparation of solid amorphous 
dispersions has received considerable attention.32, 227-230  Solid dispersions are prepared 
by rapid co-solidfication of an active pharmaceutical ingredient (API) and a carrier 
excipient (frequently a water soluble polymer), by one of several methods, including 
spray drying,231 super-critical fluid processing,232 lyophilization,233 hot-melt extrusion,234 
and high shear co-trituration.235, 236  Solid dispersions can increase the apparent solubility 
of a material by allowing the drug to persist as an amorphous solid.237 Spontaneous 
recrystallization of the drug is inhibited by its physical intercalation within interstices 
formed by entanglement of the polymeric host.230, 238-240  
Since both formation and physical stability of solid dispersions relies on 
solidification from a mutually miscible API and polymer mixture, research in this area 
has focused on predicting how the interactions between API and carrier enable 
dispersability.241-244 Despite predictive advances, dispersion formulation still relies on 
analytical techniques to confirm that a true dispersion has been formed.  Several different 
characterization approaches are reported throughout the literature, and include single-
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instrument,239, 245, 246 two-instrument242, 247 and multi-instrument methods,248 each aimed 
at demonstrating that the physical properties and microstructure of the binary solid, 
established by intimate, mutual dispersion of the components, are distinct from physical 
mixtures of the two solids.  Moreover, as solid dispersions become viable formulation 
strategies for poorly soluble API, regulatory agencies will see an increased number of 
filings for these materials.  At present, no standard guidance directs characterization of 
solid dispersions, leaving it to the literature to report best practices.   
In this study solid dispersions were attempted using a modest library of 15 model 
API in polyethylene glycol 4000 (PEG4000).  PEG4000 is a hydrophilic, semicrystalline 
polymer potentially useful as a solid dispersion carrier227, 228, 249 which has been shown to 
increase the dissolution rate of poorly water soluble drugs such as carbamezapine.250 
Despite historical use, the phase behavior of API in PEG remains challenging to 
characterize.  Upon co-solidification, PEG4000 has been shown to disperse API as pure 
amorphous solid,251 a combination of amorphous and crystalline phases,252 only 
crystalline solid,250 and form eutectic mixtures with API.253, 254 PEG4000 was, therefore, 
chosen for this study as illustrative of resulting in very complex solid mixtures with API, 
providing analytically challenging signals for interpretation using individual techniques 
commonly employed in solid dispersion characterization.  In this work, API:PEG4000 
combinations will be classified in one of three categories, 1) Fully dispersed: quenching 
of a completely miscible molten mixture results in a single amorphous phase; 2) Partially 
dispersed: quenching results in a detectable amorphous phase, and recrystallized drug 
and/or polymer; 3) Fully phase separated: quenching results in complete recrystallization 
of the drug and polymer. A fourth potential outcome might be expected in some cases, 
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where both components are in the amorphous state, but they are not dispersed in one 
another. This possibility is unlikely with the polymer used here, and was not observed, 
most likely due to the propensity of PEG4000 to rapidly crystallize. 
The key objective of this work was to demonstrate that comprehensive 
characterization is needed for PEG-based dispersions in order to properly classify 
API:polymer behavior.  Each sample in the library was characterized using a suite of 
techniques including powder X-ray diffraction (PXRD), pair distribution function (PDF) 
analysis,242, 247 hot-stage polarized-light microscopy (HSM), and differential scanning 
calorimetry (DSC).  The dispersion behavior of each API in PEG4000 was inferred using 
this suite of techniques.  In some instances, inferences drawn from single techniques 
resulted in inconsistent classifications, while complementary characterization allowed for 
better informed classification of the binary materials. 
 
A.2. Materials and Methods 
A.2.1. Materials 
Chlorpropamide, indomethacin, tolbutamide, cimetidine, and griseofulvin were all 
purchased from MP Biomedicals (Solon, OH).  Ketoconazole and ibuprofen were 
purchased from Spectrum (Gardena, CA).  Quinidine and cloperastine·HCl were 
purchased from Sigma-Aldrich (St. Louis, MO).  Terfenadine and sulfanilamide were 
purchased from Acros Organics (Geel, Belgium). Propranolol·HCl, nifedipine, and 
itraconazole were purchased from TCI Chemicals (Portland, OH).  Melatonin and 
polyethylene glycol 4000 were purchased from Alfa-Aesar (Ward Hill, MA).  The 
structures for all model drugs and PEG4000 are shown in Table A.1. 
  143 
Table A.1.  Molecular structures for model drugs and polymer used in this study. 
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A.2.2. Co-solidification of API:PEG4000 Mixtures 
Physical mixtures of each API and PEG4000 were manually prepared in a 3:1 
(%w/w) API:polymer ratio, and equilibrated at 10%RH for 24 h.  Physical mixtures 
were transferred to a crucible immersed in silicone oil maintained at Tm,API  +10°C.  The 
molten mixture was stirred for 20-30 min to ensure that all solid had disappeared. 
Mixing times were determined based durations at Tm,API +10
oC at which insignificant 
thermal degradation was observed.  Each material was held isothermally in a 
thermogravimetric analyzer (TGA) at Tm,API +10
oC, and <2% w/w weight loss was set 
as a criterion for thermal stability at this temperature. Additionally each API was heated 
in a DSC to Tm +15°C, and held isothermally for 30 min.  After the extended isothermal 
hold, samples were quenched in the DSC, before reheating. The Tg values all 
corresponded well with reported literature values, and the baseline heat flows following 
melting of these samples were steady, suggesting that each API was stable under the 
conditions used to make the dispersions.  Additionally, the literature suggests that no 
significant chemical degradation should be expected at temperatures equal to or greater 
than those used in the present experiments for chlorpropamide,255 griseofulvin,256 
indomethacin,257 itraconazole,258 ketoconazole,259 nifedipine,260 terfenedine,261 and 
tolbutamide.257 
Nitrogen gas was continuously streamed over the crucibles during preparation, to 
prevent moisture sorption.  Molten mixtures were quenched by immersion of the crucible 
in liquid nitrogen.  Pure component amorphous samples were prepared using the same 
method as the API:PEG4000 mixtures.  All preparations were repeated in triplicate. 
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A.2.3. Differential Scanning Calorimetry (DSC) 
Glass transition temperatures (Tg), melting temperatures (Tm) and recrystallization 
temperatures (Tc) were measured in triplicate for all samples using a Model Q100 DSC 
(TA Instruments, New Castle, DE), operated under a three-point temperature/enthalpy 
calibration using o-terphenyl, indium, and tin standards, and a cell constant calibration 
using indium.  All experiments were conducted using 50 mL/min nitrogen purge to the 
cell.  Sample “chips” of co-solidified mixtures (4-8 mg) were hermetically sealed in 
aluminum pans, and initially cooled at 20°C/min to -80°C.  Following in situ 
equilibration at -80oC, each sample was heated at either 2°C/min or 20°C/min to Tm,API 
+10°C. All pure component drug and polymer samples (3-5 mg) were heated at 20°C/min 
from room temperature to Tm  +10°C, held isothermally for 5 min, and then rapidly cooled 
to -80°C in situ.  Quenched samples were then re-heated at 20°C/min to  
Tm  +10°C. 
The expected Tg for drug:polymer mixtures (assuming intimate mixing of the two 
liquid phases) was calculated using the Couchman-Karasz equation:262 
𝑻𝒈 =
𝒘𝑨𝑷𝑰 𝑻𝒈,𝑨𝑷𝑰 + 𝑲𝒘𝒑 𝑻𝒈,𝒑
𝒘𝑨𝑷𝑰 + 𝑲𝒘𝒑
                                                                                        (A.1)                
where wAPI and wp were the weight fractions of API and polymer, respectively, Tg,API and 
Tg,p are the glass transition temperatures of amorphous API and polymer, respectively, 
and K= ΔCp,p/ΔCp,API, where ΔCp,p and ΔCp,API are the changes in heat capacity through 
the glass transitions of the polymer and API, respectively. Calculated Tg values were 
compared with observed Tg values for mixtures, interpolated from the DSC heat flow 
signal, measured as the midpoint of the step change in heat capacity. It is important to 
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note that Tg,p measured in these experiments was very low (-67.92°C),
263-265 and 
PEG4000 rapidly recrystallized at room temperature.  As such, pure amorphous 
PEG4000 could not be prepared as a pure component reference for use with any of the 
other characterization experiments. 
A.2.4. Optical Hot Stage Microscopy (HSM) 
             Small, intact chips of each co-solidified API:PEG4000 mixture were placed on a 
microscope slide and heated/cooled using an Instec HCS 302 Pelletier heating stage with 
an STC 200  temperature controller  (Instec, Boulder, CO). Samples were heated at 
10°C/min from ambient temperature to Tm,API +10°C, held isothermally for 5 min, and 
then cooled back to ambient temperature at 10°C/min. Observations were made using an 
Olympus BX-51 optical microscope equipped with a polarizing filter, under 10X 
magnification. Photomicrographs were obtained throughout the heating/cooling profile to 
observe phase changes in the solids as a result of heating, or to distinguish between 
crystalline polymer and crystalline API.  
A.2.5. Powder X-ray Diffraction (PXRD) 
PXRD data were collected in transmission geometry, by placing intact samples 
between two layers of Kapton® film (ChemPlex, Palm City, FL), spun (16 rpm) in a 
vertical sample stage. Sample positioning, rotation and transmission geometry allowed 
complete volume interrogation of all samples, therefore, diffraction data were collected 
from each solid, in its entirety.  An X’Pert Pro MPD system (PANalytical B.V., Almelo, 
the Netherlands), equipped with a copper anode (λ = 1.5406 Å), an auxiliary elliptical 
mirror, and X’CeleratorTM detector was used to collect diffraction data at an operational 
voltage/amperage of 45.0 kV/40.0 mA.  To maintain consistent counting statistics 
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between experiments, consistent irradiation times of 51.04 s per step (0.017° 2θ steps) 
were used to collect data over 2-100 °2θ. 
A.2.6. Pair Distribution Function (PDF) analyses of PXRD data 
The pair distribution function (PDF) is a total scattering method utilizing the 
Fourier relationship between reciprocal and real space.266, 267 The PDF reports the 
probability of finding two atoms separated by a distance r, and is obtained using 
Equation A.2: 
𝑮(𝒓) =  
𝟐
𝝅
 ∫ 𝑸[𝑺(𝑸)
𝑸𝒎𝒂𝒙
𝟎
− 𝟏] 𝐬𝐢𝐧 𝑸(𝒓)  𝒅𝑸                                                                           
(A.2) 
S(Q) is the structure function obtained from a normalized PXRD pattern, and Q is the 
magnitude of the scattering vector. To enable correct calculation of S(Q), corrections 
were made to measured diffraction data, according to those outlined in Egami and 
Billinge.259 The integration limit, Qmax, is the momentum transfer resolution of the 
diffraction experiment, which depends on both the maximum diffraction angle (100 ˚2θ) 
and the X-ray wavelength (λ = 1.5406 Å) used in PXRD data acquisition. Intensity 
corrections (e.g., background due to Kapton® film, absorption, etc.) and PDF calculations 
were performed in the MATLAB environment (v2012b, MathWorks, Natick, MA) using 
a graphical user interface programmed in-house.268 
PDF-transformed PXRD data from co-solidified samples has been shown to be 
useful in differentiating between phase-separated and completely dispersed samples.242, 
246, 247 In the present work, PDF-transformed PXRD data for co-solidified samples 
(observed PDF) were compared to calculated PDFs generated by weighted linear 
combination of the PDF transforms for individual amorphous components (theoretical 
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PDF). Dispersion behavior was inferred using the following criteria: 1. Sum-of-squares 
difference between theoretical and observed PDFs (R-value); 2. agreement or deviation 
of scaling coefficients relative to known 3:1 experimental compositions of API:polymer; 
and, 3. observation of regions in the PDF difference plot that did not contain zero in the 
3σ confidence interval (CI).269  
Cases in which the theoretical and observed PDFs were superimposable were 
concluded to be at least partially phase-separated. That is, the short-range order of the co-
solidified product was adequately described by the interatomic distances of physical 
mixtures of API and polymer. Conversely, significant deviations between 
theoretical/observed PDFs were used to suggest that short-range order unique to intimate 
API/polymer mixing was present, suggesting complete dispersion following solidification 
from a miscible mixture.242, 247 
It was noted above that, owing to rapid recrystallization of PEG4000, PXRD for 
pure amorphous polymer could not be obtained, but was required for calculation of 
theoretical PDFs. As an alternative, PXRD patterns of liquid PEGs (PEG 200, PEG 300, 
and PEG 400) were collected. The PXRD and PDF data for the three liquid PEGs were 
indistinguishable, suggesting that although the polymers differed in their degree of 
substitution, their disorder and aperiodicity were sufficiently similar that they could be 
reasonably substituted for higher molecular weight PEGs, such as amorphous PEG4000 
in the PDF routine. 
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A.3. Results and Discussion 
A.3.1. API:PEG4000 library 
15 separate API:PEG4000 binary solids (n=3) were made.  Following quenching, 
each sample was characterized using PXRD (with PDF-transformation, where 
appropriate), HSM, and DSC in order to classify co-solidified mixtures as either fully 
dispersed, partially dispersed or fully phase separated.  Inferences made using each 
technique independent of the others are detailed below, followed by a summary that 
considers collective inferences made using complementary characterization. 
A.3.2. Inferences from PXRD data 
Pure PEG4000 recrystallized rapidly on solidification, consistent with literature 
reports for high molecular weight PEGs.251, 252, 270 PXRD patterns for PEG4000 were 
collected for both untreated solid, and polymer subjected to the same melt-quench cycle 
described for API:PEG4000 mixtures.  Both PEG4000 diffraction patterns were 
superimposable, suggesting that polymer recrystallization following melt-quenching 
resulted in the same solid as received from the vendor.  PXRD patterns for API:PEG4000 
mixtures were, therefore, easily separated based on characteristic PEG4000 diffraction 
relative to peaks unique to the API.   
PXRD data are summarized in Table A.2.  Of the 15 API solidified with 
PEG4000, 10 mixtures showed evidence of some crystallinity.  In most cases, 
characteristic peaks attributable to both drug and polymer were detectable, however, 
tolbutamide:PEG4000  was unique in that it only diffracted at angles consistent with the 
API, but not the polymer.  In contrast, cloperastine·HCl:PEG4000, 
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itraconazole:PEG4000, and propranolol·HCl:PEG4000 solid mixtures all diffracted at 
angles consistent with only the polymer.  
 
 
 
 
 
 
 
  
1
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Table A.2. Summary of PXRD analyses. Cambridge Structural Database (CSD) reference codes for each API are indicated 
parenthetically below the compound name.271, 272 CSD structures were used to identify diffraction peaks for crystalline API in 
API:polymer mixtures. 
API component 
 (CSD Reference code) 
Diffraction attributable to 
API (°2θ) 
Diffraction attributable to 
PEG4000 (°2θ) 
X-ray scattering attributable 
to some amorphous content 
PXRD 
Inference 
Chlorpropamide 
(BEDMIG02) 
Minute peaks at 11.7, 19.5, 
21.6 
Minute peaks at 15.0, 19.1 Yes 
Partially 
dispersed 
Cimetidine (CIMETD) Not observed Not observed Yes Fully dispersed 
Cloperastine HCl 
(QAWNAD) 
Not observed Minute peaks at 18.6, 22.7 Yes 
Partially 
dispersed 
Griseofulvin (GRISFL01) Minute peaks at 10.8, 26.7 Minute peak at 23.9 Yes 
Partially 
dispersed 
Ibuprofen (IBPRAC01) 
Definite peaks at  6.1, 16.6, 
17.7 
Definite peaks at 22.7, 23.5 No 
Fully phase 
separated 
Indomethacin (INDMET03) Not observed Not observed Yes Fully dispersed 
Itraconazole (TEHZIP) Not observed Definite peaks at 18.6, 22.7 Yes 
Partially 
dispersed 
Ketoconazole (KCONAZ) Not observed Not observed Yes Fully dispersed 
Melatonin (MELATN01) 
Minute peak at 10.6,  
unidentified peaks* at 18.6, 
25.4 
Minute peak at 23.6 Yes 
Partially 
dispersed 
Nifedipine (BICCIZ) Not observed Not observed Yes Fully dispersed 
Propranolol HCl (FIDGAB) Not observed Minute peaks at 18.6, 22.7 Yes 
Partially 
dispersed 
Quinidine (BOMDUC) 
Minute peaks at  8.0, 18.5, 
33.0 
Minute peaks at  19.1, 23.3 Yes 
Partially 
dispersed 
Sulfanilamide (SULAMD06) 
Minute peaks at 15.7, 19.7, 
35.5 
Minute peaks at  22.7, 33.0  Barely 
Partially 
dispersed 
Terfenadine (XUHTID) Not observed Not observed Yes Fully dispersed 
Tolbutamide Form I 
(ZZZPUS02) 
Minute peaks at 11.9, 19.1. 
Some peaks attributable to 
Form II** 
Not observed Yes 
Partially 
dispersed 
*Peaks not consistent with MELATN01 structure; may be metastable form 
**Peaks consistent with ZZZPUS03 structure; metastable to Tolbutamide (Form I) 
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Recrystallization of both drug and polymer during solidification was easily 
observed in all three ibuprofen:PEG4000 samples. Characteristic diffraction from both 
drug and polymer were detected in co-solidified mixtures (Figure A.1a), and significant 
X-ray scattering was not detectable in any of the diffraction patterns, suggesting absence 
of amorphous drug.   
 
 
Figure A.1. Overlay of PXRD patterns. (a) Pure ibuprofen (IBPRAC01) is indicated in 
blue; co-solidified 3:1 w/w ibuprofen:PEG4000 is shown in black; pure PEG4000 is 
shown in red. Select characteristic diffraction peaks attributable to API and polymer are 
indicated as blue stars and red closed circles, respectively.  (b) Pure cimetidine 
(CIMETD) is indicated in blue; co-solidified 3:1 w/w cimetidine:PEG4000 is shown in 
black; pure PEG4000 is shown in red.  Characteristic diffraction from neither drug nor 
polymer was observed, suggesting no crystalline content. 
 
Taken in isolation, the PXRD data indicate that ibuprofen and PEG4000 were 
completely phase separated, suggesting that ibuprofen did not form a stable dispersion 
with PEG4000 under these conditions.  Of the 15 API tested, ibuprofen was the only API 
whose PXRD characterization demonstrated this phase behavior (Table A.2).     
Each of the 6 solid mixtures (other than ibuprofen) whose PXRD patterns 
contained at least some diffraction attributable to the API also contained evidence of 
persistent amorphous content.  These samples were largely X-ray amorphous, with 
diffuse scattering over all angles 2θ, which obscured all but the most intense Bragg 
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diffraction peaks, detectable for both the API and polymer (Table A.2).  As such, PXRD 
could not determine whether the amorphous content was from the API, polymer, or both.  
Since PEG4000 was expected to rapidly recrystallize in all samples, and the drug was 
present in 3:1 w/w ratio, the inclination might have been to assume that only drug was 
present as amorphous solid.  This would be inconsistent with the semicrystalline nature of 
PEG4000, which even when recrystallized, contributes minor diffuse scatter from the 
amorphous regions of the polymer.  More strikingly, however, were the PXRD patterns 
for 5 of the mixtures (cimetidine, indomethacin, ketoconazole, nifedipine, and 
terfenadine) all of which were completely X-ray amorphous following solidification 
(Figure A.1b, Table A.2).  This suggested that the high concentration of drug in these 
preparations inhibited PEG4000 recrystallization, contrary to its expected behavior.  As 
such, it is likely that amorphous scattering observed in PXRD for other solids contained 
contributions from both drug and polymer.  Had the PXRD data been interpreted 
independent of the other characterization data, these 5 materials would have been 
classified as fully dispersed, having solidified from fully miscible mixtures of API and 
PEG4000. The remaining 9 materials would have been classified as partially dispersed in 
PEG4000 (Table A.2), where the combination of API and polymer at this composition 
allows some amorphous solid to persist at room temperature, following quenching.   
Using PXRD data in this way ignores some important limitations of the 
technique.  X-ray scattering by most mixtures in these experiments suggested significant 
amorphous content.  In highly amorphous samples, diffraction from very small 
crystallites of API or polymer may not be detectable, potentially leading to the 
assumption that samples contained no crystalline content. A study conducted by 
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Rumondor et al., demonstrated a 1.9-2.2% limit of detection for crystalline felodipine in 
a substantially amorphous background that included poly(vinylpyrrolidone).273  
Assuming no crystalline content in X-ray amorphous patterns might lead to incorrect 
classification of systems such as cimetidine, indomethacin, ketoconazole, nifedipine, and 
terfenadine, since the presence of even small quantities of crystalline API suggests only 
partially dispersed samples at this composition.  Mixtures solidified from PEG4000 and 
chlorpropamide, cloperastine, griseofulvin, itraconazole, melatonin, propranolol·HCl, 
quinidine, sulfanilamide and tolbutamide, were classified as partially dispersed, which 
did not change when data from complementary techniques were ultimately considered, 
however, the PXRD data alone were incapable of distinguishing whether persistent 
amorphous phase was due to API, PEG4000, or both.  Identifying this particular phase 
behavior is important to suggest whether or not a different ratio of API and polymer 
might result in a fully dispersed solid, which might be useful to a formulator attempting 
to use PEG4000 as a carrier. Finally, scattering from a very small fraction of amorphous 
content may be undetected in highly crystalline PXRD patterns.  This could potentially 
lead to an improper inference for systems such as ibuprofen:PEG4000, where the PXRD 
data suggested complete recrystallization of the drug.  Even if undetected persistent 
amorphous ibuprofen was present, the results suggest insignificant ability to disperse it in 
PEG4000.   
A.3.3. Inferences from PDF-transformed PXRD data 
      Of the 15 API:PEG4000 combinations in this study, 5 mixtures, cimetidine, 
indomethacin, ketoconazole, nifedipine, and terfenadine, resulted in completely X-ray 
amorphous diffraction patterns, which, based on previous research involving analysis of 
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PDF analysis17 were the only data suited to interpretation in this manner.  Despite X-ray 
amorphous PXRD patterns, PDF analysis was not done for ketoconazole:PEG4000, 
owing to the inability to prepare a fully amorphous sample of pure ketoconazole for 
theoretical PDF calculation.  A summary of the PDF data for the remaining 4 solids is 
shown in Table A.3.   
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Table A.3. Summary of PDF analyses.  R-values were minimized by artificially scaling API:polymer w/w concentrations 
used to generate theoretical PDF. 
Solid Mixtures R-valuea 
Theoretical Drug 
Concentration (%) 
Theoretical PEG4000 
Concentration (%) 
Observed regions in r where 
0 was not contained in the CI 
PDF inference 
            
Cimetidine:PEG4000 0.259 (0.022) 54 (1) 46 (1) Yes Fully dispersed  
            
Terfenadine:PEG 4000 0.198 (0.007) 76 (2) 24 (2) Yes Fully dispersed 
            
Indomethacin:PEG 4000 0.184 (0.039) 64 (3) 36 (3) Yes Fully dispersed 
            
Nifedipine:PEG 4000 0.126 (0.010) 77 (2) 23 (2) Yes Fully dispersed 
aReported values represent the average and standard deviation of three replicate preparations 
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PDF interpretation for cimetidine:PEG4000 suggests complete dispersion at this 
composition, resulting from solidification of a completely miscible mixture of molten 
drug and polymer.  In this case, the observed and calculated PDFs were not 
superimposable (Figure A.2a), reflected in R=0.259, which was only minimized when 
the theoretical PDF drug:polymer concentration weightings were artificially adjusted to 
54% and 46% (w/w), respectively (Table A.3).  Additionally, the difference plot (ΔG(r) 
between predicted and observed data) for cimetidine:PEG4000 contained regions 
in r where the confidence intervals did not contain zero (Figure A.2b).  Taken together, 
this suggests that the PDF-transformed data for solidified cimetidine:PEG4000 contained 
new interatomic distances not explained by a physical mixture of the two amorphous 
solids, supporting its complete dispersion in PEG4000. Similar interpretations of the PDF 
patterns for indomethacin:PEG4000, nifedipine:PEG4000, and terfenadine:PEG4000 
solids are also shown in Table A.3. 
 
 
Figure A.2a and A.2b PDF analysis of 3:1 w/w co-solidified cimetidine:PEG4000 
sample (as labeled).  
 
 
  158 
This particular characterization approach, while useful, is the most ambiguous 
when interpreted without complementary techniques.  Its inclusion in a characterization 
routine can provide additional information for PXRD data, but should not be done in lieu 
of other complementary techniques.  To reinforce this, consider that the PXRD data 
suggested that cimetidine, indomethacin, nifedipine, and terfenadine had all formed 
completely amorphous binary dispersions, which was subsequently confirmed by the 
PDF analyses.  PDF interpretations suggested that each of these systems formed intimate 
drug/polymer interactions unique to a dispersion.  This interpretation required 
comparison between an observed and calculated PDF generated from PXRD data from 
amorphous pure components.  Since amorphous PEG4000 could not be prepared, PXRD 
data from liquid PEG400 were used to generate the calculated PDF.  It is easy to imagine 
that differences between liquid PEG400 and solid amorphous PEG4000 at the scale of 
drug/polymer interactions may be substantial enough that the unique separation distances 
interpreted in the data were manifestations of the theoretical PDF and not indicative of 
the actual dispersion.  Ultimately, classifications of dispersion behavior made using the 
other techniques are much more compelling, suggesting that PDF analysis is 
inappropriate for PEG-based dispersions. 
A.3.4. Inferences from HSM data 
The use of polarized light microscopy in dispersion characterization is 
widespread, where observed birefringence indicates the presence of crystallinity in a 
sample.  This technique is analytically challenging when characterizing systems 
comprised of a rapidly recrystallizing carrier polymer, such as PEG4000, as 
differentiating between birefringence from the polymer and API is required.   
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All samples were observed initially at room temperature, immediately following 
preparation, and the photomicrographs for each API:PEG4000 mixture are shown in 
Figure A.3.  Observed birefringence was interpreted as recrystallization of either drug or 
polymer during quenching.  Samples were heated and cooled, as described above, while 
observed using both polarized and un-polarized light to differentiate between crystalline 
polymer and API. 
 
 
Figure A.3. Initial room temperature polarized light microscopy images of co-solidified 
3:1 w/w samples containing PEG4000 and (a) chlorpropamide (b) cimetidine (c) 
cloperastine·HCl (d) griseofulvin (e) ibuprofen (f) indomethacin (g) itraconazole (h) 
ketoconazole (i) melatonin (j) nifedipine (k) propranolol·HCl (l) quinidine (m) 
sulfanilamide (n) terfenadine (o) tolbutamide. Image (p) represents only PEG4000 at 
room temperature.  All scale bars (in yellow) correspond to 50 µm. 
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Extensive birefringence was observed throughout the ibuprofen:PEG4000 
samples, from small crystallites not easily distinguished as either drug or polymer 
(Figure A.3e).  As the solid was heated, the polymer began melting at ~45oC, resulting in 
disappearance of some of the birefringent crystallites, while the remainder persisted as 
crystalline ibuprofen, which melted beginning at ~70oC.  Interpretation of HSM data 
alone indicated no detectable amorphous ibuprofen, suggesting complete phase 
separation when quenched in the presence of PEG4000. 
The photomicrographs for mixtures containing cimetidine, indomethacin, ketoconazole, 
nifedipine, and terfenadine (all of which resulted in completely X-ray amorphous 
diffraction patterns), showed that only cimetidine:PEG4000 resulted in a dispersion 
having no birefringence when observed under polarized light.  Moreover, this image 
showed a single, homogeneous sample, resembling a solidified glass (Figure A.3b), 
having no observed grains that might indicate trace phase separation.  When the 
cimetidine:PEG4000 was heated to Tm,API +10
oC, minor recrystallization of trace 
cimetidine was observed at 80oC (in 1/3 preparations), which then melted at 160oC.  In 
the other 2 cimetidine:PEG4000 solids, neither recrystallization nor melting of either 
polymer or drug was observed.  Taken alone, HSM suggests that cimetidine and 
PEG4000 were fully dispersed, having solidified from a completely miscible molten 
mixture at this composition.  Without the complementary techniques, however, the 
question could certainly be raised whether or not the photomicrographs were 
representative of the entire sample, as the experiments focused on a single area during 
heating, making it possible to have missed subtle phase behavior outside the field of 
view.  Here, the HSM inference for cimetidine:PEG4000 miscibility is made more 
  161 
compelling when complemented with the PXRD data, which involved complete sample 
interrogation with X-rays.   
Room temperature photomicrographs for the mixtures containing indomethacin, 
ketoconazole, nifedipine, and terfenadine clearly showed small, birefringent grains, 
representing a small fraction of the total sample, some of which melted at ~60oC 
(identifying them as PEG4000).  The other grains melted at the respective Tm,API, 
suggesting that a small amount of the drug had recrystallized during quenching of each 
sample.  These HSM data suggested that these 4 drugs were only partially dispersed with 
PEG4000, but that extensive recrystallization did not occur during quenching.  It is 
important to note that this inference was potentially complicated by observed 
recrystallization of API from molten PEG at ~80oC in each of these samples.  Since 
recrystallization began immediately following melting of the PEG4000, distinguishing 
between persistent API grains and those formed during the experiment was difficult, and 
could potentially vary from one field of view to another.  Nonetheless, at room 
temperature most of the API and polymer was initially amorphous, and the solid that 
recrystallized during quenching likely fell below the detection limit of PXRD.  This 
reinforces that classifying solids of indomethacin, ketoconazole, nifedipine, and 
terfenadine with PEG4000 as fully dispersed, made using only PXRD data were 
incorrect.   
A.3.5. Inferences from DSC data 
Of the various techniques employed in the characterization of solid dispersions, 
DSC is among the most frequently used.274  Fully dispersed systems should, in theory, 
result in thermograms containing a single Tg intermediate to the Tg of either pure 
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component amorphous phase, predictably weighted according to relationships such as the 
Couchman-Karasz Equation262 or the Gordon-Taylor Equation.275 Partially dispersed 
mixtures characteristically show two distinct Tg values, plasticized or anti-plasticized 
relative to their pure component values, and typically crystalline API formed during 
solidification.  While classifications of dispersion behavior can be straightforward for 
some API:polymer combinations, PEG4000 proved to be much more complicated.   
      DSC data for API:PEG4000 mixtures are summarized in Table A.4.   
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Table A.4. Summary of DSC analyses. 
Solid Mixture 
Pure 
component 
Tg (°C) 
Calculated 
Tg (°C) from Eq 1 
Observed Tga 
(°C) (20°C/min) 
Observed 
PEG4000 Tma (°C) 
(20°C/min) 
Observed API 
Tma (°C) (20°C/min) 
DSC Inference 
Chlorpropamide 15.39 -1.29 -4.97 (0.78) Not observed 105.21ⱡ (3.21) Fully dispersed 
Cimetidine 57.38 39.87 30.24 (2.54) 58.38; n=1 Not observed Fully dispersed 
Cloperastine 
HCl 41.47 11.05 -4.11 (0.07); n=2 50.76 (4.95) 144.40ⱡ (1.15) Partially dispersed 
Griseofulvin 98.68 67.75 30.65 (0.18) Not observed 213.92ⱡ (3.53) Fully dispersed 
Ibuprofen -35.35 -39.36 Not observed 44.86ᵼ (2.36) 69.95 (1.11) 
Fully phase 
separated 
Indomethacin 54.14 34.66 1.00 (0.70) Not observed 144.12ⱡ (1.17) Fully dispersed 
Itraconazole 66.17 45.35 -22.09; n=1 54.90ᵼ (3.82) 161.88ⱡ (0.47) Fully dispersed 
Ketoconazole 53.97 27.62 -52.28 (0.12); n=2 
55.47 (1.03); 
n=2 
149.18ⱡ (0.31) Partially dispersed 
1.24; n=1 
Melatonin 20.12 7.2 1.35 (0.34) 52.76 (1.30) 105.63ⱡ (0.67) Partially dispersed 
Nifedipine 53.35 30.83 -0.63 (5.96) Not observed 151.06ⱡ (8.13) Fully dispersed 
Propranolol 
HCl 43.45 24.15 11.79 (1.31) Not observed 157.43ⱡ (0.52) Fully dispersed 
Quinidine 68.35 51.57 10.43 (8.75) Not observed 166.40ⱡ (1.79) Fully dispersed 
Sulfanilamide N/A* N/A* -0.74 (0.9); n=2 56.00 (0.98) 153.97 (4.27) Partially dispersed 
Terfenadine 69.05 39.65 
-30.79 (3.72); n=2 TC,API = 86.14 
(1.35)** n=2 
140.15ⱡ (0.59) Partially dispersed Two Tg's: 7.95 & 
61.32*** (n=1) 
Tolbutamide 13.16 -4.10 Not observed 42.21 (0.62) 113.91 (0.57) 
Fully phase 
separated 
aReported values represent the average and standard deviation of three replicate preparations unless otherwise mentioned 
*Sulfanilamide pure component Tg unable to be determined by DSC; rapid recrystallization during in situ quench 
ᵼTm,PEG4000 preceded by PEG4000 recrystallization         ⱡTm,API preceded by API recrystallization 
**API recrystallization over expected Tm,PEG range. PEG melting confirmed in Hot Stage Microscopy 
***Two Tg's, one attributable to PEG4000 and the other to API 
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Classification of ibuprofen:PEG4000 was very straightforward using PXRD and 
HSM.  This continued with DSC, although the data suggested potential eutectic behavior 
between this drug and polymer with complete recrystallization upon cooling the 
preparation (Figure A.4).   
 
Figure A.4. Overlay of DSC thermograms. Pure ibuprofen is indicated in blue, co-
solidified 3:1 w/w ibuprofen:PEG4000 is shown in black; pure PEG4000 is shown in red. 
No Tg was observed; only melt endotherms consistent with Tm,p and Tm,API. 
 
This interpretation is supported by observations made by Law et al..255 No Tg was 
observed in these thermograms, however, distinct melting endotherms, having onsets at 
44.86oC and 69.95oC were observed, corresponding with slightly depressed values for the 
respective Tm for PEG4000 and ibuprofen.  Neither Tm were preceded by 
recrystallization, suggesting that both drug and polymer fully crystallized during 
quenching.  Taken alone, the DSC data suggest that ibuprofen and PEG4000 completely 
phase separated during solidification.  A similar inference could be made for 
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tolbutamide:PEG4000.  No Tg was observed for these solids, suggesting no amorphous 
content (Table A.4).  Melting of the PEG4000 was clearly observed for 
tolbutamide:PEG4000, which was not preceded by recrystallization, suggesting that the 
polymer had recrystallized during solidification.  Following Tm,p however, the baseline in 
these thermograms did not re-establish, prior to the signal that was clearly interpreted as 
melting of the tolbutamide.  In this case, the signals suggested that the API crystallized 
during solidification, and then dissolved/recrystallized in the molten PEG as the 
temperature was increased. The Tg region of the DSC thermogram for 
cimetidine:PEG4000 is shown in Figure A.5, relative to pure component thermograms 
obtained, respectively from melt/quenched samples of cimetidine and PEG4000.  
 
Figure A.5. Overlay of Tg regions in DSC thermograms from top to bottom: Pure 
cimetidine (in blue), co-solidified 3:1 w/w cimetidine:PEG4000 (in black) and pure 
PEG4000 (in red). A single Tg was measured for the mixture, which fell intermediate to 
Tg,p and Tg,API. 
  166 
A single Tg was observed at 30.24
oC for cimetidine:PEG4000, which was 
comparable with the theoretical Tg of the mixture (39.87
oC) predicted by Equation A.1 
(Table A.4).  In 1/3 replicates for cimetidine:PEG4000, a small endotherm at 58.38oC 
was observed, corresponding to Tm,p. None of the 3 cimetidine:PEG4000 replicates 
showed evidence of API recrystallization/melting during the temperature ramp. These 
data suggest that 1/3 cimetidine:PEG4000 solid mixtures had slight recrystallization of 
the polymer, although all three allowed persistence of amorphous cimetidine.  
Independent of the other techniques, the DSC data strongly suggest that a fully dispersed 
binary amorphous solid can form by solidification of a fully miscible 3:1 mixture of 
cimetidine and PEG4000.  These data potentially illustrate a limitation to characterizing 
dispersions using only DSC.  Given the limited sample size used in these experiments, 
sub-sampling from the co-solidified mixtures was unavoidable.  It could be argued that 
DSC might miss recrystallized drug or polymer, if the “chips” taken from the overall 
glass were selected from a persistent homogeneous region, rather than a phase separated 
region. This reinforces the necessity of complementary techniques having greater (if not 
complete) sample interrogation for confirmation that sub-sampling doesn’t bias the 
inferences made from DSC alone.   
Table A.4 also illustrates the complexity of the DSC data used to characterize 
solid mixtures with PEG4000, the behavior of which clustered into four generalized 
groups.  In DSC patterns for itraconazole:PEG4000, a distinct Tg was not observed, 
however, the predicted Tg value was expected commensurate with PEG recrystallization 
and melting..  As samples were heated, distinct crystallization/melting of the PEG4000, 
followed by distinct crystallization/melting of the itraconazole was clearly observed. This 
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suggested that solidification resulted in at least some dispersed amorphous itraconazole 
and polymer.  In particular, the enthalpies of recrystallization/melting for the drug were 
comparable, suggesting that the drug was predominantly amorphous following 
quenching.  Considered in isolation, the DSC data for itraconazole:PEG4000 appear to be 
consistent with a fully dispersed drug in polymer, however, ambiguity remains as to 
whether the entire API content was amorphous.   
In the second grouping of thermal data, cloperastine:PEG4000, 
ketoconazole:PEG4000, melatonin:PEG4000, and sulfaniliamide:PEG4000, were 
observed to have a single Tg indicating persistent amorphous content of the quenched 
solids. Clear endotherms unambiguously attributable to PEG4000 melting were also 
observed for each of these solids, none of which were preceded by clear recrystallization, 
suggesting that the polymer recrystallized during solidification.  Following Tm,p, 
recrystallization/melting of the API occurred for each solid, likely because the molten 
PEG allowed for increased mobility of the API molecules, enabling their crystallization 
during the temperature ramp.  The presence of crystalline API following solidification 
was more difficult to interpret from the DSC data alone.  Ketoconazole:PEG4000 
thermograms had only a single Tg observed per solid, however, these occurred at 
inconsistent values from sample to sample (Table A.4).  Ultimately, they were all skewed 
towards the Tg,p, suggesting that ketoconazole was partially dispersed in PEG4000, 
resulting in anti-plasticization of Tg,p.  Additionally, in the melatonin:PEG4000 mixtures, 
the recrystallization exotherm for the API integrated to a much lower enthalpy relative to 
the respective melt endotherm, potentially suggesting some crystallization of API during 
  168 
co-solidification.  Taken together, these APIs were classified as partially dispersed in 
PEG4000. 
In the third grouping, solid mixtures that included chlorpropamide, indomethacin, 
nifedipine, propranolol·HCl, griseofulvin, and quinidine, were observed to have a single 
Tg.  As the temperature was increased for these solids, neither crystallization nor melting 
of the PEG4000 was observed, suggesting that the polymer remained amorphous during 
solidification, and was inhibited from recrystallization by the very high drug 
concentration present.  Each thermogram also had a distinct recrystallization exotherm 
prior to the respective melting endotherms for the API.  This suggested that these drugs 
solidified as amorphous solids and only recrystallized as a consequence of heating in the 
DSC experiments.  It should be noted that the API recrystallization observed for 
chlorpropamide:PEG4000 overlapped with the region where Tm,p would normally be 
observed.  Since the DSC signal reports net heat flow, it is entirely possible that melting 
of polymer that recrystallized during solidification was obscured by the recrystallization 
of the chlorpropamide.  Using only the DSC data, all of the API in this grouping were, 
therefore, classified as fully dispersed in PEG4000, having no clear evidence of 
recrystallization during quenching. In the case of chlorpropamide, the ambiguity 
associated with the overlap exothermic/endothermic signals could easily result in a 
misclassification of drug:polymer dispersion behavior, highlighting a limitation of DSC 
interpretation in systems such as these.     
Finally, using only the DSC data, terfenedine:PEG4000 was classified as only 
partially dispersed.  These thermograms showed two Tg events at 7.95
oC and 61.32oC in 
1/3 of the solids, and a single Tg (average value of -30.79
oC) in the other two replicate 
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solids (Figure A.6).  Although PEG4000 melting was not observed in these samples, the 
recrystallization of the API overlapped with the temperature range where PEG melting 
was expected, potentially obscuring that signal. 
 
Figure A.6. Overlay of Tg regions in DSC thermograms from top to bottom: Pure 
terfenadine (in blue), co-solidified 3:1 w/w terfenadine:PEG4000 (in black) and pure 
PEG4000 (in red). Panel a) a single Tg was measured for the mixture (-28.16
oC in this 
replicate; mean -30.79oC; n=2), which fell intermediate to Tg,p and Tg,API.  Panel b) two Tg 
values were measured (7.96oC and 61.32oC) indicating plasticization and 
antiplasticization, respectively for Tg,API and Tg,p. 
 
 
 
A.3.6. Combined inferences from physicochemical characterization suite 
A summary of the classifications of dispersion behavior based on each technique in 
isolation is found in Table A.5, and compared with classifications made by collectively 
considering all of the characterization data.  Of the 15 API:PEG4000 combinations, only 
6 resulted in samples whose dispersion behavior was consistently categorized using each 
of the four methods.  That said, owing to limitations described for each individual 
technique, inferences in isolation of the other techniques were not made with the same 
confidence relative to those made using all of the pooled data.   
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Table A.5.  Summary of inferences from individual techniques compared with inferences 
made by collective consideration of all techniques (Combined Inference). 
Solid Mixture PXRD PDF HSM DSC Combined 
Inference 
Chlorpropamide Partially 
dispersed 
N/A Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Cimetidine Fully dispersed Fully dispersed Fully dispersed Fully dispersed 
 
Fully dispersed 
 
Cloperastine·HCl Partially 
dispersed 
N/A Partially 
dispersed 
Partially 
dispersed 
 
Partially 
dispersed 
Griseofulvin Partially 
dispersed 
N/A Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Ibuprofen Fully phase 
separated 
N/A Fully phase 
separated 
Fully phase 
separated 
 
Fully phase 
separated 
 
Indomethacin Fully dispersed Fully dispersed Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Itraconazole Partially 
dispersed 
N/A Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Ketoconazole Fully dispersed N/A Partially 
dispersed 
Partially 
dispersed 
 
Partially 
dispersed 
Melatonin Partially 
dispersed 
N/A Partially 
dispersed 
Partially 
dispersed 
 
Partially 
dispersed 
Nifedipine Fully dispersed Fully dispersed Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Propranolol·HCl Partially 
dispersed 
N/A Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Quinidine Partially 
dispersed 
N/A Partially 
dispersed 
Fully dispersed 
 
Partially 
dispersed 
Sulfanilamide Partially 
dispersed 
N/A Partially 
dispersed 
Partially 
dispersed 
 
Partially 
dispersed 
Terfenadine Fully dispersed Fully dispersed Partially 
dispersed 
Partially 
dispersed 
 
Partially 
dispersed 
Tolbutamide Partially 
dispersed 
N/A Partially 
dispersed 
Fully phase 
separated 
 
Partially 
dispersed 
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Consider the case of cimetidine, which was classified as fully dispersed in 
PEG4000 at this composition.  The PXRD data suggested a completely amorphous solid 
(Table A.2), while the PDF analysis suggested that the amorphous phases were 
intimately dispersed, allowing for interatomic distances unique to a dispersion (Figure 
A.2).  These data were made considerably more compelling, however, by the absence of 
detectable crystallinity by polarized light microscopy (Figure A.3b), and the presence of 
a single Tg value comparable to the theoretical Tg and the absence of crystallinity having 
resulted from solidification cimetidine and PEG4000 (Table A.4, Figure A.5).  
Similarly, ibuprofen:PEG4000 was unambiguously classified fully phase separated based 
on complete recrystallization prior to analysis. The PXRD data confirmed that the 
ibuprofen was entirely crystalline (Figure A.1).  The absence of a Tg in the DSC data 
(Figure A.5), and no observation of any recrystallization in both DSC and HSM further 
reinforced that no amorphous material was present in any of these samples. 
The necessity of using complementary characterization techniques on quenched 
API:PEG400 mixtures was best illustrated with samples for which inferences based on a 
single technique were inconsistent (Table A.5).  For example, the PXRD data for 
nifedipine:PEG4000 suggested a completely amorphous solid (Table A.2), supported by 
PDF analysis, which suggested intimate dispersion of amorphous drug and polymer to 
form a single phase (Table A.3). The DSC data appeared to also support formation of a 
fully dispersed solid, evidenced by a single Tg, and no detectable crystallinity from either 
component, formed during co-solidification (Table A.4).  Had the microscopy not been 
performed, these three analyses would have suggested that nifedipine was fully dispersed 
in PEG4000 at this composition.  As shown in Figure A.3j, however, tiny, birefringent 
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crystalline grains were visible in the polarized light photomicrograph, which comprised a 
small fraction of the overall sample.  This indicated some recrystallization during 
solidification.  Furthermore, the HSM routine showed that some of these crystallites did 
not melt until Tm,API, clearly indicating that the nifedipine had recrystallized to some 
extent.  Although this classified the 3:1 solid as partially dispersed, the presence of 
substantial, persistent amorphous phase suggests that at a lower drug loading a fully 
dispersed solid may be possible. 
Also of note in Table A.5 is the fact that all of the classifications made 
exclusively using HSM are identical to the final inferences from collective consideration 
of the data.  This could appear to suggest that HSM was superior to the other methods, 
and potentially the only technique needed to characterize API:PEG4000 solid mixtures.  
Indeed, polarized light microscopy appears to be able to visualize sample crystallinity too 
small to be observed in either the PXRD or DSC signals.  Like DSC, however, samples 
subjected to microscopy were limited by the necessity of sub-sampling.  Not only are 
“chips” taken from larger, co-solidified samples for visualization, the field of view at any 
given time is only a fraction of the chip.  While the presence of crystallinity is 
unambiguous, and the identity of the crystals (API or PEG) can be determined from the 
observations through the heating cycle, the absence of crystallinity in a microscopy 
experiment likely needs to be confirmed in many samples to confidently assume that the 
entire sample contains no crystals. 
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A.4. Conclusion 
A library of 15 API was co-solidified with PEG4000.  Characterization of the 
resulting solids was done using PXRD, PDF analysis, DSC and HSM, and API were 
classified as either fully dispersed, partially dispersed or fully phase separated in the 
polymer at a 3:1 weight ratio.  The dispersion behavior of only 6/15 of the mixtures was 
consistently classified using data from each of the techniques independent of the others, 
reflecting the limits of each method in individually characterizing potential dispersions 
involving PEG as a carrier.  PXRD was limited by the ability to detect diffraction from 
very small crystallites in an almost entirely amorphous sample.  HSM was able to 
confirm the presence of crystalline API in 4/5 X-ray amorphous patterns, more correctly 
identifying those API as partially dispersed in PEG4000.  The significant amorphous 
content interpreted from PXRD data complemented by the limited crystallinity observed 
using HSM suggested that indomethacin, ketoconazole, nifedipine, and terfenedine may 
be fully dispersable in PEG4000 at a lower concentration.  DSC in isolation was limited 
by potentially overlapping signals from the API and PEG, which made it difficult to 
distinguish crystallinity formed during solidification vs. recrystallization that occurs 
exclusively because of the temperature program imposed on the samples by the 
experiment.  Again, HSM was able to confirm the presence of initial drug and polymer 
crystallites that formed during solidification of the molten mixtures, as well as distinguish 
events that occurred at experimental temperatures.  Overall, the complexity of 
drug/polymer dispersion behavior, especially in mixtures involving PEG4000, combined 
with data subtleties that likely need to be interpreted to distinguish between partially and 
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fully dispersed mixtures, reinforces the need to use complementary techniques in order to 
ensure thorough characterization. 
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